<SEC-DOCUMENT>0001047469-19-002458.txt : 20190422
<SEC-HEADER>0001047469-19-002458.hdr.sgml : 20190422
<ACCEPTANCE-DATETIME>20190422161552
ACCESSION NUMBER:		0001047469-19-002458
CONFORMED SUBMISSION TYPE:	DEF 14A
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20190604
FILED AS OF DATE:		20190422
DATE AS OF CHANGE:		20190422
EFFECTIVENESS DATE:		20190422

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CATABASIS PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001454789
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEF 14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37467
		FILM NUMBER:		19759584

	BUSINESS ADDRESS:	
		STREET 1:		ONE KENDALL SQUARE
		STREET 2:		BLDG. 1400E, SUITE B14202
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139
		BUSINESS PHONE:		617-349-1971

	MAIL ADDRESS:	
		STREET 1:		ONE KENDALL SQUARE
		STREET 2:		BLDG. 1400E, SUITE B14202
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEF 14A
<SEQUENCE>1
<FILENAME>a2238509zdef14a.htm
<DESCRIPTION>DEF 14A
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->





<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg41201a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>
Washington, D.C. 20549  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B> SCHEDULE 14A</B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>Proxy
Statement Pursuant to Section 14(a) of<BR>
the Securities Exchange Act of 1934 (Amendment No.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;) </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="17pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD COLSPAN=3 style="font-family:times;"><FONT SIZE=2> Filed by the Registrant <FONT FACE="WINGDINGS">&#253;</FONT></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=3 style="font-family:times;"><BR><FONT SIZE=2>Filed by a Party other than the Registrant <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=3 style="font-family:times;"><FONT SIZE=2><BR>
Check the appropriate box:</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Preliminary Proxy Statement</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><B> Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#253;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Definitive Proxy Statement</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Definitive Additional Materials</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Soliciting Material under &sect;240.14a-12<BR></FONT>
</TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;<BR></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="17pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="20pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD COLSPAN=5 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> CATABASIS PHARMACEUTICALS,&nbsp;INC.</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=5 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> (Name of Registrant as Specified In Its Charter)</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=5 ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=5 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> (Name of Person(s) Filing Proxy Statement, if other than the Registrant)</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=5 style="font-family:times;"><FONT SIZE=2><BR>
Payment of Filing Fee (Check the appropriate box):</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#253;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><BR><FONT SIZE=2>No fee required.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><BR><FONT SIZE=2>Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and&nbsp;0-11.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Title of each class of securities to which transaction applies:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(2)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Aggregate number of securities to which transaction applies:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(3)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(4)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Proposed maximum aggregate value of transaction:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(5)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Total fee paid:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><BR><FONT SIZE=2>Fee paid previously with preliminary materials.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><BR><FONT SIZE=2>Check box if any part of the fee is offset as provided by Exchange Act Rule&nbsp;0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration
statement number, or the Form or Schedule and the date of its filing.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><BR><FONT SIZE=2>Amount Previously Paid:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(2)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Form, Schedule or Registration Statement No.:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(3)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Filing Party:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(4)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Date Filed:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=1,EFW="2238509",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=640369,FOLIO='blank',FILE='DISK121:[19ZAF1.19ZAF41201]BA41201A.;4',USER='CHE105545',CD='18-APR-2019;16:37' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->





<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg41201a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>CATABASIS PHARMACEUTICALS,&nbsp;INC.<BR>  </B></FONT><FONT SIZE=2><B>One Kendall Square<BR>
Building 1400E, Suite B14202<BR>
Cambridge, MA 02139  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> NOTICE OF&nbsp;2019 ANNUAL MEETING OF STOCKHOLDERS  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> To be held on June&nbsp;4, 2019  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You are cordially invited to attend the 2019 Annual Meeting of Stockholders (the "Annual Meeting") of Catabasis Pharmaceuticals,&nbsp;Inc., which is scheduled
to be held on Tuesday, June&nbsp;4, 2019 at 10:00&nbsp;a.m. Eastern Time, at the offices of WilmerHale located at 60 State Street, Boston, Massachusetts 02109. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At
the Annual Meeting, the stockholders will consider and vote on the following matters: </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Election
of two Class&nbsp;I Directors to our Board of Directors, to serve until the 2022 annual meeting of stockholders; </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ratification
of the appointment of Ernst&nbsp;&amp; Young&nbsp;LLP as our independent registered public accounting firm for the fiscal year ending December&nbsp;31,
2019; and </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Transaction
of any other business properly brought before the Annual Meeting or any adjournment or postponement thereof. </FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
can find more information, including the nominees for directors, in the attached Proxy Statement. The Board of Directors recommends that you vote in favor of each of proposals one
and two as outlined in the attached Proxy Statement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are pleased to take advantage of the Securities and Exchange Commission rules that allow us to furnish proxy materials to our stockholders on the internet. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
invite all stockholders to attend the Annual Meeting in person. Stockholders of record at the close of business on April&nbsp;12, 2019, the record date for the Annual Meeting, are
entitled to notice of, and to vote at, the Annual Meeting or any adjournment or postponement of the Annual Meeting. Whether or not you expect to attend the Annual Meeting in person, please vote your
shares by proxy as promptly as possible to ensure your representation and the presence of a quorum at the Annual Meeting. In addition to returning your proxy card by mail, you may vote your shares on
the internet by visiting www.proxyvote.com or by telephone by calling 800-690-6903 and following the recorded instructions. Your vote is important regardless of the number of shares you own. If you
send in your proxy card or vote by telephone or the internet and then decide to attend the Annual Meeting to vote your shares in person, you may still do so. Your proxy is revocable in accordance with
the procedures set forth in the Proxy Statement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
your shares are held in "street name," that is, held for your account by a broker or other nominee, you will receive instructions from the holder of record that you must follow for
your shares to be voted. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="48%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="48%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>By order of the Board of Directors,</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><BR><FONT SIZE=2><B>
<IMG SRC="g102608.jpg" ALT="GRAPHIC" WIDTH="148" HEIGHT="67">
 </B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Jill C. Milne, Ph.D.<BR></FONT> <FONT SIZE=2><I>President and Chief Executive Officer</I></FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><BR><FONT SIZE=2> Cambridge, Massachusetts<BR>
April&nbsp;22, 2019</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=2,EFW="2238509",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=888470,FOLIO='blank',FILE='DISK121:[19ZAF1.19ZAF41201]BE41201A.;3',USER='CHE105545',CD='18-APR-2019;16:37' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41201a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A NAME="BG41201A_main_toc"></A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="bg41201_catabasis_pharmaceuticals,_inc__cat02543"> </A>
<BR></FONT><FONT SIZE=2><B>  Catabasis Pharmaceuticals,&nbsp;Inc.<BR>  Proxy Statement<BR>  Table of Contents    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>
<A NAME="BG41201_TOC"></A> </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- COMMAND=ADD_START_LINKTABLE -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="17pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#da41201_proxy_statement"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Proxy Statement</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#da41201_proxy_statement"><FONT SIZE=2>1</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#da41201_important_information___da402374"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Important Information About the Annual Meeting and
Voting</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#da41201_important_information___da402374"><FONT SIZE=2><BR>
2</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dc41201_proposal_no._1_#151;election_of_class_i_directors"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Proposal No.&nbsp;1&#151;Election of Class&nbsp;I
Directors</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dc41201_proposal_no._1_#151;election_of_class_i_directors"><FONT SIZE=2><BR>
6</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#de41201_corporate_governance"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Corporate Governance</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#de41201_corporate_governance"><FONT SIZE=2><BR>
10</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dg41201_executive_officers"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Executive Officers</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dg41201_executive_officers"><FONT SIZE=2><BR>
19</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dg41201_executive_compensation"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Executive Compensation</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dg41201_executive_compensation"><FONT SIZE=2><BR>
20</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#di41201_certain_relationships___di402225"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Certain Relationships and Related Person Transactions</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#di41201_certain_relationships___di402225"><FONT SIZE=2><BR>
27</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#di41201_proposal_no._2_#151;ratificati__pro06296"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Proposal No.&nbsp;2&#151;Ratification of the Appointment of
Ernst&nbsp;&amp; Young&nbsp;LLP as Catabasis' Independent Registered Public Accounting Firm for the Fiscal Year Ending December&nbsp;31, 2019</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#di41201_proposal_no._2_#151;ratificati__pro06296"><FONT SIZE=2><BR>
29</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dk41201_principal_stockholders"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Principal Stockholders</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dk41201_principal_stockholders"><FONT SIZE=2><BR>
31</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dk41201_section_16(a)_benefici__dk402022"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Section&nbsp;16(a) Beneficial Ownership Reporting
Compliance</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dk41201_section_16(a)_benefici__dk402022"><FONT SIZE=2><BR>
33</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dk41201_report_of_the_audit_committee"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Report of the Audit Committee</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dk41201_report_of_the_audit_committee"><FONT SIZE=2><BR>
34</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dk41201_householding"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Householding</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dk41201_householding"><FONT SIZE=2><BR>
35</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dk41201_stockholder_proposals"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Stockholder Proposals</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dk41201_stockholder_proposals"><FONT SIZE=2><BR>
35</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dk41201_other_matters"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other Matters</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dk41201_other_matters"><FONT SIZE=2><BR>
36</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
<!-- COMMAND=ADD_END_LINKTABLE -->
 </DIV>
 <HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=3,EFW="2238509",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=608413,FOLIO='blank',FILE='DISK121:[19ZAF1.19ZAF41201]BG41201A.;5',USER='CHE105545',CD='18-APR-2019;16:37' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_da41201_1_1"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41201a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>CATABASIS PHARMACEUTICALS,&nbsp;INC.<BR>  </B></FONT><FONT SIZE=2><B>One Kendall Square<BR>
Building 1400E, Suite B14202<BR>
Cambridge, MA 02139<BR>
617-349-1971  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> <A NAME="da41201_proxy_statement"> </A>
<A NAME="toc_da41201_1"> </A>
<BR>  </B></FONT><FONT SIZE=3><B>PROXY STATEMENT  <BR>  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>FOR THE 2019 ANNUAL MEETING OF STOCKHOLDERS<BR>
to be held on June&nbsp;4, 2019</B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
proxy statement and the proxy card contain information about the 2019 Annual Meeting of Stockholders of Catabasis Pharmaceuticals,&nbsp;Inc. (the "Annual Meeting") to be held on
Tuesday, June&nbsp;4, 2019 at 10:00&nbsp;a.m. Eastern Time, at the offices of WilmerHale located at 60 State Street, Boston, Massachusetts 02109. The Board of Directors of Catabasis
Pharmaceuticals,&nbsp;Inc. is using this proxy statement to solicit proxies for use at the Annual Meeting. In this proxy statement, unless expressly stated otherwise or the context otherwise
requires, the use of "Catabasis," "our," "we" or "us" refers to Catabasis Pharmaceuticals,&nbsp;Inc. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
properly submitted proxies will be voted in accordance with the instructions contained in those proxies. If no instructions are specified, the proxies will be voted in accordance
with the recommendation of our Board of Directors with respect to each of the matters set forth in the accompanying Notice of Meeting. You may revoke your proxy at any time before it is exercised at
the meeting by giving our corporate secretary written notice to that effect. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
Annual Report to Stockholders for the fiscal year ended December&nbsp;31, 2018 and this proxy statement and proxy card are first being made available to stockholders on or about
April&nbsp;22, 2019. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>Important Notice Regarding the Availability of Proxy Materials for<BR>
the Annual Meeting of Stockholders to be Held on June&nbsp;4, 2019:  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> This proxy statement and our 2018 Annual Report to Stockholders are<BR>
available for viewing, printing and downloading at www.proxyvote.com.  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><B>A copy of our Annual Report on Form&nbsp;10-K for the fiscal year ended December&nbsp;31, 2018, as filed with the Securities and
Exchange Commission, or SEC, except for exhibits, will be furnished without charge to any stockholder upon written request to Catabasis Pharmaceuticals,&nbsp;Inc., Attention: Secretary, One Kendall
Square, Building 1400E, Suite B14202, Cambridge, MA 02139. This proxy statement and our Annual Report on Form&nbsp;10-K for the fiscal year ended December&nbsp;31, 2018 are also available on the
SEC's website at http://www.sec.gov and our website at www.catabasis.com.</B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>1</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=4,EFW="2238509",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=881150,FOLIO='1',FILE='DISK121:[19ZAF1.19ZAF41201]DA41201A.;8',USER='CHE105545',CD='18-APR-2019;16:37' -->
<A NAME="page_da41201_1_2"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41201a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="da41201_important_information___da402374"> </A>
<A NAME="toc_da41201_2"> </A>
<BR></FONT><FONT SIZE=2><B>  IMPORTANT INFORMATION ABOUT THE ANNUAL MEETING AND VOTING    <BR>    </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Purpose of the Annual Meeting  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At the Annual Meeting, our stockholders will consider and vote on the following matters: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>1.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Election
of two Class&nbsp;I directors to our Board of Directors, to serve until the 2022 annual meeting of stockholders;
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>2.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Ratification
of the appointment of Ernst&nbsp;&amp; Young&nbsp;LLP as our independent registered public accounting firm for the fiscal year ending December&nbsp;31,
2019; and
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>3.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Transaction
of any other business properly brought before the Annual Meeting or any adjournment or postponement thereof. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
of the date of this proxy statement, we are not aware of any business to come before the meeting other than the first two items noted above. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Board of Directors Recommendation  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Board of Directors unanimously recommends that you vote: </FONT></P>

<UL>
<UL>

<P style="font-family:times;"><FONT SIZE=2><B>FOR</B></FONT><FONT SIZE=2> the election of the nominees to serve as Class&nbsp;I Directors on our Board of Directors for a three-year term; and </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B>FOR</B></FONT><FONT SIZE=2> the ratification of the appointment of Ernst&nbsp;&amp; Young&nbsp;LLP as our independent registered public accounting firm for the fiscal year
ending December&nbsp;31, 2019. </FONT></P>

</UL>
</UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Notice of Internet Availability of Proxy Materials  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to rules adopted by the SEC, we have elected to provide access to our proxy materials via the internet. Accordingly, we are sending a
notice of internet availability of proxy materials to our stockholders. All stockholders will have the ability to access the proxy materials on the website referenced in the notice and to request to
receive a printed set of the proxy materials by mail. Instructions on how to access the proxy materials over the internet and how to request a printed copy may be found in the notice. In addition,
stockholders may request to receive proxy materials in printed form by mail or electronically by email on an ongoing basis. We encourage stockholders to take advantage of the availability of the proxy
materials on the internet or through email to help reduce the environmental impact of our annual meetings. The proxy materials, including this proxy statement, a proxy card or voting instruction card
and our 2018 Annual Report on Form&nbsp;10-K, are also available for viewing, printing and downloading on the internet at www.proxyvote.com. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Who Can Vote at the Annual Meeting  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Only stockholders of record at the close of business on the record date of April&nbsp;12, 2019 are entitled to receive notice of the Annual
Meeting and to vote the shares of our common stock that they held on that date. As of April&nbsp;12, 2019, there were 11,497,742 shares of common stock issued and outstanding. Each share of common
stock is entitled to one vote on each matter properly brought before the Annual Meeting. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Difference between a "stockholder of record" and a beneficial owner of shares held in "street
name"</I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stockholder of Record.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;If you have shares registered directly in your name with our transfer agent, American Stock Transfer&nbsp;&amp;
Trust
Company,&nbsp;LLC, then you are considered a "stockholder of record" of those shares. For these shares, your set of proxy materials has been made available to you directly by us. You may vote these
shares by proxy prior to the Annual Meeting by following the instructions contained on the proxy card. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>2</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=5,EFW="2238509",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=120462,FOLIO='2',FILE='DISK121:[19ZAF1.19ZAF41201]DA41201A.;8',USER='CHE105545',CD='18-APR-2019;16:37' -->
<A NAME="page_da41201_1_3"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41201a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Beneficial Owner of Shares Held in Street Name.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;If you hold shares in a brokerage account or by a bank, trust or other nominee or
custodian, then you
are considered the beneficial owner of those shares, which are held in "street name." For these shares, your set of proxy materials has been made available to you by that organization. The
organization holding your account is considered the stockholder of record for purposes of voting at the Annual Meeting. As the beneficial owner, you have the right to instruct that organization as to
how to vote the shares held in your account by following the instructions contained on the voting instruction card provided to you by that organization. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


How to Vote  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stockholder of Record.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;If you are a stockholder of record, you can vote your shares in one of two ways:
either by proxy or in person at the Annual Meeting. If you choose to vote by proxy, you may do so by telephone, via the internet or by mail. Each of these methods is explained below. </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><I> By Telephone.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;If you request printed copies of the proxy materials by mail
and you live in the United States or Canada, you may vote by proxy by calling the toll free number found on the proxy card. You must have the control number that is on the proxy card when voting. If
you choose to vote by telephone, you do not have to return the proxy card.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><I> By Internet.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;You may transmit your proxy voting instructions&nbsp;via the
internet by following the instructions provided on the notice of internet availability of proxy materials or the proxy card. You will need to have the control number that is on the proxy card when
voting. If you choose to vote via the internet, you do not have to return the proxy card.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><I> By Mail.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;If you request printed copies of the proxy materials by mail, you
may vote by proxy by completing, signing and dating the proxy card and returning it in the envelope provided.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><I> In Person at the Annual Meeting.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;You may vote in person at the Annual
Meeting. We will give you a ballot when you arrive. Even if you plan to attend the Annual Meeting, we urge you to vote your shares by proxy in advance of the Annual Meeting so that, if you should
become unable to attend the Annual Meeting, your shares will be voted as directed by you. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Telephone
and internet voting for stockholders of record will be available up until 11:59&nbsp;p.m. Eastern Time on June&nbsp;3, 2019 and mailed proxy cards must be received by
June&nbsp;3, 2019 in order to be counted at the Annual Meeting. If the Annual Meeting is adjourned or postponed, these deadlines may be extended. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Beneficial Owner of Shares Held in Street Name.</I></B></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;If your shares are held in street name (held for your account by a broker or
other
nominee): </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><I> By Telephone or Internet.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;You will receive instructions or a voting
instruction form from your broker or other nominee if you are permitted to vote by telephone or internet.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><I> By Mail.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;You will receive instructions from your broker or other nominee
explaining how to vote your shares by mail.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><I> In Person at the Annual Meeting.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;If you attend the Annual Meeting, you may
vote in person. To do so, you will need to show a picture identification as well as an account statement or a letter from the record holder indicating that you owned the shares as of the record date
and obtain from the broker or other nominee who holds your shares a legal proxy or broker's proxy card and bring it with you to the meeting. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
voting deadlines and availability of telephone and internet voting for beneficial owners of shares held in "street name" will depend on the voting processes of the organization that
holds your shares. Therefore, we urge you to carefully review and follow the voting instruction card and any other materials that you receive from that organization. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>3</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=6,EFW="2238509",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=1044772,FOLIO='3',FILE='DISK121:[19ZAF1.19ZAF41201]DA41201A.;8',USER='CHE105545',CD='18-APR-2019;16:37' -->
<A NAME="page_da41201_1_4"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>If you hold your shares of Catabasis common stock in multiple accounts, you should vote your shares as described in each set of proxy materials you
receive.</I></B></FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Quorum  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A quorum of stockholders is necessary to hold a valid meeting. Our bylaws provide that a quorum will exist if stockholders holding a majority of
the shares of stock issued and outstanding and entitled to vote are present at the meeting in person or by proxy. Abstentions and broker non-votes count as present for establishing a quorum but will
not be counted as votes cast. Broker non-votes occur when your broker or other nominee submits a proxy for your shares (because the broker or other nominee has received instructions from you on one or
more proposals, but not all, or has not received instructions from you but is entitled to vote on a particular "discretionary" matter)
but does not indicate a vote for a particular proposal because the broker or other nominee either does not have the authority to vote on that proposal and has not received voting instructions from you
or has discretionary authority but chooses not to exercise it. If a quorum is not present, the meeting may be adjourned until a quorum is obtained. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Ballot Measures Considered "Routine" and "Non-Routine"  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The election of directors (Proposal No.&nbsp;1) is a matter considered non-routine under applicable rules. A broker or other nominee cannot
vote without instructions on non-routine matters, and therefore there may be broker non-votes on Proposal No.&nbsp;1. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
ratification of the appointment of Ernst&nbsp;&amp; Young&nbsp;LLP as our independent registered public accounting firm for 2019 (Proposal No.&nbsp;2) is a matter considered
routine under applicable rules. A broker or other nominee may generally exercise discretionary authority and vote on routine matters. If they exercise this discretionary authority, no broker non-votes
are expected to exist in connection with Proposal No.&nbsp;2. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Votes Required to Elect Directors and Ratify Appointment of Ernst&nbsp;&amp; Young&nbsp;LLP  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To be elected, a director must receive a plurality of the votes cast by stockholders entitled to vote at the meeting (Proposal No.&nbsp;1).
Shares represented by proxies that withhold authority to vote for a nominee for election as a director will not be counted as votes "for" a director. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
ratification of the appointment of Ernst&nbsp;&amp; Young&nbsp;LLP as our independent registered public accounting firm requires the affirmative vote of the majority of the shares of
common stock present or represented by proxy and voted "for" or "against" such matter (Proposal No.&nbsp;2). </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Abstentions
and broker non-votes will not be counted as votes cast on any of the proposals. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Method of Counting Votes  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each holder of common stock is entitled to one vote at the Annual Meeting on each matter to come before the Annual Meeting, including the
election of directors, for each share held by such stockholder as of the record date. Votes cast in person at the Annual Meeting or by proxy by mail, via the internet or by telephone will be tabulated
by the inspector of election appointed for the Annual Meeting, who will also determine whether a quorum is present. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>4</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=7,EFW="2238509",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=25001,FOLIO='4',FILE='DISK121:[19ZAF1.19ZAF41201]DA41201A.;8',USER='CHE105545',CD='18-APR-2019;16:37' -->
<A NAME="page_da41201_1_5"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Revoking a Proxy; Changing Your Vote  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If you are a stockholder of record, you may revoke your proxy before the vote is taken at the
meeting:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> by submitting a new proxy with a later date before the applicable deadline either signed and returned by mail or transmitted using the
telephone or internet voting procedures described in the "How to Vote" section above; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> by voting in person at the meeting; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> by filing a written revocation with our corporate secretary. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
your shares are held in "street name," you may submit new voting instructions by contacting your broker or other organization holding your account. You may also vote in person at the
Annual Meeting, which will have the effect of revoking any previously submitted voting instructions, if you obtain a legal proxy from the organization that holds your shares as described in the "How
to Vote" section above. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Your
attendance at the Annual Meeting will not automatically revoke your proxy. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Costs of Proxy Solicitation  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We will bear the costs of soliciting proxies. In addition to solicitations by mail, our directors, officers and regular employees, without
additional remuneration, may solicit proxies by telephone, facsimile, email, personal interviews and other means. In addition, we have hired Morrow Sodali&nbsp;LLC, 470 West Ave., Stamford, CT 06902
to aid us in the solicitation of proxies for a fee of $6,500 plus out-of-pocket expenses. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Voting Results  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We plan to announce preliminary voting results at the Annual Meeting and to publish final results in a Current Report on Form&nbsp;8-K to be
filed with the SEC within four business days following the Annual Meeting. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>5</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=8,EFW="2238509",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=734689,FOLIO='5',FILE='DISK121:[19ZAF1.19ZAF41201]DA41201A.;8',USER='CHE105545',CD='18-APR-2019;16:37' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_dc41201_1_6"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41201a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="dc41201_proposal_no._1_#151;election_of_class_i_directors"> </A>
<A NAME="toc_dc41201_1"> </A>
<BR></FONT><FONT SIZE=2><B>  PROPOSAL NO. 1&#151;ELECTION OF CLASS I DIRECTORS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Board of Directors is divided into three classes, with one class of our directors standing for election each year, for a three-year term.
The authorized size of our Board of Directors is currently seven. Directors for each class are elected at the annual meeting of stockholders held in the year in which the term for their class expires
and hold office until their resignation or removal or their successors are duly elected and qualified. In accordance with our certificate of incorporation and bylaws, our directors may fill existing
vacancies on the Board of Directors by appointment. The members of the classes are divided as follows:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the Class&nbsp;I directors are Michael D. Kishbauch and Jill C. Milne, and their term expires at the Annual Meeting; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the Class&nbsp;II directors are Kenneth Bate, Joanne&nbsp;T. Beck and Jean George, and their term will expire at the annual meeting of
stockholders to be held in 2020; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the Class&nbsp;III directors are Burt Adelman and Gregg Lapointe, and their term will expire at the annual meeting of stockholders to be held
in 2021. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
certificate of incorporation and bylaws provide that the authorized number of directors may be changed only by resolution of our Board of Directors. Our certificate of incorporation
and bylaws also provide that our directors may be removed only for cause by the affirmative vote of the holders of at least 75% of the votes that all our stockholders would be entitled to cast in an
annual election of directors, and that any vacancy on our Board of Directors, including a vacancy resulting from an enlargement of our Board of Directors, may be filled only by vote of a majority of
our directors then in office. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
bylaws require that each of the classes of our Board of Directors consist, as nearly as may be possible, of one-third of the total number of directors constituting our entire Board
of Directors. Our Board of Directors, on the recommendation of our nominating and corporate governance committee, has nominated Michael&nbsp;D. Kishbauch and Jill&nbsp;C. Milne for re-election as
Class&nbsp;I directors at the Annual Meeting. Each Class&nbsp;I director that is elected at the Annual Meeting will be elected to serve for a three-year term that will expire at our annual meeting
of stockholders to be held in 2022. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
no contrary indication is made, proxies in the accompanying form are to be voted for Mr.&nbsp;Kishbauch and Dr.&nbsp;Milne or, in the event that any of these candidates is not a
candidate or is unable to serve as a director at the time of election (which is not currently expected), for any substitute nominee who is designated by our Board of Directors. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have no formal policy regarding diversity of our Board of Directors. Our priority in selection of Board members is identification of members who will further the interests of our
stockholders through their established record of professional accomplishment, the ability to contribute positively to the collaborative culture among Board members, knowledge of our business and
understanding of the competitive landscape and adherence to high ethical standards. Certain individual skills and qualifications of our directors, which we believe contribute to the effectiveness of
the Board of Directors as a whole, are described in the section below under "Information Regarding Directors." </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>6</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=9,EFW="2238509",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=912188,FOLIO='6',FILE='DISK121:[19ZAF1.19ZAF41201]DC41201A.;6',USER='CHE109858',CD='19-APR-2019;11:27' -->
<A NAME="page_dc41201_1_7"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Information Regarding Directors  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The information set forth below as to the directors and nominees for director has been furnished to us by the directors and nominees for
director: </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="dc41201_nominees_for_election_to_the_b__nom04874"> </A>
<A NAME="toc_dc41201_2"> </A>
<BR></FONT><FONT SIZE=2><B>  Nominees for Election to the Board of Directors<BR>  For a Three-Year Term Expiring at the<BR>  2022 Annual Meeting of Stockholders (Class&nbsp;I)    <BR>    </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="20pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="268pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Age </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Present Position with Catabasis Pharmaceuticals,&nbsp;Inc. </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Michael D. Kishbauch</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>70</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Director</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Jill C. Milne, Ph.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>51</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>President, Chief Executive Officer and Director</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>Michael D. Kishbauch</I></B></FONT><FONT SIZE=2> has served as a member of our Board of Directors since April 2016. Mr.&nbsp;Kishbauch has also served as a director
of Progenics Pharmaceuticals,&nbsp;Inc., a biopharmaceutical company, since September 2013 and of Achillion Pharmaceuticals,&nbsp;Inc., a biotechnology company, since July 2004.
Mr.&nbsp;Kishbauch previously served as President and Chief Executive Officer of Achillion Pharmaceuticals from July 2004 until his retirement in September 2013. Prior to that, he founded and, from
1996 to 2004, served as President and Chief Executive Officer of, OraPharma, a commercial-stage pharmaceutical company focused on oral health care that was acquired by Johnson&nbsp;&amp; Johnson in
2003. Mr.&nbsp;Kishbauch also held senior management positions with MedImmune,&nbsp;Inc., a biotechnology company, from 1992 to 1995. Mr.&nbsp;Kishbauch formerly served as a director of
TetraLogic Pharmaceuticals Corporation from 2014 through 2016. Mr.&nbsp;Kishbauch holds an M.B.A. from The Wharton School of the University of Pennsylvania and a B.A. in biology from Wesleyan
University. We believe that Mr.&nbsp;Kishbauch is qualified to serve on our Board of Directors because of his extensive experience as an entrepreneur and manager and as a public company senior
executive in the biopharmaceutical industry. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>Jill C. Milne, Ph.D.</I></B></FONT><FONT SIZE=2>, is a co-founder of our company and has served as a member of our Board of Directors and as our President and Chief
Executive Officer since June 2008. Prior to co-founding our company, Dr.&nbsp;Milne worked as head of discovery biology at Sirtris Pharmaceuticals, a biotechnology company, from 2004 to 2008, when
it was acquired by GlaxoSmithKline. From 1998 to 2004, Dr.&nbsp;Milne worked at Pfizer Global Research and Development, where she served as the worldwide head of the Drug Pfinder Program and head of
the Enzyme Target Group at the Pfizer Discovery Technology Center in Cambridge, Massachusetts. Prior to joining Pfizer, she was an American Cancer Society postdoctoral fellow in the department of
biological chemistry and molecular pharmacology at Harvard Medical School from 1995 to 1998. Dr.&nbsp;Milne holds a Ph.D. from Harvard University and a B.A. in biological chemistry from Wellesley
College. We believe that Dr.&nbsp;Milne is qualified to serve on our Board of Directors because of her extensive leadership experience in the life sciences industry and her extensive knowledge of
our company based on her role as co-founder and Chief Executive Officer. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Recommendation of the Board of Directors  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B>OUR BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT THE STOCKHOLDERS VOTE FOR THE ELECTION OF MICHAEL&nbsp;D. KISHBAUCH AND JILL&nbsp;C. MILNE.</B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>7</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=10,EFW="2238509",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=700187,FOLIO='7',FILE='DISK121:[19ZAF1.19ZAF41201]DC41201A.;6',USER='CHE109858',CD='19-APR-2019;11:27' -->
<A NAME="page_dc41201_1_8"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41201a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="dc41201_members_of_the_board_of_direct__mem04548"> </A>
<A NAME="toc_dc41201_3"> </A>
<BR></FONT><FONT SIZE=2><B>  Members of the Board of Directors Continuing in Office<BR>  Term Expiring at the<BR>  2020 Annual Meeting of Stockholders (Class&nbsp;II)    <BR>    </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="20pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="258pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Age </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Present Position with Catabasis Pharmaceuticals,&nbsp;Inc. </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Kenneth Bate</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>68</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Director, Chairman of the Board of Directors</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Joanne&nbsp;T. Beck, Ph.D.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>58</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Director</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Jean George</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>61</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Director</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>Kenneth Bate</I></B></FONT><FONT SIZE=2> has served as a member of our Board of Directors since January 2014, as Co-Chairman from February 2016 to February 2019, and
as Chairman since February 2019. Mr.&nbsp;Bate has served as an independent consultant in the biotechnology field since 2012. From April 2009 until December 2011, Mr.&nbsp;Bate was the President
and Chief Executive Officer of Archemix, a privately held biotechnology company. From March 2006 to April 2009, Mr.&nbsp;Bate served in various positions at NitroMed, a public pharmaceutical
company, most recently as President and Chief Executive Officer. From 2002 to 2005, Mr.&nbsp;Bate was head of commercial operations and Chief Financial Officer at Millennium Pharmaceuticals. Prior
to joining Millennium, Mr.&nbsp;Bate co-founded JSB-Partners,&nbsp;LLC, a banking and advisory services firm for biopharmaceutical and life sciences companies. From 1990 to 1996, Mr.&nbsp;Bate
was employed with Biogen,&nbsp;Inc., a public biotechnology company, first as its Chief Financial Officer and then as head of the commercial organization. Mr.&nbsp;Bate is a director of four other
public biopharmaceutical companies, AVEO Pharmaceuticals, Genocea Biosciences, Epizyme Pharmaceuticals and Madrigal Pharmaceuticals. During the last five years, Mr.&nbsp;Bate served as a member of
the board of directors of public biopharmaceutical companies Cubist Pharmaceuticals, Biomarin Pharmaceutial and Vanda Pharmaceuticals. He holds an M.B.A. from The Wharton School of the University of
Pennsylvania and a B.A. in chemistry from Williams College. We believe that Mr.&nbsp;Bate's qualifications to serve on our Board of Directors include his operating, finance, commercial,
transactional and senior management experience in the industry, as well as his experience serving on the boards of directors of other public companies in the life sciences industry. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>Joanne T. Beck, Ph.D.,</I></B></FONT><FONT SIZE=2> has served as a member of our Board of Directors since February 2019. Dr.&nbsp;Beck is currently the Executive
Vice President of Pharmaceutical Development and Operations and a member of the Executive Committee at Celgene Corporation, a publicly held biopharmaceutical company. From 2012 to 2016,
Dr.&nbsp;Beck was Senior Vice President of Pharmaceutical Development at Shire&nbsp;Plc, a former publicly held biopharmaceutical company. Prior to Shire, she held positions of increasing
responsibility in Global Pharmaceutical Operations at Abbott Laboratories, a publicly held pharmaceuticals and healthcare products company, and was the site head of Abbott Vascular
Instruments&nbsp;GmbH. Prior to Abbott, Dr.&nbsp;Beck held positions in Process Development at Genentech and Amgen. Dr.&nbsp;Beck currently serves as a member of the board of directors of public
biopharmaceutical company Orchard Therapeutics. Dr.&nbsp;Beck holds a Ph.D. in biochemistry and molecular biology from
Oregon Health and Science University and completed a postdoctoral fellowship in the department of Pharmaceutical Chemistry at the University of California, San Francisco, and holds a B.A. in chemistry
from Lewis and Clark College. We believe that Dr.&nbsp;Beck is qualified to serve on our Board of Directors because of her significant experience in the areas of process development, manufacturing
and supply chain of biopharmaceuticals and her experience as an executive officer and board member in the pharmaceutical industry. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>Jean George</I></B></FONT><FONT SIZE=2> has served as a member of our Board of Directors since October 2013. Since February 2002, she has been a Managing Director at
Advanced Technology Ventures, a venture capital fund, where she currently serves as the East Coast lead partner for healthcare investments. Since March 2012, Ms.&nbsp;George has served as Managing
Director at Lightstone Ventures, a venture capital firm. Ms.&nbsp;George currently serves as a member of the board of directors of the public companies Acceleron Pharma and Calithera Biosciences,
and, during the past five years, previously served as a member of </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>8</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=11,EFW="2238509",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=904602,FOLIO='8',FILE='DISK121:[19ZAF1.19ZAF41201]DC41201A.;6',USER='CHE109858',CD='19-APR-2019;11:27' -->
<A NAME="page_dc41201_1_9"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>the
board of directors of Zeltiq Aesthetics from 2005 to 2015. Ms.&nbsp;George holds an M.B.A. from Simmons College Graduate School of Management and a B.S. in biology from the University of Maine.
Because of Ms.&nbsp;George's extensive investment and financial experience, we believe she is able to add valuable expertise in guiding the strategic direction of our Board of Directors. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="dc41201_members_of_the_board_of_direct__mem04589"> </A>
<A NAME="toc_dc41201_4"> </A>
<BR></FONT><FONT SIZE=2><B>  Members of the Board of Directors Continuing in Office<BR>  Term Expiring at the<BR>  2021 Annual Meeting of Stockholders (Class&nbsp;III)    <BR>    </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="20pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="246pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Age </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Present Position with Catabasis Pharmaceuticals,&nbsp;Inc. </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Burt Adelman, M.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>66</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Director</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Gregg Lapointe</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>60</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Director</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>Burt Adelman, M.D.</I></B></FONT><FONT SIZE=2>, has served as a member of our Board of Directors since April 2016. Dr.&nbsp;Adelman has served as a Senior Advisor
at Novo Ventures US&nbsp;Inc., a venture capital firm, since September 2017. Previously, Dr.&nbsp;Adelman was Executive Vice President, Research and Development and Chief Medical Officer of Dyax,
a biotechnology company, from February 2012 until its acquisition by Shire in January 2016. Prior to joining Dyax, he worked at Eleven Biotherapeutics, a biotechnology company, where he served as
interim President of Research and Development from 2010 to 2011 and as Senior Advisor from February 2011 until December 2011. From 1991 to 2007, Dr.&nbsp;Adelman held positions of increasing
responsibility at Biogen, a global biotechnology company, ultimately as Executive Vice President, Portfolio Strategy. Since 1998, Dr.&nbsp;Adelman has served as a lecturer in medicine at Harvard
Medical School and as an Associate Physician at Brigham and Women's Hospital. Dr.&nbsp;Adelman holds an M.D. from Cornell Medical College and a B.S. in biology from Trinity College. He completed
residency training and a hematology fellowship at the Peter Bent Brigham Hospital. We believe that Dr.&nbsp;Adelman is qualified to serve on our Board of Directors because of his broad experience in
drug development. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>Gregg Lapointe</I></B></FONT><FONT SIZE=2> has served as a member of our Board of Directors since January 2019. Since 2012, Mr.&nbsp;Lapointe has served as
Co-Founder and Chief Executive Officer of Cerium Pharmaceuticals, a privately held biopharmaceutical company. He previously held varying roles at Sigma-Tau Pharmaceuticals,&nbsp;Inc., a privately
held biopharmaceutical company, from 2001 through 2012, including Chief Operating Officer from 2003 to 2008 and Chief Executive Officer from 2008 to 2012. From 1996 to 2001, Mr.&nbsp;Lapointe served
as Vice President of Operations and Vice President, Controller of AstenJohnson,&nbsp;Inc. (formerly JWI&nbsp;Inc.). Mr.&nbsp;Lapointe began his career at Price Waterhouse and is a Certified
Public Accountant. He currently serves on the Board of Directors of three public biopharmaceutical companies: Soligenix,&nbsp;Inc., Cytori Therapeutics,&nbsp;Inc., and Rigel
Pharmaceuticals,&nbsp;Inc. During the last five years, Mr.&nbsp;Lapointe served as a member of the Board of Directors of public biotechnology companies SciClone Pharmaceuticals,&nbsp;Inc.,
Raptor Pharmaceuticals,&nbsp;Inc., and ImmunoCellular Therapeutics,&nbsp;Inc. He holds an M.B.A. from Duke University, is a Certified Public Accountant, and holds a Bachelor of Commerce from
Concordia University. We believe that Mr.&nbsp;Lapointe is qualified to serve on our Board of Directors because of his significant experience in the areas of finance, management and specialty drug
commercialization and his experience as an executive officer and board member in the pharmaceutical industry. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>9</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=12,EFW="2238509",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=311338,FOLIO='9',FILE='DISK121:[19ZAF1.19ZAF41201]DC41201A.;6',USER='CHE109858',CD='19-APR-2019;11:27' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_de41201_1_10"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41201a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="de41201_corporate_governance"> </A>
<A NAME="toc_de41201_1"> </A>
<BR></FONT><FONT SIZE=2><B>  CORPORATE GOVERNANCE    <BR>    </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


General  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We believe that good corporate governance is important to ensure that Catabasis is managed for the long-term benefit of our stockholders. This
section describes key corporate governance practices that we have adopted. We have adopted a code of business conduct and ethics, which applies to all of our officers, directors and employees, and
corporate governance guidelines and charters for our audit committee, our compensation committee, our nominating and governance committee and our science and technology committee. We have posted
copies of our code of business
conduct and ethics and corporate governance guidelines, as well as each of our committee charters, on the "Corporate Governance" page of the "Investors" section of our website, www.catabasis.com,
which you can access free of charge. Information contained on the website is not incorporated by reference in, or considered part of, this proxy statement. We will also provide copies of these
documents, as well as our other corporate governance documents, free of charge, to any stockholder upon written request to Catabasis Pharmaceuticals,&nbsp;Inc., One Kendall Square, Building 1400E,
Suite B14202, Cambridge, MA 02139, Attention: Investor Relations. We intend to disclose on our website any amendments to, or waivers from, our code of business conduct and ethics that are required to
be disclosed by law or Nasdaq listing standards. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Director Independence  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Rule&nbsp;5605 of the Nasdaq Listing Rules requires a majority of a listed company's board of directors to be comprised of independent
directors within one year of listing. In addition, the Nasdaq Listing Rules require that, subject to specified exceptions, each member of a listed company's audit, compensation and nominating and
corporate governance committees be independent, that audit committee members also satisfy independence criteria set forth in Rule&nbsp;10A-3 under the Securities Exchange Act of 1934, as amended, or
the Exchange Act, and that compensation committee members also satisfy heightened independence requirements contained in the Nasdaq Listing Rules as well as Rule&nbsp;10C-1 under the Exchange Act. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under
Rule&nbsp;5605(a)(2), a director will only qualify as an "independent director" if, in the opinion of our Board of Directors, that person does not have a relationship that would
interfere with the exercise of independent judgment in carrying out the responsibilities of a director. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
order to be considered independent for purposes of Rule&nbsp;10A-3, a member of an audit committee of a listed company may not, other than in his or her capacity as a member of the
audit committee, the board of directors, or any other board committee, accept, directly or indirectly, any consulting, advisory, or other compensatory fee from the listed company or any of its
subsidiaries or otherwise be an affiliated person of the listed company or any of its subsidiaries. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;When
determining the independence of the members of our compensation committee under the heightened independence requirements contained in the Nasdaq Listing Rules and Rule&nbsp;10C-1,
our Board of Directors is required to consider all factors specifically relevant to determining whether a director has a relationship with us that is material to that director's ability to be
independent from management in connection with the duties of a compensation committee member, including, but not limited to: (1)&nbsp;the source of compensation of that director, including any
consulting, advisory or other compensatory fee paid by us to that director; and (2)&nbsp;whether that director is affiliated with our company, a subsidiary of our company or an affiliate of a
subsidiary of our company. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
Board of Directors has reviewed the composition of our Board of Directors and its committees and the independence of each director. Based upon information requested from and provided
by each director concerning his or her background, employment and affiliations, including family relationships, our Board of Directors has determined that each of our directors, other than </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>10</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=13,EFW="2238509",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=139608,FOLIO='10',FILE='DISK121:[19ZAF1.19ZAF41201]DE41201A.;12',USER='CHE109858',CD='19-APR-2019;11:28' -->
<A NAME="page_de41201_1_11"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Dr.&nbsp;Milne,
is an "independent director" as defined under Rule&nbsp;5605(a)(2) of the Nasdaq Listing Rules. Our Board of Directors also has determined that Mr.&nbsp;Bate,
Mr.&nbsp;Kishbauch and Mr.&nbsp;Lapointe, who comprise our audit committee, and Mr.&nbsp;Kishbauch, Dr.&nbsp;Beck and Ms.&nbsp;George, who comprise our compensation committee, satisfy the
independence standards for such committees established by the SEC and the Nasdaq Listing Rules, as applicable. Our Board of Directors also has determined that Dr.&nbsp;Ross, who served on our audit
committee during 2018, and Mr.&nbsp;Bate, who served on our compensation committee during 2018, satisfy the independence standards for such committees established by the SEC and the Nasdaq Listing
Rules, as applicable. In making such determinations, our Board of Directors considered the relationships that each such non-employee director has with our company and all other facts and circumstances
our Board of Directors deemed relevant in determining independence, including the beneficial ownership of our capital stock by each non-employee director. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Board Leadership Structure  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Board of Directors has chosen to separate the role of our Chief Executive Officer and the role of Chairman of the Board of Directors. Our
Board of Directors is currently chaired by Mr.&nbsp;Bate, who possesses an in-depth knowledge of the issues, opportunities and challenges we face. We believe he is the person best positioned to
ensure our Board of Directors' time and attention is focused on the most critical matters. We currently separate the roles of Chairman of the Board of Directors and Chief Executive Officer because we
believe that this structure enhances the Board's oversight of, and independence from, management, and enables the Board to carry out its responsibilities on behalf of our stockholders. This leadership
structure also allows Dr.&nbsp;Milne, our Chief Executive Officer, to focus her time and energy on operating and managing the Company, while leveraging the experience and perspective of
Mr.&nbsp;Bate. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


The Board's Role in Risk Oversight  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Board of Directors has responsibility for the oversight of the company's risk management processes and, either as a whole or through its
committees, regularly discusses with management our major risk exposures, the potential impact of these risks on our business and the steps we take to manage them. The risk oversight process includes
receiving regular reports from Board committees and members of senior management to enable our Board to understand the company's risk identification, risk management and risk mitigation strategies
with respect to areas of potential material risk, including operations, finance, legal, regulatory, strategic and reputational risk. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
audit committee reviews information regarding liquidity and operations and oversees our management of financial risks. Periodically, the audit committee reviews our policies with
respect to risk assessment, risk management, loss prevention and regulatory compliance. Oversight by the audit committee includes direct communication with our external auditors, and discussions with
management regarding significant risk exposures and the actions management has taken to limit, monitor or control such exposures. The compensation committee is responsible for assessing whether any of
our compensation policies or programs has the potential to encourage excessive risk-taking. The nominating and corporate governance committee manages risks associated with the independence of the
Board of Directors, corporate disclosure practices, and potential conflicts of interest. The science and technology committee has responsibility for risk management in areas affecting our research and
development. While each committee is responsible for evaluating certain risks and overseeing the management of such risks, the entire Board of Directors is regularly informed through committee reports
about such risks. Matters of significant strategic risk are considered by our Board of Directors as a whole. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>11</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=14,EFW="2238509",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=1047748,FOLIO='11',FILE='DISK121:[19ZAF1.19ZAF41201]DE41201A.;12',USER='CHE109858',CD='19-APR-2019;11:28' -->
<A NAME="page_de41201_1_12"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Board of Directors Meetings  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Board of Directors met seventeen times during 2018. During the year, each of our directors attended 75% or more of the total number of
meetings of the Board of Directors and the committees on which he or she served. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Committees of the Board of Directors  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have four standing committees: the audit committee, the compensation committee, the nominating and corporate governance committee and the
science and technology committee. Each of these committees has a written charter approved by our Board of Directors. A copy of each charter can be found on the "Corporate Governance" page of the
"Investors" section of our website at www.catabasis.com. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Audit Committee  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The members of our audit committee are Mr.&nbsp;Bate, Mr.&nbsp;Kishbauch and Mr.&nbsp;Lapointe. Mr.&nbsp;Lapointe is the chair of the
audit committee. Our Board of Directors has determined that each of Mr.&nbsp;Bate, Mr.&nbsp;Kishbauch and Mr.&nbsp;Lapointe qualifies as an "audit committee financial expert" within the meaning
of SEC regulations and the Nasdaq Listing Rules. In making this determination, our Board of Directors has considered the formal education and nature and scope of each such director's previous
experience, coupled with past and present service on various audit committees. Our audit committee assists our Board of Directors in its oversight of our accounting and financial reporting process and
the audits of our financial statements. The audit committee met four times during 2018. The audit committee's responsibilities include:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> appointing, approving the compensation of, and assessing the independence of our registered public accounting firm; </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> overseeing the
work of our registered public accounting firm, including through the receipt and consideration of reports from such firm;
</FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> reviewing and discussing with management and the registered public accounting firm our annual and quarterly financial statements and related
disclosures; </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> monitoring our internal control over financial reporting, disclosure controls and procedures and code of business conduct and ethics; </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT
SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> overseeing our internal audit function, if any; </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> discussing our risk management policies; </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT
SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> establishing policies and procedures for the receipt, retention and treatment of accounting-related complaints and concerns;
</FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> meeting independently with our registered public accounting firm and management; </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> reviewing and approving or ratifying
any related person transactions; and </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> preparing the audit committee report required by SEC rules. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
believe that the composition of our audit committee meets the requirements for independence under current Nasdaq listing standards and SEC rules and regulations. Our Board of
Directors has determined that Mr.&nbsp;Bate, Mr.&nbsp;Kishbauch and Mr.&nbsp;Lapointe are independent as independence is currently defined in applicable Nasdaq listing standards and SEC rules
and regulations. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Compensation Committee  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The current members of our compensation committee are Dr.&nbsp;Beck, Ms.&nbsp;George and Mr.&nbsp;Kishbauch. Mr.&nbsp;Kishbauch is the
chair of the compensation committee. Our compensation committee assists our Board of Directors in the discharge of its responsibilities relating to the </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>12</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=15,EFW="2238509",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=967945,FOLIO='12',FILE='DISK121:[19ZAF1.19ZAF41201]DE41201A.;12',USER='CHE109858',CD='19-APR-2019;11:28' -->
<A NAME="page_de41201_1_13"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>compensation
of our executive officers. The compensation committee met seven times during 2018. The compensation committee's responsibilities include:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> reviewing and approving, or making recommendations to our Board of Directors with respect to, the compensation of our chief executive officer
and our other executive officers; </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> overseeing the evaluation of senior executives; </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> overseeing and administering our cash
and equity incentive plans; </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> reviewing and making recommendations to our Board of Directors with respect to director compensation; and </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT
SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> preparing the compensation committee report required by SEC rules, if applicable. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
believe that the composition of our compensation committee meets the requirements for independence under current Nasdaq listing standards and SEC rules and regulations. Our Board of
Directors has determined that Dr.&nbsp;Beck, Ms.&nbsp;George and Mr.&nbsp;Kishbauch are independent as independence is currently defined in applicable Nasdaq listing standards and SEC rules and
regulations. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
compensation committee engaged Radford, an AON Hewitt company, as its compensation consultant during the fiscal year ended December&nbsp;31, 2018. Our compensation committee
considered the relationship that Radford has with us, the members of our Board of Directors and our executive officers. Based on the committee's evaluation, the compensation committee has determined
that no conflicts of interest exist between our company and Radford. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Radford
assisted the committee in conducting a competitive compensation assessment for our executive officers for the fiscal year ended December&nbsp;31, 2018. In evaluating the total
compensation of our executive officers, the compensation committee, with the assistance of Radford, established a peer group of 15 publicly traded companies in the biopharmaceutical industry that was
selected based on companies whose market capitalization, number of employees, maturity of product development pipeline and area of therapeutic focus are similar to ours. Certain of the peer companies
previously included in our peer group were excluded from the current peer group analysis because at the time of the analysis these companies had market capitalizations in excess of $250&nbsp;million
or no longer had late phase&nbsp;2 or early phase&nbsp;3 programs. Radford identified new companies for our peer group analysis with market values in closer proximity to our market value, with
similar public trading tenure, stage of development, and number of employees. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
peer group for our executive benchmarking as approved by the compensation committee for 2018 was comprised of the following companies: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="32%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="32%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="196pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Akari Therapeutics</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Cidara Therapeutics</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Matinas BioPharma Holdings,&nbsp;Inc.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>aTyr Pharma,&nbsp;Inc.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Eiger BioPharmaceuticals</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Proteon Therapeutics,&nbsp;Inc.</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>Capricor Therapeutics,&nbsp;Inc.</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>Endocyte</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>Pulmatrix</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>Cellular Biomedicine Group</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>Fate Therapeutics</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>Trevena,&nbsp;Inc.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Chiasma</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Immune Design Corp.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Vital Therapies,&nbsp;Inc.</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Radford
then supplemented the peer group information with published survey data, which provided a broader market representation of companies and deeper position reporting. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
compensation committee approves the compensation objectives for our company, provides a recommendation to our Board of Directors on the compensation of the Chief Executive Officer
and our other executive officers. The compensation committee reviews all compensation components including base salary, bonus, benefits, equity incentives and other perquisites, as well as severance
arrangements, change-in-control benefits and other forms of executive officer compensation. See "Executive Compensation&#151;Narrative to Summary Compensation Table" below for more information
regarding the roles of the compensation committee, the Board of Directors, and compensation consultants in determining or recommending the amount or form of executive compensation. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>13</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=16,EFW="2238509",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=878791,FOLIO='13',FILE='DISK121:[19ZAF1.19ZAF41201]DE41201A.;12',USER='CHE109858',CD='19-APR-2019;11:28' -->
<A NAME="page_de41201_1_14"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Nominating and Corporate Governance Committee  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The members of our nominating and corporate governance committee are Mr.&nbsp;Bate and Ms.&nbsp;George. Mr.&nbsp;Bate is the chair of the
nominating and corporate governance committee. The nominating and corporate governance committee met two times during 2018. The nominating and corporate governance committee's responsibilities
include:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> identifying individuals qualified to become members of our Board of Directors; </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> recommending to our Board of Directors the persons to
be nominated for election as directors and to each committee of our Board of Directors; </FONT></DD>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> reviewing and making recommendations to the Board of Directors relating to management succession planning; </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> developing and
recommending corporate governance principles to the Board of Directors; and </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> overseeing periodic evaluations of the Board of Directors. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
believe that the composition of our nominating and corporate governance committee meets the requirements for independence under current Nasdaq listing standards and SEC rules and
regulations. Our Board of Directors has determined that Mr.&nbsp;Bate and Ms.&nbsp;George are independent as independence is currently defined in applicable Nasdaq listing standards. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Science and Technology Committee  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The members of the science and technology committee are Dr.&nbsp;Adelman and Dr.&nbsp;Beck. Dr.&nbsp;Adelman is the chair of the science
and technology committee. The science and technology committee met three times during 2018. The science and technology committee's responsibilities include:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> reviewing, evaluating, and advising the Board of Directors and management regarding the long-term strategic goals and objectives and the
direction of our research and development programs; </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> monitoring and evaluating trends in research and development, and recommending to the Board of Directors and management emerging
technologies
for building our technological strength; </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> recommending approaches to acquiring and maintaining technology positions; </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>
regularly reviewing our research and development pipeline; and </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT>
<DD style="font-family:times;"><FONT SIZE=2> assisting the Board of Directors with its oversight responsibility for enterprise risk management in areas affecting our research and
development. </FONT></DD></DL>
</UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Code of Business Conduct and Ethics  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have adopted a written code of business conduct and ethics that applies to our directors, officers and employees, including our principal
executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. We have posted on our website, www.catabasis.com, a current copy of
the code and all disclosures that are required by law or Nasdaq stock market listing standards concerning any amendments to, or waivers from, any provision of the code. Information contained on the
website is not incorporated by reference in, or considered part of, this proxy statement. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Director Nomination Process  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our nominating and corporate governance committee is responsible for identifying individuals qualified to serve as directors, consistent with
criteria approved by our Board of Directors, and recommending the persons to be nominated for election as directors. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>14</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=17,EFW="2238509",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=323748,FOLIO='14',FILE='DISK121:[19ZAF1.19ZAF41201]DE41201A.;12',USER='CHE109858',CD='19-APR-2019;11:28' -->
<A NAME="page_de41201_1_15"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Director Qualifications  </I></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In evaluating director nominees, the nominating and corporate governance committee will consider, among other things, the following
factors:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> reputation for integrity, honesty and adherence to high ethical standards; </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> demonstrated business acumen, experience and ability to
exercise sound judgments in matters that relate to the current and long-term objectives
of our company; </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> commitment to understand our company and its industry; </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> interest and ability to understand the sometimes
conflicting interests of the various constituencies of our company, which include
stockholders, employees, customers, governmental units, creditors and the general public, and to act in the interests of all stockholders; and </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> diversity of expertise and experience in
substantive matters pertaining to our business relative to other members of our Board of Directors. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
nominating and corporate governance committee's goal is to assemble a Board of Directors that brings to the Company a variety of perspectives and skills derived from high quality
business and professional experience. Moreover, the nominating and corporate governance committee believes that the background and qualifications of the Board of Directors, considered as a group,
should provide a significant mix of experience, knowledge and abilities that will allow the Board of Directors to fulfill its responsibilities. Nominees are not discriminated against on the basis of
race, religion, national origin, sex, sexual orientation, disability or any other basis proscribed by law. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
nominating and corporate governance committee has not adopted a formal policy with respect to a fixed set of specific minimum qualifications for its candidates for membership on the
Board of Directors. The committee may consider such other facts, including, without limitation, diversity, as it may deem are in the best interests of our company and its stockholders. The committee
further believes it is appropriate for at least one member of our Board of Directors to meet the criteria for an "audit committee financial expert" as that phrase is defined under the regulations
promulgated by the SEC, and that a majority of the members of our Board of Directors be independent as required under the Nasdaq qualification standards. The committee believes it is appropriate for
our chief executive officer to serve as a member of our Board of Directors. Our directors' performance and qualification criteria are reviewed periodically by the nominating and corporate governance
committee. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Identification and Evaluation of Nominees for Directors  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The nominating and corporate governance committee identifies nominees for director by first evaluating the current members of our Board of
Directors willing to continue in service. Current members with qualifications and skills that are consistent with the nominating and corporate governance committee's criteria for board of director
service and who are willing to continue in service are considered for re-nomination, balancing the value of continuity of service by existing members of our Board of Directors with that of obtaining a
new perspective or expertise. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
any member of our Board of Directors does not wish to continue in service or if our Board of Directors decides not to re-nominate a member for re-election, the nominating and
corporate governance committee identifies a new nominee that meets the criteria above. The committee generally inquires of our Board of Directors and members of management for their recommendations.
The committee may also review the composition and qualification of the boards of directors of our competitors and may seek input from industry experts or analysts. The nominating and corporate
governance committee reviews the qualifications, experience and background of suggested candidates. Final candidates, if other than our current directors, would be interviewed by the members of the
nominating and corporate governance committee and by certain of our other independent directors and executive management. In making its determinations, the nominating and corporate governance
committee evaluates each individual in the context of our Board of Directors as a whole, with the </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>15</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=18,EFW="2238509",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=589088,FOLIO='15',FILE='DISK121:[19ZAF1.19ZAF41201]DE41201A.;12',USER='CHE109858',CD='19-APR-2019;11:28' -->
<A NAME="page_de41201_1_16"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>objective
of assembling a group that can best contribute to the success of our company and represent stockholder interests through the exercise of sound judgment. After review and deliberation of all
feedback and data, the nominating and corporate governance committee makes its recommendation to our Board of Directors. The nominating and corporate governance committee utilized a third-party search
firm to identify Board of Director candidates, including Dr.&nbsp;Beck and Mr.&nbsp;Lapointe, both of whom joined our Board of Directors in the first quarter of 2019. The nominating and corporate
governance committee may in the future continue to use a third party search firm in those situations where particular qualifications are required or where existing contacts are not sufficient to
identify an appropriate candidate. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have not received director candidate recommendations from our stockholders. However, any recommendations received from stockholders will be evaluated by following substantially the
same process, and applying the same criteria, used to evaluate potential nominees suggested by members of our Board of Directors, management or other parties. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under
our bylaws, stockholders wishing to suggest a candidate for director should write to our corporate secretary. In order to give the nominating and corporate governance committee
sufficient time to evaluate a recommended candidate and/or include the candidate in our proxy statement for the 2020 annual meeting, the recommendation should be received by our corporate secretary at
our principal executive offices in accordance with our procedures detailed in the section below entitled "Stockholder Proposals." Such submissions must state the nominee's name, together with
appropriate biographical information and background materials, and information with respect to the stockholder or group of stockholders making the recommendation, including the number of shares of
common stock owned by such stockholder or group of stockholders, as well as other information required by our bylaws. We may require any proposed nominee to furnish such other information as we may
reasonably require to determine the eligibility of such proposed nominee to serve as an independent director or that could be material to a reasonable stockholder's understanding of the independence,
or lack thereof, of such proposed nominee. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Director Attendance at Annual Meetings  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under our corporate governance guidelines, members of our Board of Directors are responsible for attending our Annual Meeting, and we encourage
all of our directors to attend. All of our directors then serving attended our 2018 annual meeting of stockholders. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Communications with Our Board of Directors  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stockholders seeking to communicate with our Board of Directors should submit their written comments to Catabasis Pharmaceuticals,&nbsp;Inc.,
One Kendall Square, Building 1400E, Suite B14202, Cambridge, MA 02139, Attention: Corporate Secretary. The corporate secretary will forward such communications to each member of our Board of
Directors; provided that, if, in the opinion of our corporate secretary, it would be inappropriate to send a particular stockholder communication to a specific director, such communication will only
be sent to the remaining directors (subject to the remaining directors concurring with such opinion). </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Director Compensation  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We do not provide any compensation to Dr.&nbsp;Milne, our President and Chief Executive Officer, for her service as a director.
Dr.&nbsp;Milne's compensation as an executive officer is set forth below under "Executive Compensation&#151;2018 Summary Compensation Table." </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under
our director compensation program, we pay our non-employee directors a cash retainer for service on the Board of Directors and for service on each committee on which the director
is a member. The Chairman of the Board of Directors and the chairman of each committee receive higher </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>16</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=19,EFW="2238509",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=560480,FOLIO='16',FILE='DISK121:[19ZAF1.19ZAF41201]DE41201A.;12',USER='CHE109858',CD='19-APR-2019;11:28' -->
<A NAME="page_de41201_1_17"> </A>


<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>retainers
for such service. These fees are payable in arrears in four equal quarterly installments on the last day of each quarter, provided that the amount of such payment is prorated for any portion
of such quarter that the director is not serving on our Board of Directors. The fees paid to non-employee directors for service on the Board of Directors and for service on each committee of the Board
of Directors on which the director is a member are as follows: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="58pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Member<BR>
Annual<BR>
Fee </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Chairman<BR>
Incremental<BR>
Annual Fee </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Board of Directors</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>35,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>35,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(1)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Audit Committee</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Compensation Committee</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Nominating and Corporate Governance Committee</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,750</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,750</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Science and Technology Committee</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:15%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>In
the event co-chairmen are appointed, the retainer for Chairman of the Board will be divided equally between the co-chairmen.  </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
also reimburse our non-employee directors for reasonable travel and out-of-pocket expenses incurred in connection with attending our Board of Directors and committee meetings. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
February 2019, our Board of Directors adopted an amended non-employee director equity compensation program, effective as of January&nbsp;1, 2019. Under the amended non-employee
director equity compensation program, each new non-employee director elected to our Board of Directors receives an option to purchase 15,000 shares of our common stock, which option vests in equal
annual installments over a three-year period measured from the date of grant, subject to the director's continued service as a director. Further, on the date of the first Board of Directors meeting
held after each annual meeting of stockholders, each non-employee director that has served on our Board of Directors for at least six months will receive an option to purchase 7,500 shares of our
common stock. Each of these options will vest in full after a one-year period measured from the date of grant, subject to the director's continued service as a director. The exercise price of all
options granted to directors will equal the fair market value of our common stock on the date of grant. Options granted to non-employee directors become exercisable in full upon a change in control of
Catabasis. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
policy is intended to provide a total compensation package that enables us to attract and retain qualified and experienced individuals to serve as directors and to align our
directors' interests with those of our stockholders. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>17</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=20,EFW="2238509",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=469224,FOLIO='17',FILE='DISK121:[19ZAF1.19ZAF41201]DE41201A.;12',USER='CHE109858',CD='19-APR-2019;11:28' -->
<A NAME="page_de41201_1_18"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following table sets forth information regarding compensation earned by our non-employee directors during 2018. Dr.&nbsp;Ross resigned as a Class&nbsp;III director on
February&nbsp;14, 2019. Mr.&nbsp;Lapointe joined our Board of Directors in January 2019 and Dr.&nbsp;Beck joined our Board of Directors in February 2019. Dr.&nbsp;Milne is excluded from the
table because she is an executive officer, and her compensation is set forth in the compensation section below under the heading "Executive Compensation." </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="72pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name


<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Fees Earned or<BR>
Paid In Cash<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Option<BR>
Awards<BR>
($)(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Total<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Michael Ross, Ph.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>72,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>14,354</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>86,854</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Jean George</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>43,752</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>14,354</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>58,106</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Kenneth Bate</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>77,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>14,354</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>91,854</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Burt Adelman, M.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>45,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>14,354</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>59,354</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Michael Kishbauch</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>52,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>14,354</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>66,854</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:15%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
amounts included in the "Option Awards" column reflect the aggregate grant date fair value of awards granted during 2018 calculated in accordance with Financial
Accounting Standards Board, or FASB, Accounting Standard Codification, or ASC, Topic 718. Assumptions used in the calculation of these amounts are included in Note&nbsp;12 to the consolidated
financial statements included in our Annual Report on Form&nbsp;10-K previously filed with the SEC. As of December&nbsp;31, 2018:</FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Dr.&nbsp;Ross held stock options to purchase an aggregate of 3,809 shares of common stock, 2,409 shares of which were vested as of
December&nbsp;31, 2018. Dr&nbsp;Ross' non-vested options were cancelled as of his resignation on February&nbsp;14, 2019, the remainder of his options will expire three months subsequent to that
date to the extent that he does not exercise them. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Ms.&nbsp;George held stock options to purchase an aggregate of 3,809 shares of common stock, 2,409 shares of which were vested as of
December&nbsp;31, 2018; 1,400 of the shares are scheduled to vest on June&nbsp;7, 2019. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Mr.&nbsp;Bate held stock options to purchase an aggregate of 4,797 shares of common stock, 3,397 shares of which were vested as of
December&nbsp;31, 2018; 1,400 of the shares are scheduled to vest on June&nbsp;7, 2019. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Dr.&nbsp;Adelman held stock options to purchase an aggregate of 3,350 shares of common stock, 1,517 of which were vested as of
December&nbsp;31, 2018; 433 of the shares vested on April&nbsp;5, 2019; and 1,400 of the shares are scheduled to vest on June&nbsp;7, 2019. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Mr.&nbsp;Kishbauch held stock options to purchase an aggregate of 3,350 shares of common stock, 1,517 of which were vested as of
December&nbsp;31, 2018; 433 of the shares vested on April&nbsp;5, 2019; and 1,400 of the shares are scheduled to vest on June&nbsp;7, 2019.  </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>18</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=21,EFW="2238509",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=603918,FOLIO='18',FILE='DISK121:[19ZAF1.19ZAF41201]DE41201A.;12',USER='CHE109858',CD='19-APR-2019;11:28' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_dg41201_1_19"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41201a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="dg41201_executive_officers"> </A>
<A NAME="toc_dg41201_1"> </A>
<BR></FONT><FONT SIZE=2><B>  EXECUTIVE OFFICERS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth information regarding our executive officers as of April&nbsp;21, 2019: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="20pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="268pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Age </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Position(s) </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Jill C. Milne, Ph. D.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>51</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>President and Chief Executive Officer, Director</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Joanne Donovan, M.D., Ph. D.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>62</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Chief Medical Officer</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Andrew Nichols, Ph. D.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>58</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Chief Scientific Officer</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Deirdre A. Cunnane</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>54</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Chief Legal Officer and Treasurer</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
biography of Dr.&nbsp;Milne can be found under "Proposal 1&#151;Election of Class&nbsp;I Directors&#151;Information Regarding Directors." </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>Joanne M. Donovan, M.D., Ph.D.</I></B></FONT><FONT SIZE=2>, has served as our Chief Medical Officer since July 2011. Since 1989, she has worked as a staff physician
at the VA Boston Healthcare System, where she was formerly Chief of Gastroenterology. Dr.&nbsp;Donovan has held an appointment at Harvard Medical School since 1990, most recently as associate
clinical professor of medicine. From 1998 to July 2011, Dr.&nbsp;Donovan served in positions of increasing responsibility, ultimately as vice president of clinical development, at Genzyme, a
biotechnology company, which she joined through its acquisition of GelTex. Dr.&nbsp;Donovan holds a Ph.D. in medical engineering and medical physics from the Massachusetts Institute of Technology,
an M.D. from Harvard Medical School and an S.B. from the Massachusetts Institute of Technology. She completed residency training in internal medicine and a fellowship in gastroenterology at the
Brigham and Women's Hospital. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>Andrew Nichols, Ph.D.,</I></B></FONT><FONT SIZE=2> has served as our Chief Scientific Officer since October 2016. Previously, he served as our Senior Vice President,
Research and Development from February 2014 to October 2016. From October 2013 to February 2014, Dr.&nbsp;Nichols was Associate Vice President, Cardiometabolic Diseases at Merck Research Labs, a
pharmaceutical research company, leading drug discovery and early clinical development programs. Dr.&nbsp;Nichols was also Associate Vice President/Executive Director, In Vivo Pharmacology at Merck
Research Labs from August 2010 to October 2013, and Executive Director, In Vivo Sciences at Merck Research Labs from August 2009 to August 2010. Prior to Merck, Dr.&nbsp;Nichols was Vice President
of Preclinical Research at Zafgen, Vice President of Research at Alinea, Vice President of Drug Discovery Project Leadership at Millennium and Director of the Alliance Management Group at SmithKline
Beecham. He holds an M. Phil. and Ph.D. in Cardiovascular
Pharmacology from the University of Cambridge, England and a B.Sc. in Pharmacology from the University of Leeds, England. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>Deirdre A. Cunnane</I></B></FONT><FONT SIZE=2> has served as our Chief Legal Officer since February 2018 and as our Treasurer since April 2016. Previously, she served
as our Senior Vice President and General Counsel from November 2015 to February 2018. Prior to joining Catabasis, Ms.&nbsp;Cunnane served as General Counsel at Advanced Technology Ventures, or ATV,
from January 2006 to October 2015, and at Lightstone Ventures, or Lightstone, from its founding in January 2012 until October 2015. Prior to ATV and Lightstone, Ms.&nbsp;Cunnane was an investment
officer at BancBoston Ventures and Deputy General Counsel at BancBoston Capital. Ms.&nbsp;Cunnane started her law career with, and later became a Partner in, Goodwin Procter's corporate department.
Ms.&nbsp;Cunnane holds a J.D. from Boston College Law School and a B.S. in Finance from the Boston College School of Management. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>19</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=22,EFW="2238509",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=802911,FOLIO='19',FILE='DISK121:[19ZAF1.19ZAF41201]DG41201A.;8',USER='CHE105545',CD='18-APR-2019;16:37' -->
<A NAME="page_dg41201_1_20"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41201a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="dg41201_executive_compensation"> </A>
<A NAME="toc_dg41201_2"> </A>
<BR></FONT><FONT SIZE=2><B>  EXECUTIVE COMPENSATION    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This section describes the material elements of compensation awarded to, earned by or paid to each of our named executive officers, or NEOs. Our
NEOs for 2018 are Jill C. Milne, Joanne M. Donovan, and Andrew Nichols. This section also provides qualitative information regarding the manner and context in which compensation is awarded to and
earned by our executive officers and is intended to place in perspective the data presented in the tables and narrative that follow. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


2018 Summary Compensation Table  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth information regarding compensation earned in 2018 and 2017 by our NEOs. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:57%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"140%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="140%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="30pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="70pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="67pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name and Principal Position

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Salary<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Bonus<BR>
($)(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Option Awards<BR>
($)(2) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>All Other<BR>
Compensation<BR>
($)(3) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Total<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Jill C. Milne, Ph.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2018</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>476,132</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>349,259</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>309,085</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,693</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,136,169</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=2><I>President and Chief Executive Officer</I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2017</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>462,264</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>168,710</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,645</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>632,619</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Joanne M. Donovan, M.D., Ph.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
2018</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
411,440</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
256,347</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
157,568</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
1,732</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
827,087</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><I>Chief Medical Officer</I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2017</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>389,621</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>84,355</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,645</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>475,621</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Andrew Nichols, Ph.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
2018</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
357,204</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
198,770</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
157,568</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
1,732</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
715,274</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=2><I>Chief Scientific Officer</I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2017</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>346,800</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>84,355</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,645</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>432,800</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
amounts reported in the "Bonus" column represent discretionary cash bonuses awarded to our NEOs.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
amounts reported in the "Option Awards" column reflect the aggregate grant date fair value of share-based compensation awarded during the year computed in
accordance with the provisions of FASB ASC Topic 718. See Note&nbsp;12 to the consolidated financial statements included in our Annual Report on Form&nbsp;10-K previously filed with the SEC.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
amounts reported in the "All Other Compensation" column reflect, for each NEO, the cost to us of life insurance premiums paid for the NEO.  </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Narrative to Summary Compensation Table  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We review compensation annually for all employees, including our executives. In setting executive base salaries and bonuses and granting equity
incentive awards, we consider compensation for comparable positions in the market, the historical compensation levels of our executives, individual performance as compared to our expectations and
objectives, our desire to motivate our employees to achieve short- and long-term results that are in the best interests of our stockholders, and a long-term commitment to our company. We do not target
a specific competitive position or a specific mix of compensation among base salary, bonus or long-term incentives. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
Chief Executive Officer typically proposes base salary, target bonuses, and equity incentive compensation for members of our executive team (excluding herself) to the compensation
committee. Her proposals are based on the Company's pay philosophy and methodology and in-line with executive compensation for similarly situated executives at peer companies. Our compensation
committee then typically reviews and discusses the proposals with the Chief Executive Officer for all executives other than the Chief Executive Officer. The compensation committee, without the
applicable members of management present, further discusses the Chief Executive Officer's recommendations and ultimately recommends for our Board of Directors' approval the base salary, target bonuses
and equity incentive compensation of our executive officers for the current year, as well as the amount of executive officer </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>20</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=23,EFW="2238509",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=987766,FOLIO='20',FILE='DISK121:[19ZAF1.19ZAF41201]DG41201A.;8',USER='CHE105545',CD='18-APR-2019;16:37' -->
<A NAME="page_dg41201_1_21"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>cash
bonuses for the prior year, based on the attainment of corporate and individual goals. The Chief Executive Officer is not present during voting or deliberations regarding her compensation by the
compensation committee or the Board of Directors. During 2018, our compensation committee engaged Radford as its independent compensation consultant, to review our executive compensation peer group
and program design and assess our executives' compensation relative to comparable companies. See "Corporate Governance&#151;Committees of the Board of Directors&#151;Compensation
Committee" for more information about the engagement of Radford by the compensation committee. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Base salary.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;In 2018, we paid annual base salaries to Dr.&nbsp;Milne, Dr.&nbsp;Donovan and Dr.&nbsp;Nichols in the amounts of $476,132,
$411,440, and $357,204, respectively. These 2018 annual base salaries reflected a market-based merit increase from 2017 of 3%, and an additional market adjustment of 2.6% for Dr.&nbsp;Donovan. These
base salaries were determined using a competitive assessment of similarly situated executives at our peer companies to make them competitive with the 50<SUP>th</SUP>&nbsp;percentile, as well as
to address customary annual base salary increases and to recognize their individual performance. We use base salaries to recognize the experience, skills, knowledge and responsibilities required of
all our employees, including our NEOs. None of our NEOs is currently party to an employment agreement or other agreement or arrangement that provides for automatic or scheduled increases in base
salary. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Bonuses.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Our Board of Directors may, in its discretion, award bonuses to our NEOs from time to time. We typically establish annual
bonus targets
based around a set of specified corporate goals for our NEOs, along with individual goals, and conduct an annual performance review to determine the attainment of such goals. Our compensation
committee recommends, and our Board approves, target percentages of annual base salary for our NEOs based on target percentages for similar executives at our peer companies to make these percentages
competitive with the 50<SUP>th</SUP>&nbsp;percentile, which for 2018 were 50%, 40% and 40% for Drs. Milne, Donovan and Nichols, respectively. Our management may propose bonus awards to the
compensation committee or the Board of Directors primarily based on such review process and such target percentages. Our compensation committee makes a recommendation to the Board of Directors
regarding eligibility requirements for and the amount of such bonus awards. With respect to 2018, we paid annual bonuses to Drs. Milne, Donovan or Nichols, in the amounts of $214,259, $156,347, and
$118,770, respectively. Drs. Milne, Donovan and Nichols were not awarded or paid 2017 annual bonuses in order to reduce cash expenditures. However, in September 2018, after our June 2018 financing, we
paid special incentive bonuses to Drs. Milne, Donovan or Nichols, in the amounts of $135,000, $100,000, and $80,000, respectively. Our Board of Directors awarded these special incentive bonuses
because they believe that our future success depends, in large part, upon our ability to maintain a competitive position in attracting, retaining and motivating persons who are expected to make
important contributions to our company by providing such persons with competitive compensation. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Equity incentives.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Although we do not have a formal policy with respect to the grant of equity incentive awards to our executive
officers, or any
formal equity ownership guidelines applicable to them, we believe that equity grants provide our executives with a strong link to our long-term performance, create an ownership culture and help to
align the interests of our executives and our stockholders. In addition, we believe that equity grants with a time-based vesting feature promote executive retention
because this feature incentivizes our executive officers to remain in our employment during the vesting period. Accordingly, we typically grant stock option awards at the start of employment to each
executive officer and our other employees and our compensation committee and Board of Directors periodically review the equity incentive compensation of our NEOs and other employees and from time to
time may grant equity incentive awards to them in the form of stock options. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
2018, our Board of Directors granted options to purchase 23,000, 10,000 and 10,000 shares of our common stock to Drs.&nbsp;Milne, Donovan and Nichols, respectively, as part of a
review of their </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>21</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=24,EFW="2238509",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=480427,FOLIO='21',FILE='DISK121:[19ZAF1.19ZAF41201]DG41201A.;8',USER='CHE105545',CD='18-APR-2019;16:37' -->
<A NAME="page_dg41201_1_22"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>overall
annual compensation. Our Board of Directors granted additional special incentive options to purchase 23,000, 15,000 and 15,000 shares of our common stock to Dr.&nbsp;Milne,
Dr.&nbsp;Donovan and Dr.&nbsp;Nichols, respectively, in September 2018. For grants in connection with initial employment, vesting begins on the initial date of employment. Time vested stock option
grants to our executives and other employees typically vest 25% on the first anniversary of grant or, in the case of new hire grants, the initial employment date, if earlier, and 2.0833% per month
thereafter, through the fourth anniversary of the vesting commencement date, and have a term of 10&nbsp;years from the grant date. The special incentive options granted in September 2018 are subject
to vesting over a two-year period, with 50% of the shares vesting on the first anniversary of grant and the remainder vesting at a rate of 4.1667% per month thereafter, through the second anniversary
of the vesting commencement date, and have a term of 10&nbsp;years from the grant date. The exercise price of all options is equal to the fair market value of our common stock on the date of grant.
We granted the special incentive options to Drs. Milne, Donovan and Nichols described above because their outstanding incentive equity holdings were significantly diluted by our June 2018 financing.
Following the June 2018 financing, 100% of the outstanding stock options of the Company held by Drs. Milne, Donovan and Nichols were underwater. The special incentive options were granted in order to
provide Drs. Milne, Donovan and Nichols with the opportunity to participate in the future appreciation in the value of our common stock and create retention value. These special incentive option
grants are consistent with our compensation philosophy and core objectives of aligning the interests of employees with those of stockholders. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>22</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=25,EFW="2238509",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=365943,FOLIO='22',FILE='DISK121:[19ZAF1.19ZAF41201]DG41201A.;8',USER='CHE105545',CD='18-APR-2019;16:37' -->
<A NAME="page_dg41201_1_23"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Outstanding Equity Awards at 2018 Fiscal Year End Table  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth information regarding outstanding stock options held by our NEOs as of December&nbsp;31, 2018. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="58pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="65pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=11 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Option Awards </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
Securities<BR>
Underlying<BR>
Unexercised<BR>
Options (#)<BR>
Exercisable </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
Securities<BR>
Underlying<BR>
Unexercised<BR>
Options (#)<BR>
Unexercisable </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Option<BR>
Exercise<BR>
Price<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Option<BR>
Expiration<BR>
Date </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Jill C. Milne, Ph.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>8,427</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>16.70</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2/28/2021</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,229</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>23.10</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12/17/2022</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,247</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>23.10</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12/17/2022</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,860</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>23.10</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4/16/2023</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,836</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>68.10</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3/18/2024</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>876</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>57</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(1)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>110.50</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3/25/2025</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>13,670</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,330</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(2)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>140.50</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7/16/2025</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7,304</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,996</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(3)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>45.70</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2/10/2026</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,537</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,963</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(4)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>43.10</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>9/7/2026</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>9,172</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>10,828</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(5)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12.40</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2/8/2027</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>23,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(6)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12.80</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2/7/2028</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>23,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(7)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7.10</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>9/6/2028</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Joanne M. Donovan, M.D., Ph.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
2,723</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
19.30</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
9/6/2021</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>720</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>23.10</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12/17/2022</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,049</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>23.10</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12/17/2022</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,458</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>23.10</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12/17/2022</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,430</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>23.10</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4/16/2023</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,529</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>68.10</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3/18/2024</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>437</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>29</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(1)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>110.50</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3/25/2025</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,682</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,918</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(3)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>45.70</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2/10/2026</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,538</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,962</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(4)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>43.10</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>9/7/2026</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,588</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,412</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(5)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12.40</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2/8/2027</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>10,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(6)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12.80</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2/7/2028</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>15,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(7)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7.10</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>9/6/2028</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Andrew Nichols, Ph.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
5,836</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
68.10</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
3/18/2024</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>257</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>15</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(1)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>110.50</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3/25/2025</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>682</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>96</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(8)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>110.50</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4/29/2025</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,844</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>756</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(3)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>45.70</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2/10/2026</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,255</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,745</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(4)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>43.10</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>9/7/2026</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>705</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>595</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(9)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>57.90</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>10/2/2026</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,588</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,412</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(5)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12.40</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2/8/2027</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>10,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(6)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12.80</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2/7/2028</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>15,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(7)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7.10</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>9/6/2028</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
unvested awards had vested in full as of March&nbsp;26, 2019.  </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
unvested awards are scheduled to vest in equal monthly installments through July&nbsp;8, 2019.  </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
unvested awards are scheduled to vest in equal monthly installments through February&nbsp;11, 2020.  </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(4)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
unvested awards are scheduled to vest in equal monthly installments through September&nbsp;8, 2020. </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>23</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=26,EFW="2238509",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=490564,FOLIO='23',FILE='DISK121:[19ZAF1.19ZAF41201]DG41201A.;8',USER='CHE105545',CD='18-APR-2019;16:37' -->
<A NAME="page_dg41201_1_24"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41201a_main_toc">Table of Contents</A></FONT></P>
 <DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(5)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
unvested awards are scheduled to vest in equal monthly installments through February&nbsp;9, 2021.  </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(6)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>25%
of the unvested awards vested on February&nbsp;7, 2019. The remaining unvested awards will vest in equal monthly installments through February&nbsp;8, 2022. </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(7)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>50%
of the unvested awards are scheduled to vest on September&nbsp;6, 2019. The remaining unvested awards will vest in equal monthly installments through
September&nbsp;6, 2020.  </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(8)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
unvested awards are scheduled to vest in equal monthly installments through June&nbsp;1, 2019.  </FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(9)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
unvested awards are scheduled to vest in equal monthly installments through October&nbsp;3, 2020.  </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Employment Agreements, Severance and Change in Control Arrangements  </I></B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2><B>Employment Agreements with NEOs</B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have entered into an employment agreement with Dr.&nbsp;Milne, dated as of April&nbsp;7, 2010. The employment agreement confirms Dr.&nbsp;Milne's title, compensation
arrangements and eligibility for benefits made available to employees generally. The employment agreement with Dr.&nbsp;Milne provides that she is eligible to receive an annual cash bonus, as
determined by the Board of Directors in its sole discretion, with a target of 40% of her annual base salary earned in such particular calendar year, which percentage shall be subject to adjustment
from time to time by the Board of Directors in its sole discretion. The Board of Directors has approved for 2019 a target cash bonus (expressed as a percentage of base salary) of up to 50% for
Dr.&nbsp;Milne based on its assessment of the Company's performance against established annual goals. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Board of Directors has approved for 2019 a target cash bonus of up to 40% of annual base salary for each of Dr.&nbsp;Donovan and for Dr.&nbsp;Nichols, as determined in the sole
discretion of the Board of Directors, based on its assessment of their respective performance and that of Catabasis against established annual goals. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
of Drs. Milne, Donovan and Nichols is an employee at will and is entitled to certain benefits upon termination pursuant to our Severance Benefits Plan, or the Severance Plan, which
was adopted by the Board of Directors in April 2016, as further described below. In connection with the adoption of the Severance Plan, each of Drs. Milne, Donovan and Nichols has acknowledged that
their entitlement to severance benefits is governed by the terms of the Severance Plan and that any terms of their employment agreement or offer letter, as applicable, relating to severance have been
superseded in their entirety by the terms of the Severance Plan. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Severance Plan  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Severance Plan provides eligible full time executives holding the title of vice president or above ("Covered Employees") certain severance
benefits upon a termination without cause (as defined in the Severance Plan) or a resignation for good reason (as defined in the Severance Plan), including in each case within one year following a
change in control (as defined in the Severance Plan) (each, a "Covered Termination"). Pursuant to the Severance Plan, each Covered Employee who is subject to a Covered Termination is entitled
to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> continuation of such Covered Employee's monthly base salary (as defined in the Severance Plan) for a period ranging from six months to
18&nbsp;months (the "Severance Period") following such termination depending on the title/role of the Covered Employee and the type of Covered Termination; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> payment by Catabasis of a portion of the cost of COBRA continuation of benefits coverage for the Covered Employee and his or her applicable
dependents for no longer than the Covered Employee's applicable Severance Period or until the Covered Employee commences new employment and is eligible for new plan coverage, if sooner, subject to
certain conditions set forth in the Severance Plan; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>24</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=27,EFW="2238509",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=910927,FOLIO='24',FILE='DISK121:[19ZAF1.19ZAF41201]DG41201A.;8',USER='CHE105545',CD='18-APR-2019;16:37' -->
<A NAME="page_dg41201_1_25"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41201a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> any unpaid annual bonus in respect to any completed bonus period which has ended prior to the date of the Covered Employee's Covered
Termination and which the Board of Directors deems granted to the Covered Employee in its discretion pursuant to Catabasis' contingent compensation program; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> in the case of the chief executive officer of Catabasis, a bonus amount equal to one-half of the average annual bonus paid to the chief
executive officer over the three calendar years preceding the calendar year in which the Covered Termination occurs, which bonus shall be prorated to reflect the number of days served in the calendar
year in which such Covered Termination occurs; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> in the case of a change in control termination, full vesting of any unvested equity awards. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Receipt
of any severance benefits under the Severance Plan requires that the Covered Employee: (a)&nbsp;comply with the provisions of any applicable noncompetition, nonsolicitation,
and other obligations
to us; and (b)&nbsp;execute and deliver a suitable waiver and release under which the Covered Employee releases and discharges us and our affiliates from and on account of any and all claims that
relate to or arise out of the employment relationship between us and the Covered Employee, which release will become binding within 60&nbsp;days following the Covered Employee's termination of
employment. If a Covered Employee dies following a Covered Termination but before such Covered Employee has received all of the severance benefits to which such Covered Employee is entitled under the
Severance Plan, the remaining payments will be made to the Covered Employee's designated beneficiary or estate. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Severance Plan provides that the following employees will not be eligible for severance benefits, except to the extent specifically determined otherwise by the Severance Plan's
administrator:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> an employee who is terminated for cause (as defined in the Severance Plan); </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> an employee who retires, terminates employment as a result of an inability to perform his or her duties due to physical or mental disability or
dies; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> an employee who voluntarily terminates his or her employment, except in the case of a Covered Termination for good reason (as defined in the
Severance Plan); </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> an employee who is employed for a specific period of time in accordance with the terms of a written employment agreement; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> an employee who promptly becomes employed by another member of the controlled group of entities of which Catabasis (or its successor in the
change in control (as defined in the Severance Plan)) is a member as defined in Sections&nbsp;414(b) and (c)&nbsp;of the Internal Revenue Code of 1986, as amended. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Severance Plan provides for recoupment of severance benefits under specified circumstances if the Covered Employee fails to comply with the terms of the Severance Plan. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Severance Plan supersedes (i)&nbsp;existing severance plans and separation policies applying to Covered Employees with respect to any termination that would constitute a Covered
Termination and (ii)&nbsp;the provisions of any agreements between any Covered Employee and us that provide for severance benefits. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>25</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=28,EFW="2238509",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=209948,FOLIO='25',FILE='DISK121:[19ZAF1.19ZAF41201]DG41201A.;8',USER='CHE105545',CD='18-APR-2019;16:37' -->
<A NAME="page_dg41201_1_26"> </A>


<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following table summarizes the schedule of severance payments our NEOs would receive, assuming a qualifying termination occurred on December&nbsp;31, 2018. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:73%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"110%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="110%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="47pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="79pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Cash<BR>
Severance<BR>
($)(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Bonus<BR>
($)(2) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>COBRA<BR>
Continuation<BR>
($)(3) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Value of<BR>
Accelerated<BR>
Vesting of Equity<BR>
Awards<BR>
($)(4) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Total<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=2><I>Jill C. Milne, Ph.D.</I></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Termination without cause or upon resignation with good reason</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>476,132</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>62,902</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>23,733</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>562,767</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Termination upon a change in control</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>714,198</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>62,902</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>35,600</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>812,700</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><I>Joanne M. Donovan, M.D., Ph.D.</I></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Termination without cause or upon resignation with good reason</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>411,440</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>23,733</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>435,173</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Termination upon a change in control</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>411,440</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>23,733</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>435,173</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=2><I>Andrew Nichols, Ph.D.</I></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Termination without cause or upon resignation with good reason</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>357,204</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>23,733</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>380,937</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Termination upon a change in control</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>357,204</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>23,733</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>380,937</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>These
amounts represent, in the case of Dr.&nbsp;Milne, 12&nbsp;months' base salary for a termination without cause or resignation with good reason and
18&nbsp;months' base salary for a termination upon a change of control; and, in the case of Dr.&nbsp;Donovan and Dr.&nbsp;Nichols, 12&nbsp;months' base salary; each at the rate in effect
immediately prior to the executive's termination of employment.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>These
amounts represent 50% of the average performance bonus received by Dr.&nbsp;Milne for the three most recently completed years.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>These
amounts represent paid health coverage for 12&nbsp;months and, in the case of Dr.&nbsp;Milne for a change in control termination, 18&nbsp;months' paid
health coverage.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(4)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
values of accelerated vesting of equity awards included in the table above are based on the intrinsic values of such unvested awards on December&nbsp;31, 2018
(i.e.,&nbsp;the difference between the closing price of our common stock on the Nasdaq Global Market on that date and the exercise price multiplied by the number of shares for which vesting would
have been accelerated). The closing price of our common stock on December&nbsp;31, 2018 was below the exercise price of all equity awards held by our NEOs.  </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have also entered into employee confidentiality, non-competition and proprietary information agreements with each of our NEOs. Under the employee confidentiality, non-competition and
proprietary information agreements, each NEO has agreed (1)&nbsp;not to compete with us during his or her employment and for a period of 18&nbsp;months after the termination of his or her
employment, (2)&nbsp;not to solicit our employees during his or her employment and for a period of 18&nbsp;months after the termination of his or her employment, (3)&nbsp;to protect our
confidential and proprietary information and (4)&nbsp;to assign to us related intellectual property developed during the course of his or her employment. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


401(k) retirement plan  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We maintain a 401(k) retirement plan that is intended to be a tax-qualified defined contribution plan under Section&nbsp;401(k) of the
Internal Revenue Code. In general, all of our employees are eligible to participate, beginning on the first day of the month following commencement of their employment. The 401(k) plan includes a
salary deferral arrangement pursuant to which
participants may elect to reduce their current compensation by up to the statutorily prescribed limit, equal to $18,500 in 2018, and have the amount of the reduction contributed to the 401(k) plan.
Participants over the age of 50 are entitled to an additional catch-up contribution up to the statutorily prescribed limit, equal to $6,000 in 2018. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>26</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=29,EFW="2238509",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=503400,FOLIO='26',FILE='DISK121:[19ZAF1.19ZAF41201]DG41201A.;8',USER='CHE105545',CD='18-APR-2019;16:37' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_di41201_1_27"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41201a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="di41201_certain_relationships___di402225"> </A>
<A NAME="toc_di41201_1"> </A>
<BR></FONT><FONT SIZE=2><B>  CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following is a description of transactions since January&nbsp;1, 2018 to which we have been a party, and in which any of our directors,
executive officers or beneficial owners of more than 5% of our voting securities, or affiliates or immediate family members of any of our directors, executive officers or beneficial owners of more
than 5% of our voting securities, had or will have a direct or indirect material interest. We believe the terms obtained or consideration that we paid or received, as applicable, in connection with
the transactions described below were comparable to terms available or the amounts that would be paid or received, as applicable, from unrelated third parties. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Employment, Severance and Change in Control Agreements  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;See "Executive Compensation&#151;Employment Agreements, Severance and Change in Control Arrangements" above for a discussion of these
arrangements. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Indemnification of Officers and Directors  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our certificate of incorporation provides that we will indemnify our directors and officers to the fullest extent permitted by Delaware law. In
addition, we have entered into indemnification agreements with each of our directors and executive officers that may be broader in scope than the specific indemnification provisions contained in the
Delaware General Corporation Law. These indemnification agreements require us, among other things, to indemnify each such director and executive officer for some expenses, including attorneys' fees,
judgments, fines and settlement amounts incurred by him or her in any action or proceeding arising out of his or her service as one of our directors or executive officers. In addition, we maintain
standard policies of insurance under which coverage is provided to our directors and officers against losses arising from claims made by reason of breach of duty or other wrongful act, and to us with
respect to payments which may be made by us to such directors and officers pursuant to the above indemnification provisions or otherwise as a matter of law. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Policies and Procedures for Related Person Transactions  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Board of Directors has adopted a written related person transaction policy to set forth policies and procedures for the review and approval
or ratification of related person transactions. This policy covers any transaction, arrangement or relationship, or any series of similar transactions, arrangements or relationships, in which we were
or are to be a participant, the amount involved exceeds $120,000, and a related person had or will have a direct or indirect material interest, including, without limitation, purchases of goods or
services by or from the related person or entities in which the related person has a material interest, indebtedness, guarantees of indebtedness and employment by us of a related person. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
related person transaction policy contains exceptions for any transaction or interest that is not considered a related person transaction under SEC rules as in effect from time to
time. In addition, the
policy provides that an interest arising solely from a related person's position as an executive officer of another entity that is a participant in a transaction with us will not be subject to the
policy if each of the following conditions is met:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the related person and all other related persons own in the aggregate less than a 10% equity interest in such entity; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the related person and his or her immediate family members are not involved in the negotiation of the terms of the transaction with us and do
not receive any special benefits as a result of the transaction; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the amount involved in the transaction equals less than the greater of $200,000 or 5% of the annual gross revenue of the company receiving
payment under the transaction. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>27</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=30,EFW="2238509",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=745821,FOLIO='27',FILE='DISK121:[19ZAF1.19ZAF41201]DI41201A.;6',USER='CHE105545',CD='18-APR-2019;16:37' -->
<A NAME="page_di41201_1_28"> </A>


<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
policy provides that any related person transaction proposed to be entered into by us must be reported to our chief legal officer or chief financial officer and will be reviewed and
approved by our audit committee in accordance with the terms of the policy, prior to effectiveness or consummation of the transaction whenever practicable. The policy provides that if our chief legal
officer or chief financial officer determines that advance approval of a related person transaction is not practicable under the circumstances, our audit committee will review and, in its discretion,
may ratify the related person transaction at the next meeting of the audit committee. The policy also provides that alternatively, our chief legal officer or chief financial officer may present a
related person transaction arising in the time period between meetings of the audit committee to the chair of the audit committee, who will review and may approve the related person transaction,
subject to ratification by the audit committee at the next meeting of the audit committee. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, the policy provides that any related person transaction previously approved by the audit committee or otherwise already existing that is ongoing in nature will be reviewed
by the audit committee annually to ensure that such related person transaction has been conducted in accordance
with the previous approval granted by the audit committee, if any, and that all required disclosures regarding the related person transaction are made. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
policy provides that transactions involving compensation of executive officers will be reviewed and approved by our compensation committee in the manner to be specified in the
charter of the compensation committee. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
related person transaction reviewed under this policy will be considered approved or ratified if it is authorized by the audit committee in accordance with the standards set forth in
the policy after full disclosure of the related person's interests in the transaction. As appropriate for the circumstances, the policy provides that the audit committee will review and
consider:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the related person's interest in the related person transaction; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the approximate dollar value of the amount involved in the related person transaction; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the approximate dollar value of the amount of the related person's interest in the transaction without regard to the amount of any profit or
loss; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> whether the transaction was undertaken in the ordinary course of business of our company; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> whether the transaction with the related person is proposed to be, or was, entered into on terms no less favorable to us than the terms that
could have been reached with an unrelated third party; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the purpose of, and the potential benefits to us of, the transaction; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> any other information regarding the related person transaction or the related person in the context of the proposed transaction that would be
material to investors in light of the circumstances of the particular transaction. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
policy provides that the audit committee will review all relevant information available to it about the related person transaction. The policy provides that the audit committee may
approve or ratify the related person transaction only if the audit committee determines that, under all of the circumstances, the transaction is in, or is not inconsistent with, our best interests.
The policy provides that the audit committee may, in its sole discretion, impose such conditions as it deems appropriate on us or the related person in connection with approval of the related person
transaction. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>28</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=31,EFW="2238509",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=799283,FOLIO='28',FILE='DISK121:[19ZAF1.19ZAF41201]DI41201A.;6',USER='CHE105545',CD='18-APR-2019;16:37' -->
<A NAME="page_di41201_1_29"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41201a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="di41201_proposal_no._2_#151;ratificati__pro06296"> </A>
<A NAME="toc_di41201_2"> </A>
<BR></FONT><FONT SIZE=2><B>  PROPOSAL NO. 2&#151;RATIFICATION OF THE APPOINTMENT OF ERNST&nbsp;&amp; YOUNG&nbsp;LLP AS<BR>  CATABASIS' INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE<BR>  FISCAL YEAR ENDING DECEMBER 31, 2019    <BR>
</B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our stockholders are being asked to ratify the appointment by the audit committee of the Board of Directors of Ernst&nbsp;&amp; Young&nbsp;LLP
as our independent registered public accounting firm. Ernst&nbsp;&amp; Young&nbsp;LLP has served as the company's independent registered public accounting firm since 2010. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
audit committee is solely responsible for selecting our independent registered public accounting firm for the fiscal year ending December&nbsp;31, 2019. Stockholder approval is not
required to appoint Ernst&nbsp;&amp; Young&nbsp;LLP as our independent registered public accounting firm. However, the Board of
Directors believes that submitting the appointment of Ernst&nbsp;&amp; Young&nbsp;LLP to the stockholders for ratification is good corporate governance. If the stockholders do not ratify this
appointment, the audit committee will reconsider whether to retain Ernst&nbsp;&amp; Young&nbsp;LLP. If the selection of Ernst&nbsp;&amp; Young&nbsp;LLP is ratified, the audit committee, in its
discretion, may direct the appointment of a different independent registered public accounting firm at any time it decides that such a change would be in the best interest of Catabasis and its
stockholders. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
representative of Ernst&nbsp;&amp; Young&nbsp;LLP is expected to be present at the Annual Meeting and will have an opportunity to make a statement if he or she desires to do so and to
respond to appropriate questions from our stockholders. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following table summarizes the fees Ernst&nbsp;&amp; Young&nbsp;LLP, our independent registered public accounting firm, billed to us for each of the last two fiscal years. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year Ended December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2018 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Audit Fees(1)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>560,700</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>438,478</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Audit-Related Fees(2)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Tax Fees(3)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11,730</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11,220</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>All Other Fees(4)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151; </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>572,430</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>449,698 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:15%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Audit
fees consist of fees billed for professional services performed by Ernst&nbsp;&amp; Young&nbsp;LLP for the audit of our annual consolidated financial
statements, the review of interim consolidated financial statements, and related services that are normally provided in connection with registration statements.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Audit-related
fees may consist of fees billed by an independent registered public accounting firm for assurance and related services that are reasonably related to
the performance of the audit or review of our consolidated financial statements. There were no such fees incurred in 2018 or 2017.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Tax
fees may consist of fees for professional services, including tax consulting and compliance performed by an independent registered public accounting firm.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(4)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>There
were no such fees incurred in 2018 or 2017.  </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
such accountant services and fees for 2018 were pre-approved by our audit committee in accordance with the "Pre-Approval Policies and Procedures" described below. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>29</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=32,EFW="2238509",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=75313,FOLIO='29',FILE='DISK121:[19ZAF1.19ZAF41201]DI41201A.;6',USER='CHE105545',CD='18-APR-2019;16:37' -->
<A NAME="page_di41201_1_30"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41201a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Pre-approval Policy and Procedures  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Board of Directors adopted policies and procedures for the pre-approval of audit and non-audit services for the purpose of maintaining the
independence of our independent auditor. We may not engage our independent auditor to render any audit or non-audit service unless either the service is approved in advance by the audit committee, or
the engagement to render the service is entered into pursuant to the audit committee's pre-approval policies and procedures. Notwithstanding the foregoing, pre-approval is not required with respect to
the provision of services, other than audit, review or attest services, by the independent auditor if the aggregate amount of all such services is no more than 5% of the total amount paid by us to the
independent auditor during the fiscal year in which the services are provided, such services were not recognized by us at the time of the engagement to be non-audit services and such services are
promptly brought to the attention of the audit committee and approved prior to completion of the audit by the audit committee. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;From
time to time, our audit committee may pre-approve services that are expected to be provided to us by the independent auditor during the following 12&nbsp;months. At the time such
pre-approval is granted, the audit committee must identify the particular pre-approved services in a sufficient level of detail so that our management will not be called upon to make a judgment as to
whether a proposed service fits within the pre-approved services and, at each regularly scheduled meeting of the audit committee following such approval, management or the independent auditor shall
report to the audit committee regarding each service actually provided to us pursuant to such pre-approval. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During
our 2018 fiscal year, no services were provided to us by Ernst&nbsp;&amp; Young&nbsp;LLP or any other accounting firm other than in accordance with the pre-approval policies and
procedures described above. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Recommendation of the Board of Directors  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><B>OUR BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT THE STOCKHOLDERS VOTE FOR THE RATIFICATION OF ERNST&nbsp;&amp;
YOUNG&nbsp;LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM.</B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>30</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=33,EFW="2238509",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=487493,FOLIO='30',FILE='DISK121:[19ZAF1.19ZAF41201]DI41201A.;6',USER='CHE105545',CD='18-APR-2019;16:37' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_dk41201_1_31"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41201a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="dk41201_principal_stockholders"> </A>
<A NAME="toc_dk41201_1"> </A>
<BR></FONT><FONT SIZE=2><B>  PRINCIPAL STOCKHOLDERS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth information, to the extent known by us or ascertainable from public filings, with respect to the beneficial
ownership of our common stock as of April&nbsp;17, 2019 by:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> each person, or group of affiliated persons, who is known by us to beneficially own more than 5% of our common stock; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> each of our directors and our director nominees; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> each of our NEOs; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> all of our current directors and executive officers as a group. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Beneficial
ownership is determined in accordance with the rules and regulations of the SEC. These rules generally attribute beneficial ownership of securities to persons who possess sole
or shared voting power or investment power with respect to those securities and include shares of common stock issuable upon the exercise of stock options that are immediately exercisable or
exercisable within 60&nbsp;days after April&nbsp;17, 2019. Except as otherwise indicated, all of the shares reflected in the table are shares of common stock and all persons listed below have sole
voting and investment power with respect to the shares beneficially owned by them, subject to community property laws, where applicable. The information is not necessarily indicative of beneficial
ownership for any other purpose. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
percentage ownership calculations for beneficial ownership are based on 11,498,742 shares of common stock outstanding as of April&nbsp;17, 2019. Except as otherwise indicated in
the table below, addresses of named beneficial owners are in care of Catabasis Pharmaceuticals,&nbsp;Inc., One Kendall Square, Building 1400E, Suite B14202, Cambridge, MA 02139. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
computing the number of shares of common stock beneficially owned by a person and the percentage ownership of that person, we deemed outstanding shares of common stock subject to
options held by that person that are currently exercisable or exercisable within 60&nbsp;days after April&nbsp;17, 2019. We did not deem these shares outstanding, however, for the purpose of
computing the percentage ownership of any other person. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="63pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name of Beneficial Owner

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
Shares<BR>
Beneficially<BR>
Owned </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Percentage of<BR>
Shares<BR>
Beneficially<BR>
Owned </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B><I>5% Stockholders</I></B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Affiliates of Federated Investment Management Company(1)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,043,400</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>9.1</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Affiliates of Stonepine Capital Management,&nbsp;LLC(2)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>758,333</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6.6</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Affiliates of Armistice Capital,&nbsp;LLC(3)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>585,185</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5.1</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Affiliates of Corriente Advisors,&nbsp;LLC(4)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>603,129</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5.2</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:11pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B><I>NEOs and Directors</I></B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Jill C. Milne, Ph.D.(5)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>96,493</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Joanne M. Donovan, Ph.D., M.D.(6)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>29,197</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Andrew Nichols, Ph.D.(7)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>21,852</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Burt Adelman, M.D.(8)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,350</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Kenneth Bate(9)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,797</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Jean George(10)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>192,894</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.7</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Michael D. Kishbauch(11)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,350</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Gregg LaPointe</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Joanne Beck</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>All current executive officers and directors as a group (10 persons)(12)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>370,260</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3.2</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>*</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Represents
beneficial ownership of less than 1% of our outstanding stock. </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>31</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=34,EFW="2238509",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=213879,FOLIO='31',FILE='DISK121:[19ZAF1.19ZAF41201]DK41201A.;9',USER='CHE105545',CD='18-APR-2019;16:37' -->
<A NAME="page_dk41201_1_32"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41201a_main_toc">Table of Contents</A></FONT></P>
 <DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Consists
of 1,043,400 shares of common stock beneficially owned by registered investment companies and separate accounts advised by subsidiaries of Federated
Investors,&nbsp;Inc. ("Federated") that have been delegated the power to direct investment and power to vote the securities by the registered investment companies' board of trustees or directors and
by the separate accounts' principals. All of the voting securities of Federated are held in the Voting Shares Irrevocable Trust ("Trust"), the trustees of which are Thomas R. Donahue, Rhodora J.
Donahue and J. Christopher Donahue (collectively, the "Trustees"). Federated and the Trust each reported sole voting and dispositive power, and the Trustees reported shared voting and dispositive
power, with respect to the shares of common stock owned by the registered investment companies and separate accounts advised by subsidiaries of Federated, however they expressly disclaimed that they
were the beneficial owners of such shares. The address for each of the foregoing persons and entities is Federated Investors Tower, Pittsburgh, PA 15222-3779. The foregoing information is based on a
Schedule&nbsp;13G filed with the SEC on February&nbsp;13, 2019 that reported beneficial ownership as of December&nbsp;31, 2018.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Consists
of 758,333 shares of common stock with respect to which each of Stonepine Capital,&nbsp;L.P. (the "Partnership"), Stonepine Capital Management,&nbsp;LLC
(the "General Partner"), Jon M. Plexico and Timothy P. Lynch reported sole voting and dispositive power. The warrants are subject to a limitation on exercise that does not permit the exercise of such
warrants to the extent that the Partnership and certain related persons and entities would beneficially own after any such exercise more than 9.99% of the outstanding shares of common stock, which
limitation did not limit the exercisability of such warrants as of the date of such report. The General Partner is the general partner and investment adviser the Partnership and Mr.&nbsp;Plexico and
Mr.&nbsp;Lynch are the control persons of the General Partner. Each of the foregoing persons and entities disclaimed membership in a group and disclaimed beneficial ownership of the shares except to
the extent of that entity's or person's pecuniary interest therein. The address for each of the foregoing persons and entities is 919 NW Bond Street, Suite&nbsp;204, Bend, OR 97703. The foregoing
information is based on a Schedule&nbsp;13G filed with the SEC on February&nbsp;13, 2019 that reported beneficial ownership as of December&nbsp;31, 2018.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Consists
of 585,185 shares of common stock with respect to which each of Armistice Capital,&nbsp;LLC ("Armistice"), Armistice Capital Master Fund&nbsp;Ltd.
("Armistice Master Fund") and Steven Boyd reported shared voting and dispositive power. Steve Boyd is a managing member of Armistice and a director of Armistice Master Fund. Each of Armistice and
Mr.&nbsp;Boyd disclaimed beneficial ownership in such shares of common stock except to the extent of his or its pecuniary interest therein. The address for Armistice and Steve Boyd is 510 Madison
Avenue, 22<SUP>nd</SUP>&nbsp;Floor, New York, NY 10022. The address for Armistice Master Fund is 20 Genesis Close, P.O.&nbsp;Box&nbsp;314, Grand Cayman, KY1-1104, Cayman Islands. The
foregoing information is based on a Schedule&nbsp;13G filed with the SEC on February&nbsp;19, 2019 that reported beneficial ownership as of December&nbsp;31, 2018.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(4)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Consists
of 603,129 shares directly beneficially owned by Corriente Master Fund II,&nbsp;LP ("Corriente Master Fund II"). Corriente Advisors,&nbsp;LLC
("Corriente Advisors") acts as an investment adviser to, and manages investment and trading accounts of, other persons, including Corriente Master Fund II. Corriente Advisors may be deemed, through
investment advisory contracts or otherwise, to beneficially own securities held by other persons, including Corriente Master Fund II. Mark L. Hart III is the Chairman and Chief Executive Officer of
Corriente Advisors and may be deemed to control Corriente Advisors and beneficially own securities owned by Corriente Advisors. The address for each of the foregoing persons and entities is 1401 Foch
St., Suite&nbsp;100, Fort Worth, TX&nbsp;76107. The foregoing information is based on a Schedule&nbsp;13G filed with the SEC on February&nbsp;13, 2019 that reported beneficial ownership as of
December&nbsp;31, 2018.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(5)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
70,231 shares of common stock issuable upon the exercise of options exercisable within 60&nbsp;days after April&nbsp;17, 2019.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(6)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
29,157 shares of common stock issuable upon the exercise of options exercisable within 60&nbsp;days after April&nbsp;17, 2019. </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>32</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=35,EFW="2238509",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=425569,FOLIO='32',FILE='DISK121:[19ZAF1.19ZAF41201]DK41201A.;9',USER='CHE105545',CD='18-APR-2019;16:37' -->
<A NAME="page_dk41201_1_33"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41201a_main_toc">Table of Contents</A></FONT></P>
 <DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(7)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Consists
of 21,852 shares of common stock issuable upon the exercise of options exercisable within 60&nbsp;days after April&nbsp;17, 2019.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(8)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Consists
of 3,350 shares of common stock issuable upon the exercise of options exercisable within 60&nbsp;days after April&nbsp;17, 2019.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(9)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Consists
of 4,797 shares of common stock issuable upon the exercise of options exercisable within 60&nbsp;days after April&nbsp;17, 2019.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(10)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
113,394 shares held by Advanced Technology Ventures VIII,&nbsp;L.P. ("ATV VIII"). ATV Associates VIII, L.L.C. ("ATV A VIII") is the General Partner of
ATV VIII and exercises voting and dispositive authority over the shares held by ATV VIII. Voting and dispositive decisions of ATV A VIII are made collectively by Michael A. Carusi, Jean George, a
member of our Board of Directors, Steven N. Baloff, Robert C. Hower and William C. Wiberg (collectively, the "ATV VIII Managing Directors"). ATV A VIII and the ATV VIII Managing Directors disclaim
beneficial ownership of the shares held by ATV VIII except to the extent of their pecuniary interest therein. The address for each of the foregoing persons and entities is 500 Boylston Street,
Suite&nbsp;1380, Boston, MA 02116. The information about ATV VIII share ownership is based on a Schedule&nbsp;13G filed with the SEC on February&nbsp;14, 2018 that reported ownership as of
December&nbsp;31, 2017. Also includes 66,615 shares of common stock held by Lightstone Ventures,&nbsp;L.P. and 9,076 shares of common stock held by Lightstone Ventures (A),&nbsp;L.P. LSV
Associates,&nbsp;LLC ("LSV&nbsp;GP") is the General Partner of Lightstone Ventures,&nbsp;L.P. and Lightstone Ventures (A),&nbsp;L.P. (collectively, "LSV") and exercises voting and dispositive
authority over the shares held by LSV. Voting and dispositive decisions of LSV&nbsp;GP are made collectively by Michael A. Carusi, Jean George, a member of our Board of Directors, Ralph E.
Christoffersen and Henry A. Plain, Jr. (collectively, the "LSV Managing Directors"). LSV&nbsp;GP and the LSV Managing Directors disclaim beneficial ownership of the shares held by LSV except to the
extent of their pecuniary interest therein Ms.&nbsp;George disclaims beneficial ownership of the shares held by ATV VIII and LSV except to the extent of any pecuniary interest therein.
Ms.&nbsp;George's address and the address for the Lightstone Ventures members and entities is 500 Boylston Street, Suite&nbsp;1380, Boston, MA 02116. Also includes 3,809 shares of common stock
issuable upon the exercise of options held by Ms.&nbsp;George exercisable within 60&nbsp;days after April&nbsp;17, 2019.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(11)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Consists
3,350 shares of common stock issuable upon the exercise of options exercisable within 60&nbsp;days after April&nbsp;17, 2019.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(12)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Consists
154,873 shares of common stock issuable upon the exercise of options exercisable within 60&nbsp;days after April&nbsp;17, 2019. </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="dk41201_section_16(a)_benefici__dk402022"> </A>
<A NAME="toc_dk41201_2"> </A>
<BR></FONT><FONT SIZE=2><B>  SECTION&nbsp;16(a) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;16(a) of the Exchange Act requires our directors, executive officers, and persons holding more than 10% of Catabasis common stock
to report their initial ownership of our common stock and other equity securities and any changes in that ownership in reports that must be filed with the SEC. The SEC has designated specific
deadlines for these reports, and we must identify in this proxy statement those persons who did not file these reports when due. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based
solely on a review of reports furnished to us, or written representations from reporting persons, we believe all directors, executive officers, and 10% owners timely filed all
reports regarding transactions in Catabasis' securities required to be filed for 2018 by Section&nbsp;16(a) under the Exchange Act. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>33</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=36,EFW="2238509",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=118834,FOLIO='33',FILE='DISK121:[19ZAF1.19ZAF41201]DK41201A.;9',USER='CHE105545',CD='18-APR-2019;16:37' -->
<A NAME="page_dk41201_1_34"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41201a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="dk41201_report_of_the_audit_committee"> </A>
<A NAME="toc_dk41201_3"> </A>
<BR></FONT><FONT SIZE=2><B>  REPORT OF THE AUDIT COMMITTEE    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The audit committee is appointed by the Board of Directors to assist the Board of Directors in fulfilling its oversight responsibilities with
respect to (1)&nbsp;the integrity of our financial statements and financial reporting process and systems of internal controls regarding finance, accounting, and compliance with legal and regulatory
requirements, (2)&nbsp;the qualifications, independence, and performance of our independent registered public accounting firm, (3)&nbsp;the performance of our internal audit function, if any, and
(4)&nbsp;other matters as set forth in the charter of the audit committee approved by the Board of Directors. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Management
is responsible for the preparation of the Catabasis financial statements and the financial reporting process, including its system of internal control over financial reporting
and its disclosure controls and procedures. The independent registered public accounting firm is responsible for performing an audit of the Catabasis financial statements in accordance with the
standards of the Public Company Accounting Oversight Board, or PCAOB, and issuing a report thereon. The audit committee's responsibility is to monitor and oversee these processes. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
connection with these responsibilities, the audit committee reviewed and discussed with management and the independent registered public accounting firm the audited consolidated
financial statements of Catabasis for the fiscal year ended December&nbsp;31, 2018. The audit committee also discussed with the independent registered public accounting firm the matters required to
be discussed by the PCAOB's Auditing Standard No.&nbsp;1301, </FONT><FONT SIZE=2><I>Communications with Audit Committees</I></FONT><FONT SIZE=2>. In addition, the audit committee received written
communications from the independent registered public accounting firm confirming its independence as required by the applicable requirements of the PCAOB and has discussed with the independent
registered public accounting firm its independence. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based
on the reviews and discussions referred to above, the audit committee recommended to the Board of Directors that the audited consolidated financial statements of Catabasis be
included in its Annual Report on Form&nbsp;10-K for the fiscal year ended December&nbsp;31, 2018, that was filed with the SEC. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="48%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="48%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>THE AUDIT COMMITTEE OF THE BOARD<BR>
OF DIRECTORS OF CATABASIS<BR>
PHARMACEUTICALS,&nbsp;INC.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Gregg Lapointe, Chairman<BR>
Kenneth Bate<BR>
Michael D. Kishbauch</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>34</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=37,EFW="2238509",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=80842,FOLIO='34',FILE='DISK121:[19ZAF1.19ZAF41201]DK41201A.;9',USER='CHE105545',CD='18-APR-2019;16:37' -->
<A NAME="page_dk41201_1_35"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41201a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="dk41201_householding"> </A>
<A NAME="toc_dk41201_4"> </A>
<BR></FONT><FONT SIZE=2><B>  HOUSEHOLDING    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Some banks, brokers and other nominee record holders may be participating in the practice of "householding" proxy statements and annual reports.
This means that only one copy of our documents, including the annual report to stockholders and proxy statement, may have been made available to multiple stockholders in your household. We will
promptly deliver a separate copy of either document to you upon written or oral request to Catabasis Pharmaceuticals,&nbsp;Inc., One Kendall Square, Building&nbsp;1400E, Suite B14202, Cambridge,
MA 02139, Attention: Corporate Secretary, or telephone:&nbsp;(617)&nbsp;349-1971. If you want to receive separate copies of the proxy statement or annual report to stockholders in the future, or
if you are receiving multiple copies and would like to receive only one copy per household, you should contact your bank, broker or other nominee record holder, or you may contact us at the above
address and phone number. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="dk41201_stockholder_proposals"> </A>
<A NAME="toc_dk41201_5"> </A>
<BR></FONT><FONT SIZE=2><B>  STOCKHOLDER PROPOSALS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A stockholder who would like to have a proposal, including director nominations, considered for inclusion in our 2020 proxy statement must
submit the proposal in accordance with the procedures outlined in Rule&nbsp;14a-8 of the Exchange Act so that it is received by us no later than December&nbsp;24, 2019, which is 120&nbsp;days
prior to the first anniversary of the mailing date of this proxy statement. However, if the date of the 2020 annual meeting of stockholders is changed by more than 30&nbsp;days from the date of this
year's meeting, then the deadline is a reasonable time before we begin to print and send our proxy statement for the 2020 annual meeting of stockholders. SEC rules set standards for eligibility and
specify the types of stockholder proposals that may be excluded from a proxy statement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
a stockholder wishes to propose a nomination of persons for election to our Board of Directors or present a proposal at an annual meeting but does not wish to have the proposal
considered for inclusion in our proxy statement and proxy card, our amended and restated bylaws establish an advance notice procedure for such nominations and proposals. Stockholders at an annual
meeting may only consider proposals or nominations specified in the notice of meeting or brought before the meeting by or at the direction of the Board of Directors or by a stockholder of record on
the record date for the meeting, who is entitled to vote at the meeting and who has delivered timely notice in proper form to our corporate secretary of the stockholder's intention to bring such
business before the meeting. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
required notice must be in writing and received by our corporate secretary at our principal executive offices not less than 90&nbsp;days nor more than 120&nbsp;days prior to the
first anniversary of the preceding year's annual meeting. However, in the event that the date of the annual meeting is advanced by more than 30&nbsp;days, or delayed by more than 60&nbsp;days,
from the first anniversary of the preceding year's annual meeting, a stockholder's notice must be so received no earlier than the 120th&nbsp;day prior to such annual meeting and not later than the
close of business on the later of (A)&nbsp;the 90th&nbsp;day prior to such annual meeting and (B)&nbsp;the tenth day following the day on which notice of the date of such annual meeting was
mailed or public disclosure of the date of such annual meeting was made, whichever first occurs. For stockholder proposals to be brought before the 2020 annual meeting of stockholders, the required
notice must be received by our corporate secretary at our principal executive offices no earlier than February&nbsp;5, 2020 and no later than March&nbsp;6, 2020. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stockholder
proposals should be addressed to Catabasis Pharmaceuticals,&nbsp;Inc., Attention: Corporate Secretary, One Kendall Square, Building 1400E, Suite B14202, Cambridge, MA
02139. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>35</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=38,EFW="2238509",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=297561,FOLIO='35',FILE='DISK121:[19ZAF1.19ZAF41201]DK41201A.;9',USER='CHE105545',CD='18-APR-2019;16:37' -->
<A NAME="page_dk41201_1_36"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg41201a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="dk41201_other_matters"> </A>
<A NAME="toc_dk41201_6"> </A>
<BR></FONT><FONT SIZE=2><B>  OTHER MATTERS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Board of Directors does not know of any other matters to be brought before the Annual Meeting. If any other matters not mentioned in this
proxy statement are properly brought before the meeting, the individuals named in the proxy made available to stockholders intend to use their discretionary voting authority under the proxy to vote
the proxy in accordance with their best judgment on those matters. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="48%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="48%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>By Order of the Board of Directors</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><B>
<IMG SRC="g102608.jpg" ALT="GRAPHIC" WIDTH="148" HEIGHT="67">
 </B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Jill C. Milne, Ph.D.<BR></FONT> <FONT SIZE=2><I>President and Chief Executive Officer</I></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>36</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=39,EFW="2238509",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=975811,FOLIO='36',FILE='DISK121:[19ZAF1.19ZAF41201]DK41201A.;9',USER='CHE105545',CD='18-APR-2019;16:37' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<div id="container" style="width:100%;"><div id="ImgContainer" style="border:0;width:100%;height:auto;">
<p style="margin:0in 0in .0001pt;height:1px;"><font size="1" color="white" face="Times New Roman" style="color:white;font-size:1.0pt;">VOTE BY   INTERNET - www.proxyvote.com Use the Internet to transmit your voting   instructions and for electronic delivery of information up until 11:59 P.M.   Eastern Time on June 3, 2019. Have your proxy card in hand when you access   the web site and follow the instructions to obtain your records and to create   an electronic voting instruction form. CATABASIS PHARMACEUTICALS, INC. One   Kendall Square, Building 1400E Suite B14202 Cambridge, MA 02139 ELECTRONIC   DELIVERY OF FUTURE PROXY MATERIALS If you would like to reduce the costs   incurred by our company in mailing proxy materials, you can consent to   receiving all future proxy statements, proxy cards and annual reports   electronically via e-mail or the Internet. To sign up for electronic   delivery, please follow the instructions above to vote using the Internet   and, when prompted, indicate that you agree to receive or access proxy   materials electronically in future years. VOTE BY PHONE - 1-800-690-6903 Use   any touch-tone telephone to transmit your voting instructions up until 11:59   P.M. Eastern Time on June 3, 2019. Have your proxy card in hand when you call   and then follow the instructions. VOTE BY MAIL Mark, sign and date your proxy   card and return it in the postage-paid envelope we have provided or return it   to Vote Processing, c/o Broadridge, 51 Mercedes Way, Edgewood, NY 11717. TO   VOTE, MARK BLOCKS BELOW IN BLUE OR BLACK INK AS FOLLOWS: KEEP THIS PORTION   FOR YOUR RECORDS DETACH AND RETURN THIS PORTION ONLY THIS PROXY CARD IS VALID   ONLY WHEN SIGNED AND DATED. For Withhold For All Except To withhold authority   to vote for any individual nominee(s), mark &#147;For All Except&#148; and write the   number(s) of the AllAll The Board of Directors recommends you vote FOR the   following: nominee(s) on the line below. 0 0 0 1. Election of Directors   Nominees 01 Michael D. Kishbauch 02 Jill C. Milne, Ph.D. The Board of   Directors recommends you vote FOR the following proposal: 2. Ratification of   the appointment of Ernst &amp; Young LLP as our independent registered public   accounting firm for the fiscal year ending December 31, 2019. NOTE: The   shares represented by this proxy when properly executed will be voted in the   manner directed herein by the undersigned stockholder(s). If no direction is   made, this proxy will be voted FOR the election of the nominees listed in   item 1 and FOR item 2. If any other matters properly come before the meeting,   the persons named in this proxy will vote in their discretion. ForAgainst   Abstain 0 0 0 Please sign exactly as your name(s) appear(s) hereon. When   signing as attorney, executor, administrator, or other fiduciary, please give   full title as such. Joint owners should each sign personally. All holders   must sign. If a corporation or partnership, please sign in full corporate or   partnership name, by authorized officer. Signature [PLEASE SIGN WITHIN BOX]   Date Signature (Joint Owners) Date 0000418198_1 R1.0.1.18 </font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman"><img width="1008" height="1304" src="g26122bgi001.gif"></font></p>    </div></div>
</div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</div>
<!-- ZEQ.=1,SEQ=40,EFW="2238509",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=751085,FOLIO='',FILE="DISK123:[19ZAF2.19ZAF41202]2612-2-BG_ZAF41202.CHC",USER="JTAYLORA",CD='Apr 17 17:33 2019' -->

<div style="page-break-before:always;"></div>
<div>
<div align="center">
<div id="container" style="width:100%;"><div id="ImgContainer" style="border:0;width:100%;height:auto;">
<p style="margin:0in 0in .0001pt;height:1px;"><font size="1" color="white" face="Times New Roman" style="color:white;font-size:1.0pt;">Important   Notice Regarding the Availability of Proxy Materials for the Annual Meeting:   The Notice &amp; Proxy Statement, Annual Report is/ are available at   www.proxyvote.com THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS   OF CATABASIS PHARMACEUTICALS, INC. June 4, 2019 at 10:00 AM ET The   stockholder(s) hereby appoint(s) Jill C. Milne, Ph. D., and Deirdre A.   Cunnane, or either of them, as proxies, each with the power to appoint her   substitute, and hereby authorize(s) them to represent and to vote, as   designated on the reverse side of this ballot, all of the shares of Common   Stock of Catabasis Pharmaceuticals, Inc. that the stockholder(s) is/are   entitled to vote at the Annual Meeting of Stockholders to be held at 10:00   a.m., Eastern Time, on June 4, 2019, at the offices of WilmerHale located at   60 State Street, Boston, MA 02109, and any adjournment or postponement   thereof. THIS PROXY, WHEN PROPERLY EXECUTED, WILL BE VOTED AS DIRECTED BY THE   STOCKHOLDER(S). IF NO SUCH DIRECTIONS ARE MADE, THIS PROXY WILL BE VOTED FOR   THE ELECTION OF THE NOMINEES LISTED ON THE REVERSE SIDE FOR THE BOARD OF   DIRECTORS, AND FOR PROPOSAL 2. IN THEIR DISCRETION, THE PROXIES ARE   AUTHORIZED TO VOTE UPON SUCH OTHER BUSINESS AS MAY PROPERLY COME BEFORE THE   MEETING OR ANY POSTPONEMENT OR ADJOURNMENT THEREOF. PLEASE MARK, SIGN, DATE   AND RETURN THIS PROXY CARD PROMPTLY USING THE ENCLOSED REPLY ENVELOPE.   Continued and to be signed on reverse side 0000418198_2 R1.0.1.18 </font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman"><img width="1008" height="1305" src="g26122bgi002.gif"></font></p>    </div></div>
</div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</div>
<!-- ZEQ.=1,SEQ=41,EFW="2238509",CP="CATABASIS PHARMACEUTICALS, INC",DN="1",CHK=665545,FOLIO='',FILE="DISK123:[19ZAF2.19ZAF41202]2612-2-BG_ZAF41202.CHC",USER="JTAYLORA",CD='Apr 17 17:33 2019' -->

<BR>
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g102608.jpg
<DESCRIPTION>G102608.JPG
<TEXT>
begin 644 g102608.jpg
M_]C_X  02D9)1@ ! 0$!&@$:  #__@!%35),3%]'4D%02$E#4SI;0T%404)!
M4TE37U!(05)-04-%551)0T%,4U])3D-=2DE,3%]#7TU)3$Y%7TM?4TE'+D50
M4__; $,  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_   L( $, E $!$0#_Q  =  $
M @,! 0$!            " D!!@<* @0%_\0 +A   00#  (! P,$ P #
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MOJIGZ\::XVS\[8UQC.,8T"M;GJ^X7%DM:RF8B9*U#9TAIFQLALNE4(O9\3'
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M>/6:#9]A-3+557&FV<19[)[AJGBN-10E.(]95D36P7DF;UW3M,19M,;2F[.
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M#@9!FYT>#B(F WE9EAP5B2$/$TW00BC&\/@J^F%1:[3?'U>608QC7'QC\?\
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M!QA+33Z-2 P=, YAJ.?8T^=,.V22"_T9VT^Y].V<9@ZOZ9_7'EXS:#Z(D<9
MCU5WPZ$P?H?IN UN-</]MM7N!M90FY %?#F[M)JT:N&;*,H,U631HPW0RS:M
MT$Y7<X\8<H\ALR8OFCGZK:9P>10Q)"T+B@YC*I7EIG35IO+YFNFYETN4;8UQ
?ENK)#911';YW3VUVVSG,H/'CQX\>/'CQX\>/'CS_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g26122bgi001.gif
<DESCRIPTION>G26122BGI001.GIF
<TEXT>
begin 644 g26122bgi001.gif
M1TE&.#=A\ ,8!7<  "'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E "P
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M0\ $C' )#&!!"#D#@">,L 21$80-AB@;&?HA,3]$0EIN&X7^Z,"(-6S# 1@
M ,=VL(T0K"!Q;'C'$FX !4LPX0,K(T$10"@_Q!$.(0BP!B>HD8<;V(('1]#
M#/](8(T;$*$'^H#%'EK! R.,(@F,T$/=V- //H @9"#(@PH^@ $?',$1/7 :
M E:@@A%PP@H^,,0GZ&"$*E1@!H[@8!6,1P3<[2 $==A! ]JP- H88G1WF^/1
MC,<'"=2!"5?<82/T 0@>N )6Z(OD03JQMCOX(6>8D 3A.E$'MO%B"G13X!+T
MP8(HW,)\]2J$/J) ODA)P ]2JYM <C#$@]& =49@VP,:<8FX&8$,46 !(3[
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M":)P!CBU#3S  CO !5)@#42 ,F+@634UB.18$!<8!5<@ ]R3CGKD?V^P ;<
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M=\D.+0"9=Y<$4/]@0AQ0A]F"IQH@GF7H"!LPD]+S!=3PGCX@HV!0!6IY G3
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MQ0;/V<?8<-8Z,P%!H)JI>]E-D%J$AF&]7+:?^ LO@ T(-0*_@*VX<PN4T&1
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M"E'N&*&*-B"N8](<LK Y/VE$G, .$W*X90$*LFB@$W9,P".,1^X0 JI6)0:
M8%'"6^"A-\)"H8H0D%;H%FI4I6F'.]* XHX5%@?I@14L^&RU/DH+@;VE0 5@
M9D'(RJ&$76PX@@-WE\JC[2@TRRKC%4)9('D7*'\6"21D0 RA!X9H ;DV7OCH
M 334&-" #6"XR?-6F^@ OQPN<0,"GJR!)'2T#<!$\_QG@B:4P$?\0F "%;A
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MX A9^$ %;EBAU!Y$0D?H@ B\0($C6& *6>AP2"K0#AH(P1P30!  4N>O(]3
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MOA)X! < @G^()=N0 B!P--9X@(5Q S6H)=K@A=Z!K JP@!2+"JOJ@L+JER2
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MPD(X$ (^@)P0Z-8NT !7^( :&-<[?$1K( (X^ $,F !".  ;R--?@(5'P .
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M$#O*87(,TNRV*"@!^-CBK#X .K"$*2 $,>"%$=B#K&85+'B"+%B!;F**!I"
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MG5@)(%$"N_AT,(![425-(-")U"A+3^2%<MR%2;B"(Q"#'LA$1P!&&;"$_#0
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M0*-?$& %+."!&TEQ%W4!@ 16L+/J_ I,[+CC) Z0@R=8@$<#\80*WE2 &'C
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MG$TDP?_ FP$ %HC; 2:@0E <"QR!*!B )]R 2"%1$@A!!SQ-Y'G?0E $&>@
MDW&! T!3*2" =S2")(@"DVT# /1!&M  $M3 %)! $>Q#!<Q "2#!8AC!+2!!
M#P@!$CH<#(C"':A< VR $4C"#JV )+0 &Q0"!UA(&""!/.%<\W"",?2 >!Q
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M 1FH@+-$3"G2 0L4@J9L0!UBP KL@ -L ".0P7YX @06 !_"B2'46P], :X
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M)%@!%V07I)8B0=!!@:1$#F @%R2F4-;!P-CH$ZP!+QC!$NA#%BC!(T9B"JS
M5QY$\^Q K>9!*?#",=98!%!J'40"YC1!2$&34$+I7+@B%41 D,W_8CHEYL6P
MP1XH +D2A"=(H'><IAM\JWGAJQ6Z*P9T0AX(3;Z^)@JX DI(0;[*!S01J#S&
MA.00R3%: 37$P]#!AU#21"10@Q_LP \D%62@0'_*UH/"R2+J$Q$J@%!"5#44
MPAY4P=L8P2@$)A@8 BPPPN?TB!!\#KQRP3;$@P$8(Q.  #5<"!6 01S4@MOL
M01;X 1.<B6V@Y%,(@0+TPPY@GZO>F=*LYHP: B"L 'E2B5[.Z!14:QPX@">P
M -NJ#;#:@B<(31)80B$()5#2CDJX@244(9O"APJ\P!0<P2[D02&@917HX@HV
M90'XP0V\: V@P1AH@ T<P1N,64[(!2:L_V9!DD$4L(!2L %@NH 0-,4(MEB"
M;,=D.:IR-6H65$!(TH$'H!]!^!O?,@1%M-93^ $-B$ [A$(.(.36?B$;U.04
M3 $--,##XF4CW$ 4!*XH2,%7L*F=!"L 4$ >Z -:\D&P*$%V"H2/>D;,*L%:
MYBH=)&<U>.A!:&R>#"AUWD#Q'H\O7JM S,8>/08L7,6ZZD/QMA8=L!E:$L&;
M =(2O.= ]((*R$HG+(,TR($?%$+SUFA"]4/SPH :0.IJ)JQ9N<T,,"<*).=D
M<6NI2#"03J&"NB^@HH3W<$(7J-]6E,$-[,$21,+J>(+"MBGWBD3_2D(*J 4)
MRJY*5(,*6((DM/_#$2PH\G[LT79OCQ3(F?2O_DZ!E;1O%"P!$SP0CVX2]R8M
M0F( "A"I2O2 'RR! MQE\-)9V !*$3S"(PB!/M# '@"PH,2G[;&?$.Q "*Q
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M+!7  UI-(>@#)PS!&60M%QN":^^!/L" %32!'_3#-,H6#XSI\: )"D2!'_$
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M! K< ,VHA+X7;R$*!57C5WW>@%A/@"48@O,&ES\R)_%,0?/"428.1Q/,P Z
MP,.'O%65'T6/(!Q7X1HHD@WL[]>AJ30X@-_625@"=4%*0BTT@@J\ ??* 1I
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MA1 8C8&[T)C_U@ P0 VE8(-6;*T:GZ ##>Y@"!-L+YA!CE?&5&0+,$AW!6-
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M"!D0@1=Z<(1_&=Y$1#B#$5I!0$K >M(DG]SDJ-) !ZB& O;@%UX !JR OVC
M$E8+#%1@"-) G3R!DI2 $VJA%YA@:S#!$/_4+V9N1@'U8@+\@!.NX&) ( U^
MP0G\X*;(21M$@D\499M@T GV $6PI'MN1M@F8 H< 06B@ ;20 6TSU!\H,QJ
MXP7-#0#X!!NNP+(F0 B(P!)P  CV@!->( .>AG"X[W(PJ]!V+>5T( :@8/.R
M(A9PH <NH:/PP')N)@S. '<83]<,X %(H1:4X 2ZJPA#H0:TA@YZR".L8:<N
M@1?V8#\*31\LP *PR",H( OD0!>4)@?>#0"P( @^@&>.P (*J )L80$F  _H
MRP!PR 5H0$=*"1(EL4QRH JFZ!.J#0K ( HB$;<V(@?LH",00 GL* GX@()@
MH ;4 *(^0+-HP%W_O*()AH :2"&W@@ 04,!1$, -+^L2W, 3^? 35R */"#\
MD, .7DL0XD:,(DP)'*$'<, 3(('K0&^;@D #^""WE. -8H 6\.+Y.B8'(DJ9
M4J "6J&[1 $!>$ /F@!9#H0#7* &K&<,FN 7B?$ @*\"+.NH;& @QP4(!.$D
MNNP3^H &:.D)6L!N:F / N0,Z*N.)G(!#-$%!.$ JFUR%M(!&$44(,!;JD$/
M * /(. $>.:FS$\4P.!J**R$;*#\S, 1PB9\=&#Q0JP!)=$*;( $S"F>-* &
M1( )/L EKP "'F\,R=) \ 0.X H.= 0(*J, *@ ,=6A'U!( * !9^J &_X(
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M!^XU#* @ J)UF[2V T1!#H+*!2  E.)O;ZNAA& A!1[T#3"A_BR!#XJ@#HB
M1ZD0!R2@&J7 &O3@G3K@!3AA/L5 =J/6!+" %J2@7=FU$PPL#$9S)(2D?9AH
M2,CD?SB.3@NU(8!@!-0G)-I@!8#)4*#E%QQU+P3@.A2# $#!7$&C /9A'[A
MQLBW@3=B&PR@"+IB)7C@ )NB.;0("2JB*@@% >+A._] @ HT @-   32H@ *
M!#RVX0/PHHTD^"$6  ,*I ! 8!]@HRFXH"G^ 8)7(@*\0@)\@R%HF LB($A
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M=B]!_]@ ERPD#1PEJO5ZK_FZK_WZK]GC6X1 !7;JDW@A#;2FKVS((7S@> 1
MMYK*$J)@<CQB!68@"O9 &A0$@&K$9V'ACY8D?S%FBCA.<SBG6-X7L%5[M5F[
MM5W[M4>"6!Q!4>=)"7I(J&N$9]+$4.I@R[9)"'; ":)3)?*)"+8!$Y2PE (%
MZ^9GP&K$!2P! J6P31J.1*!%6& [N_6Z /X!+S#@DAL# ;" -T4B1!E8+\+7
M!>BF(;  #TR43G]@-?A,)1H9._OBN^W[,PH@%A:Z<((6,O0FO_O".M)9NZ-$
MF3@!"33@1QJ!";:DS*20A!J"9R9+HM* ".SE $<"/_@ "?]60-.PCM$0P >"
MP!)NX!=,8 +,@!.@H#G(B0@6_!-X(:!$8;T-_,8#^HH$1<<?HR"J @.XN# H
M0! T8 @H51-*H 4L@PTV5C7@-2^2X OZFVWL8 E1HQ-(X8@,@QBS2#$F(!.F
MG#"*-,QQ'$JN\ :B #3!X,1K1D'N"1$1J?Q$#0:2VIR-8 D*X;?(+@=CN DX
MQ@ \@0P4@ R"!P'F+ I$00J800'Z(<_KO,PA73/ZP X^P'&D5PE8@ \:H VV
M^0%FDB;(AQ"&K0**2\&" !OV@*- ?0]$'0'(9P98*@9D8 _B8-AX@ 6ZY%N,
M8,JDH!JX)0RHH)AN3YG(8 ?><P;_5HKK8L 2XL *5H!9= ,_..:W9X#1%A(,
M:@0('@$(INH)KF _%D">HJ $[D8DH!O7+=(.BGQ)DB /) $69K((:F 7(JD5
M-& ,I" 'H* -.FL-H$5GAF+QOCVC?. %ID 4*@#96Z (8F#-H( @#4 ":L *
M8M2W1($7X,LATZ 0JN!&;D '(H0%&"T'7J"_"&D'J,,%R,L6!B@#_ "P/&&P
M=J^I((<.B,"WQ* (\" -XF ^9X!,)B 7I  (NJ '0$3B)V?#.&&ZR"MF"IX(
M>V /+, 5D&ZPD45HGSV "L &4#W(,, 3#$$$1D%0V@#3NR0)SD $9H#*N-XX
MU^P7VT!)_[# $@J!0/CP +RBX U!#'B@"T^@>2W $&)&1?0A3.M4LJ.@72J
MMKPTTJ7D9 !@ <QU-W8#JCU#7AT_\S%CQ*D,#&QA$F*F5AO,S([T!G7!$7Q
M!WI@"*B  C(!!):OEI#I 4X_]5V@ Q0L#0#A_ X@2EU [*:5#L*T"7R.&:H
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M#25 R$ "P1& -IF0C'Q BG0*T0&#@ 7_/**!'Y%0 P$'"-3QR54%*I1#%@X
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M0RA>KIT'F"'SC2_/LBY9^M2K7CR84,&V9PP%&TPA(ISXE@B(P -)0 &9))B
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M61!/0@ 4"70".1 'J%<20P@ S)0"CW()/3![(= (5G*"_:8C$2" UE$-.^
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M%$0A"C%0!>7S 9@0"0AT!5:0 X2@43H@!VD "- A 3( !3VP RX0!%9 4R'
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M\ A?( =YL/\@-F"0_@K  2S  YP>L40&A5 (,( $LIL'A7 #A2!9<2 @%7(
M*=L)TK, K"0*#7(OI$)!< H7(% #?I!V&XH"ZY,&5A $@(@D08 $)6 GG; /
M-J @EO=E>?# -V"E$1 !(OL!=, $"^ "T2%G!=H*.8 #<M"C"D$!0=P)T)$P
M2[,!.X ;=K  W;:_!ZP/WSD@$:,$)\ C7TN)*W# A1 5(P#&@F!L&[H"1H#
M6;$9 X@!?^1P)P, ?9 ?5H&%G  +:O HN\"7@T@P3G  #X E!50-+((#/5 L
M10!'5@'%64!K&VH[E-K&#WP$2+ E#5P(^E "/0 CO$ #!^ AB;+_4X\C"D[@
M(-70>V>P"QV0EUD;"@;@/KO0" ]<"$1P!\7["4D  2\< 8V P(4P"BX0((D2
M'*;4;BX 8 \""#8P!.V@Q;DY,4JP8>E2 C#!#$N P$P@86&L!-MB4W< M17P
M#;;SQS3Y"X90 ]%!P.\,S_$LS]-1.Z+@8UK "[*;!I<D $6P 1)<!/% "5EP
M #G@*IL32&FP"[#@"(=;+KP0!H:T#T P L9 4^JJ!WFR -;P"W)+J?&BK>BC
M 1GP S2U;9U@!I<$"EJ0 U/P"UTP$A30@I-@'U! #6%Q![!@M%>1$1@@/8<B
MQ1)<+@[@(7(@"+7!#T?F+./U"?7\SP=0_P&Y5@ -D!,M\  UU D5H+U4@0#Q
M8 ":L%/740%MFB$&X)S8T@:@8@AO\+?EB"<$\Q]O,AV]\(V)&T/>JTK_ ATH
MX$(F80L]\DJ)@EH8H 4I4PMF$"$KS3IPP@44@+<> FUVD-" ;"^'DA-(( .&
M5)(\G26>>Q?WG*L0TE-3T J=< :JM-+LPVTO #[6X<,HO04VD 5?H!]3S0L0
MH8@<\#L]\ 2MP ,)400. #17+09UL"C]<AQOU I3\3 R8 (QD 95  :_H /,
M.<_7C=W9G8OM>5<RP!RL@0+ <A/E] 7N! 17$"[I*!(0@ <E( $<G,BSB0<9
M< :W< <R, 3S]/\&N-)25SP#;:J2/A!^[%HM+P '\^2X]>L$=F#/S#H2W2;$
M,@!9-% #5X"D0Z#$K54]7V #7_"Y8V!-$R ""BK9W>8 8$ #"WXT7?P!S&!/
M/=(&AB &0" #3I!0;7 &5BT(5J"AMB"R0Q $..  /?!\GT8=<]RF25!>04!4
M"6<#\A0&D/4&/<!?:7 )[O-$2ZP0WK=HBZPI3&ZXCB4'&0 !'0X">  FTT$!
M_!7D;D #BI,!<% 05RU.S/$"HH )+1@$$+#@VZ#*R=7*S5<"(W +KT3>>/"[
M/9 !_04%*1$"S/*/O#6(*5X0O) :C**'5>$&PG(506<#)4 -&UH!7^#_!'>>
M$Q0N!'I0 7=U!H[ $W!PYQ)VU8Y "6%@XWH"M1M* 1G@!$$>I#,P!I@@"?^K
MW<5N[,>.AFIC R1E.HO9 W!@#%6Q=**@!:CH"&T 8EY36 =@.M(!!!_ #X;6
M!QH !PU0 '< !TB@ 0U #;VR9JW]=FW3!G9*[DCP" $V-4Y F?ET.A*PEF.S
M !)06/L0EB"  5<V'9@R(@N !9Q^LTT@"EQ@: 7P[^2^[PMA!5(P;P"P#_'@
M:3ZB:*L2DD_S#]4N <.S-CC0:2LW1>.9< B'!<LN2EA3 W#0 C+< - &"TH
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MS#$VUF@C0Q">%H*&?!VA0_'CW&!GW0XZ'0B%)X:N(@0S:$!"AB]JR""%'BR
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MPPB1&!D )A '*=C "PN8@"!,0) (6@$%1<+! DKF"-LD80_Z8($^M"&13MA
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MA6)@:4*A$,\4R'2P!3#9'00ABB1P46OL=0A!Z' +S7"0#J&0@-CN\ 1'4*#
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M&.>A4!L<@0P0@4\PL04C,3^R!"((@BLX 1>PA!+H AG(@ R@ 4=(@@*5 2O
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M@> %$=!7%JB"1UBH*=!7?4@R)U++"G 9(F"]%9BK(J( 4OB #> #*I GA7(
MM6R#+M  =1DX:H"%%*@ 4> %D1D()3*!&&@%*;"&'&*('L !%3K8+ JJ0(J]
M3HHG1YB --"'J.6B@6@#.]@&VU@!R-V#'>"".T""%8@";C6 "6"$'R*C:3U=
MU$U=5FRJ(9B2A8(%E5V!+8B!?,  .F "$(B >'@N4> "-^BC')"=$EB3)'"Q
M@2BJN .!>. 0;1@(@7($:I#,2,,O&1A>M:("!_^1B"0(,@ H(B"P@X>3@8+A
M@P]@!EYS4#,0# "@@.UQ@VU +2#0 "6 !.NH@2?0BE:$A34AT2  0C6;#AS
M !2X <&PC&)S"WJ:)Z.P#$7ZNC,8 N3IMQ+PW1$TBJ:" J^[ ]T(' YX  VP
M 1A@TB1 O.B-J%S( 8G)70ZI2!GT E)#&$LX"C8(!1<0F;.E!I%\L[IH*FP;
M 5MP.VJ  $!( B( I[<B!1/0) 3H)(*H):6=JUA8!,LZ *TQ /GXFA.8@ [8
M!=^M0 2@#2<  3-( 1#(722"@CM(.]HM%;OLN?E473B.8SD.*P18 2B(@!6
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M_^2956:$<-J;B&HT&N "%]@#,< #6@A#&'"4+P N?9QCH1YJH@:7)!""(X"
M+QB2*?@%$=B"6*"6]47J%#  V-"'$I +QX6"P(D"+_@0'&.(FSR"&BH",#B<
M3AX!%:"^("P ._F()A "3FC0R1V!**@2+#"+N5 "3OB"U:N4C3$P)0!=I(E:
MJS(7S0VH,YB!K!Z(/FBP*; J67F*V8F"%  +-8B*S3)7%YT$-\&\M&B!"?"#
M(Z"!'T2!(VB!"M#<SSZD' !5I.Z7#ZWG-#B"13#/O/-J P "6I ""IB"%ER
M HB!/? "I)$!"#"V+8P"ZFL#L^ %KO:$$]",/> #!_^@ #3XA1<0N,JM <'
M!&E0MTGX@#L0 UH"QA(3!2G@!2'XA5>I%"* &FSHD^8[I$Z,@KDC"%YX L$P
MERCHG"VL;AM(@5@P!MG3A!D(82;KL:)N< =_\&WI!*6L@0ZH"]C4*@3(B0>
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M0CP,@ !^^*4(;@!!"7G0BB7:#0,Y@ $0B[ /)OJ$"Q) X4"L."*C3. )BW!
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M!9W0'A L(8)?#/4,1[C"+\8@!1\8 AL>J((!FK#3 C9B!TN-FU]%$/\&,6!
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M*X ;0B8-.;R@W9# @ 9$D8-?S9L4(;>#0'@1!PTL+ZAOH !_:^N)!%$B"T"
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M",!"&NC $I73O-D #B !#TB#"[R #&)"@@"!#<C ]10%!QY #\C 2CB8N1U
M 3R!(R2!# S*#$Y($W 6',4#GRW$A1#+&'!>S@6!&&!"*,#1/HS20$2:^:G
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MJ)5H;L,@%:) "A6G'> *B,$4<4$.,.<#FL$G2"#VA4$M(%01H$ 6M($M>J!
MA.(V@,$O4$$O(M 0] "Y/"((R  4 %P5W$$&'"!* @'[80'OE6$FO$$3A,MQ
MB($+%*%"C8 7*-DEA( ,D( !G(\4?-N0H)B*&444$L04:@<!/("DE0E&5H,7
M8$ /X !$76642NGO],$*%,*/$(5(T$T)]< ,8"D\E0W_$VB #""!$W@("G"
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MG,O[0M)1) '&DM("8 "SU!*SK"W^?D\1@(*S((  E!)2($ 2.,$'",#4N9
M-\LL-8M18 'AT0$,;.Y3X4L.* 08M(+ ZL#8A$S=M >^- %)'06]V.,#"-YV
MB*\+%0'[NA &_._:DM+:!O!VT)(+(0 &^$4!E)  G,NRX._:%H$ D,@ ;T=B
MW>_]SC \Q;! B6\2G0O51<"F/,]VV"^UC*_P5@&SB%#YQB___!)%#D? M#*/
M#@- $;QPD]K!-JP3*3WQ=F"Q#+.'4[WP$R?QV @ 4C*+=M!2!!B1N_&"#"QO
M]!)R(=<''8S"#D_"& T$WDCJ]4[!+[@G1H !^&*!)43!9I67"$P!$2#!"MQ
M%5SM%!Q!V@&H!4# $Q"!$!P!RAC%".9/GO7 +US!'F2!#70R5YW!0; IC4''
M$4"!!(S +Y!RW!P%!<"!'.A"9'B@'#P!-J2!(>@M$)S!JT:M4>2>Y8(1(5!#
M&O3$89:7#,A W1C014P "R)E'9PP*9A $?# %$1!:X%!@=": _2 "'3?KTF
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MP)L911*(%GLX81/XW@0P LV%@15,T0>T@1T\FBE^VP(4H"BD@388S(,=11-
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M_$ 3 %$.=, ' +(@EW63.WE9T,$1?($3P$(ZW4T'5&<;>, =O$#_]QI%+\"
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M[ .'!J!ZW24$@.C7101BJ4O& AX)R8P.L_\?@ $4X  )B#T$%($+(#!,$;0
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M2QT!F*#]@B]9A#I$@F8^B()+T6T6":F@]=_:0W=(MH,##&0,6!""I*=2B'Y
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M&)G(,5'3K9A% EJ@<%;37FHS,Q? ,U&S-O]A/") "_Y&"]Q@ :RS*##@-!T
M X:S ;@1!/Y!-)'@$<Z@9W:3"S"@"/X!!%!3B_;A$1C++MR -(N*/"L$![8!
M=(H@'L03"23S- ]@)KN(%W3!+1-" MKB,^&3!M- &R*-&N#3,^_ ,OT"%'Y@
M'\BS,X$ -=E3/AO@ 5;@CV+S$;C 7,AJ@S" .YM3(3('OS03,\ES,SMS'^Y
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M=4 JT91PO083OD$K>N +<K03X  )SF ':O^A%UIA/V;@"$"Q66:K!GZ ,>Y
M!DQ@ DJEKP9C"/*F #0 "6)@ WG "^YC#)K@%J2  OB@%A*"2OB' XKJ$91@
M33#+!2S  EY@#_"O$Q+$<S0 )NZE%?" %@R #2[A 3(@!12"MVR!$ZN@"<(@
MUAJO ,X@.F( &T[@=$7!!6"-44&B#T2A"%"7!Q0+I0R@LQP@"5Z@8N!&%#3
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M!Y!"+*C!#D2! N+@ U"@ ZC &EQL0!R  B@X$FF@%AJ!+0/<H@\ HW,%J9H
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M12Q.!$IKN_JD$,4F"9(R\$-?]$>?]$O?]$\?]5-?]5>_1^A@WB,Q"P0S5VK
MN'&D#8PA[%O$?LAWT/PB%B2_*)(@+<PY9>0'KE>D@FZ@5\P72'@!8G,$A^$G
M![2$53K_11QZ;3KAO?PQ?6B$%X*E$5]*>U^E&:5"5[@O1W)@TEV$IG8&#/@;
M;C!)1BB ^LD R!(BJ=]>2-P+[UF?]!$ (#!$<-,  P(M$AH@ ,5%BX$"#@!@
MF!BQ2+PF?#X 8!AA@40W^S(  D 2@P0N$0M$B!<1@,H(#DPV1.!#QH>. (HL
MP%"$(*@($;20+ G*4Y6620C_.3+0L^#0 C4<D41!8B,(AP4FK9&" 03,H0C
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M1GB$2)B$2KB$3-B$3OB$4!B%4CB%5*@V2@8<L/ &3;!O!0 'Z=8K=G!0@&,
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M(,#4)%$ \;P&38#>M%:/:O'(U:!\ . ).W '&< K9$@((_CA]NT8GK $ 5D
M6O  02#70X$)2^:,C+ #'T '?#T43? $XV;D5* $VI >34 (2RX)+,+9@C$!
MKG ST3(&$X &NQ$M7G#E[=W9,C &F/ ;2%8'% 1?3^!,?5!X:,!B"ST@=],9
MM,8"55 $>$ #3^ %39 J)+B'-- (NQ/A$PX ?<!0@D$'+S"2K#Q ZMT"U"W7
M$W %[HT!,7#H;$ &DD "'!P6%%4XB,YZ1I5A)$L'Z&T ;* "MA%?MHPOL)?)
M+]!+DF ;628C_B0"@. 8=1 *-< S_^5-$@_ #A P [\@ XM0.8X !C*"6%F
M!!7@ 1! ;*\](*=V!+" !R3>/&V2X*Y!"$C '4]A!K_0WA$T T0@"CW<0MAN
M R*= [\P!(_P",HB/0+Y3!Z0#U-A!)(@!N[D(Q,)%CZ YF]S!2(P!I_D@4W
M"%F@*&/@+H2]&(<-57'P ]K4!?2#9*MNZV8@9XRP"'?  YL-QLO !S7PRZ*]
M /?2,&]P!CK0!''@D/Y$;%-@Y6 QV6WAWT[P!&+ VT)0[JXT(%*4 WQM<+]@
M-:V! .F2!1J \6>P3#// 6T@TK%!D.Y=8$\. +Q@!#=@"TV0!2&0.=EW!%
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M/@1\F($%"^7S;:$<GMB+H21>Z!&X$MR:@)$6V@#QLS9D\&RA B990R4Z&/%
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MXQ*A.J%NX1MH$"+B"HZP0L("1EA$I>>L& $'H>H#<R%>7B@Z!T+V8@.U#:Z
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M!W(2TK1 L"TD<RM<)U@!N$%PA!1<X$]8U!(T,>#34("PO)ZLM@WV!$ ;X'
M+. ! G! Z>5B<%E1K&U&PJ4L3H/ 7)6@R@E0T,(#YJO/1QI7G["50 7^N0VY
M(O8J"]"K@R4\80I7V,(7]B-)3H" ',# "G7X!01<^P$U[D#$0[A#'HA0QB.T
M0$)-A8#V,K +"!'&!\)I0Q#VP E1% $%G!C"&7X1HH>M8$5GF((.W/ "&M@
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MP 4W*$$XQSX,RK@PM:-@0%O6Z@$:).$%A;"!$%RP>@3\W&\ K!N2[>X#2@Q
M@/I0PPSIV48,8I5F9Q5= F?8.QUT,:EGY< 0BV1(#J[@!#G-Z!9$T@4-OD0
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MI*  O9$6$7@73&""$#@X, B%!=BTFP*#\;D@D:N/%%"U*MB&G8R ^G. -N@
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M!=-0=50W8 A)-=07J%1'S5,X=50Z90@[-=18!0 Q=50S==0U98A-?5.&4-1
M9=1?=51(78@X-50_K55'!=5<W51$90A/Y=-GQ8!?<-1170A6#51*90A+#51,
M70A-%8$M?1X=1%<+0%=L8%8 Z (O+5=UY=)X5=<N^%9YG=<^E5<1"%8 V--]
MS5=U95=L@+].%=AR15B E5=<%=.$35A\35=>A5B"'=-R/=6% -B'I5?XLX!^
M_=>-K=@M==5:35>-'5-<=9LK4("59=F6=5D%X%2&B(>7I=F6U58 4-F:I=DI
M, J=K5E<K0&??5DR,(HH$%J7]=9M/?]:ES6*/5A:ENT A@"%IV79;:A5JE6
M*# *,L#:9P4 )\!:%C"*0L!:.(!3K%4 H_  K*55D4';?L59K#V"^4!;<06
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M(VZ@ PVD(6AM\$.U[N 'MYV($V*HQ@U(,! P^ L#*)@![THRQ3& @ =D*!H
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M1PZ68-7Z+J%%.=A#%"R:'2R@@0D@$,*@Z+4'-0$ %#40@RU#R0).V(8"5UN
M=XOJ W,:('C>1 DF^GL1AHK( $6(!W4O8K*'951$ %A<%,C I/H&D@ ?F8@^
M4+4R=]67EB516R#-4@=]I,")E 3=PX F-$L980T:V(.YXM(+MQ5!  R]1,&,
MH(T2,@)K_T##ILD4\+7_BG4D*Z/43.-1OKR-HBY]P-&("K"/;<!S"1K;W-XH
M[)$F&*$$.@5:F<\(XT)8U4TQY<#B)G3)#R  $X]4J1$>QM\6P5C&@@EQBYBV
MC*)>* ^2MD8N4RP3J8!@&Q'HB 1 P 4W@ "@H#A,$1I3!+&XX0Y/(4@$H(*
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M&Z $/(T,'<P ?1F,N:#3 :013MG$#U@AD[SGR(0I003IF;I29VD1#D!%)]@
MG7:!(\'#';B1 ;1D/C+4RCGJ!Z C)SC!%01J?BB!/KQI#5@"L*2= ?""$.C,
M3F5!&R63Y*@ ! #JS!&KL2*KA4PI*7Z<L=9 "P 5YEEK=K1!$/P+BJ:KNJXK
MN[8K$G'7_?7H1%Q1_BQ!V&V,!"A!&))!X)A$786G!<JK,TF6P=R+'P6/"H@!
M1M1!(?12 =[B28A4&.J##N",T*G()MU!GQU ].B )]0*N'B!Q8B$:[&-V/]!
MS'O>2[B,K$CPF=#=$0<QY!KTDP*&';-L .?$5)213M@1 :*8Q( :P1*0 1,8
M5G,"0 Y$&LZ0P="2 =$.)B=@$X-X6J_,ET!PI_Q<S=(VK;9T#9,022"=Q']-
M[!A( 08XD@(L@8L!0!_HJQSN@!HL3IMUP@K<P"(4 <MP+0=8F )JBQG-2KVD
MDQ(6@C:TP1Y(0V3:+=X.K=CQJ4JQ#!G< !%P <QF!UO>E89ZEP)&;CZ23N1^
MT$6X$ >Z*^F6KNF>+NK>& 8X@&"L+KD1!&HX@*_-A@0@ 16P[N 8Y4=@P'HQ
MAZX5 0C\0P24%KTA@!8T!@+@;DI@0!O\P#8,1 '_X <"E \HU 4&%,&<O!J_
M+6\1F ?R B\2P,7RS@E!" "] 8#YQF2N7:^N@0+[KAES","L+4#ZX=H_M-IM
M\$;L) 4H="\&Y-I%2 '+C@3V7@3NKF[Y((#Y&@ &N.__.D#YN&Y2[.])@$+P
MBJ_O;B^@U"X5)+  ' 8![._K\"[O,O#UDH^I>@0%>]O^8H 4P.Z<3*_[%O!)
MG-L#'X;YBEM').]S1*_L7J]%C$_W\@\/IZX1'S$2)[$2+['\U2]<.O&(+DU'
M0/&"4#$37S$69[$6;S$7=[$7?S$8A[$8CS$9E[$9GS$:I[$:KS$;M[$;OS$<
MQ[$<SS$=U[$=WS$>Y[$>_^\Q'_>Q'_\Q( >R( \R(1>R(=\Q!ICP @#CG##R
M(@/C(S<R)#LR)4^R)4LR)D>R)E=R)G/R)E_R)W<R*'LR*8^R*8LR*H>R*I=R
M*K/R*I_R*TLR 4@! <S)+!/ +=?R(B>%+D<P+B- +R?%(C\R,5LR+_LR 0!S
M^?0R S=S(C^S,T=S(RNR)1=S(V/%+,=P#-\R+9NM"9OP,P,C.(^S(T_O+^/R
M,D>P)%LS.XLS!C S-,<S R_R/%^S,K?S.EOR-[OS,]_R-+^SV69S. \T.?-S
M/O?S-2>T)(/S*PMT4G@S/R?%/SMS4C!P4EQT,H<S-6,R(W=T)=>S-->SM]%R
M0O\/<S6?]#-WLSS'LS #,TG3\SMO\S\?-#[7-$K;-$W?M$[G-$_CM$_O]$_W
M-% /M5 7=5 ?-2P[\BL"8P1L@QNDA:DY=5-'P%,WM1M,=55+M:EE]55O=51W
M-55_-5:+M5=;]5B;=5EK=5BC]5JK-5>?M5N3=5N#]5NG-5W+=5W/-5S?-5OG
MM5_C-6#W=6#'=004M@1(M6''0P0<]E5SP6%3=02 0&%S000H-K==-F1K]55G
MMF1'-L1-=F%W]E5+-FE[=FF?MF=?-F4_]F:W=F%?M6);=FQ+@&(O=FU+MF,[
M]C8X]6[' S7$0UKH=FZ_MF*;FF+_-K=Y=F9W-7._-EK_5[5J1W=N8[9DQX,$
M0/9L+[9F/[=5FYID\[9G@[=VCW9A&S9E\_8V^#9P7_8V##=R;[5SB_=5T_9U
M-[=\[_54AW9E+[9N5[5H0UQRXW98J_=O?[9_.W=;1[6"-S5[S_=T/SAM%SAC
M0[:#:_=R<W=A6S>$/SAV)S9[4W5MD_>%;S>)V[>)<W>)H_B)ISB+K[B+JSB,
MMWB,O[B,USB-W_B,YSB+Z[6IT7#\,7!D(T'P!N\^"/G]"OD^@("1*SD()/F2
M(SF3'WF31SF3._F00_F33WF66[F4<WF54SF67[F6B[F7AWF7@_F8G_F6HWF9
MI_F7KSF<DSF;SWF<J[F8'WF;__^#D>>YFSMYDELYE-^OH _YH/]#DM^OE?OY
MD/_YE#.ZHS<ZD;]YH1/ZHJ.YE-OYI3/ZDI\YHBMYFQ\ZE7OYI5,Z$FCZF'.Y
MEXMZJE.YH*MZI2/!H ,ZJKMYJ=,ZI1LZJ^=ZJ].YEA>YFT]ZK$,ZJ)LZJ..Z
MFBMZK6\ZH2?ZEXLZJ?_YDCO[J&?YJ /ZG=\ZI:]ZM(<ZMV^[M[\ZN'?ZMXM[
MN/=YMY>[MJ/[N9,[NYO[N+N[NK][NK?[O/\ZJ5_YK%=O_&' OR7YD#_;E$\Z
MI'=ZP/\[HQ-\L3_;P4]YP=_OP#-\PC^\OT?\PD\\I4N\PE]\Q6?\H&-\PV?\
ML'.\P?\7O,5W_,9_O,=3/,F#O,A#_+,YO,EK_,5#N:G_.\R_/,YWNI5C.[#S
M_,B#NLWCO)@7_,CK/,M3^<KOO,,S^L.C/-#[>\P'>Z<[?-!W_,VC_-5/?<Y7
M?:5#>K.+_-(S/-5K?=!S?<B3/='?_-53^YSO/->'O;"7?=AKO9 3_;]GN\S'
M_*,_NM2W?-US/=87/>!'?-0/_L47OMJ#_=8'_MP;OM4+?N(SON+GO>-7?N03
M/N0O/N:7O;\?_?V>K\890*H-.K>I&INH6NE'=K3]&Q>PV^FOVL-!FZJIFNNS
M_NFK_NRW/NR;?NRO/NWO_N[C/NO7/N^3MN_K_NO?ONP//_#_*__Q$W_P+__O
M)W_OYS[T.[_U-W_U,S_U&W_V=[_P3_^_^?[J$[_OEWZT_7;NEYKTMWZT";_R
M[[Y3LS[[LW_IG[Y3I_^_;</LSS_[_QM 2. "@MK "" &QD,(0F%!@@,=(A3H
M!J+"@PHK+L2H$<3$@2"V+>3BD2''C04I@GR8,N1 +BFIG1S8LJ/+DB@A@KBX
M$.="@36!;F/)<V;*GP=?)N28=&%(G25MVJ1)4R'-F4\--DVY,RM3D#"5"AV9
M-212EF!+AA0+-27$M@^UVHS %"G0L7 A,LW[UB5?E3A[XH0I\VU@O2OWVC1<
MF&G/Q(B)@F4L67'CPXLK4X[\^+%C_\B>,6^&W/FRY<F<@?X\RE;O/A @_ND$
M,)MV;=NW<>?6O9MVA-BO,1A8P)MX<>/'D2=7OIQY<^?/H4>7/IUZ=>O7L6?7
MOIW[<P+=P8<7/YY\^>8&/NZ+8,!\\9"NM;27/Y]^??OW\>?7OY]_?___ 0PP
M/ 04B@T4_C  P34N!&S0P0<AC%#""2FLT,(+,?0/@]_BXV^@?R3(4,0122SQ
M. 2^JXV %'%#L387M2,  P P&,[$&W',4<<'$XPM @05E&W'(8DL\K8"W'A-
M"Q:90X"?> S 0*#@)(C'!3@^H V#"D1Q8+8"-(#"QB-CR(<]&GM8Q,O<D%32
M."FW&0Z!'O]P  $/-9S# )0(^(Q@3.8PJ+%% 5X4@,G;BN#S3QJ#DPX! <X\
M48!%,422BTB-S'3"!6 3<K\@?]14U%%%W("1&?3184WGK-GA  F4X,01 #P)
MHX8CWD  "#4*&(&(!KY< 09@<7O C"IL1&"%'8C%C0(T])G!"TIQFR"-7UJ8
MK8XX7#!D#&J-Z\.2*%B(XHA9G>MCA&P!F)/= B9AM]UX==/U#$),L(T";595
M#H$FT(577N.411< .APYM+@<3KCN@4>:/>X!/+[ X0!2,18P0=A"U0^#@?;I
M,..120:0#B-T0(+8(F;4LF7B$$!!$A.2R*.?,:1HY)) #9@ #3W_"E!B#2UF
M+&"%7U\.-+@'TEAC 03T/ .&BW/+@9$L5/X.%!N_XYDV%(RX80SVZ@CE#@]$
MP30YJ)LPQ)$BP-V-2:A31* .#F9[0!!Y'YC$X-F8Q. !=AJN+8=;U%81 !93
MK+L:O '0.UO&%4=@@<8%;1>,,11?O%X,[NZ\2=J2L"'+VE[6+8D2K'CYT$"-
M.U3ADFD_;L/7.M8/U-IY[WT^.A@9 P,"BJB##!54Q40%$5PU#G@2<MACABH>
MR*.5'HZH80\%;BAAW#W$+F(%%<"?M@TECA]# E\= ./X/9K/K8D]''DZ:#+T
M&<,!3"01X1:J[::"(Q#! 0C@01R X*VX_QEG IDH'!;0QXFTY:839G $"@@!
M@B]8P7AQR-($A+"$&\#@ P]XPA18P DUF!"%L@) $X10B!V@JX(-TY4?]#&%
M6\3-$S,@PPZL, %2F  !,5A$&T(XPA*>L!#G>F$,=Z &!/@@ S%<@P.L,8,;
M-.Q^QSO! X*0M@V$X72W :$(=_ !#%!@#S*T0N)F$[,K,LT11BO7%4_6CT(X
M#0-@V(,^UA"Q%X%-A%60POJ,H(*Q)6$$5S "$\IXFYBU458L3*$C)B"#637!
M#H+T'>\XI:#<X6=CZOGD*5&YG9,=H0.[L(8*1+&"*#C"$V1@@C'ZM9L)Y $2
M%?! &HC@ D9\ O\%1Q!##HP0"B2,0 50:$0DJ% '%<!""9+XP J.L LEJ. '
M37/!#/B@ 2/$#S?(Y$0'?@ &2<32F)A80B@F&#D_: ,,1\@6,W8  D/$LSD;
M($0M %  /"S" +P@!-5P@X)6U($3-8!%EIAV.KM](F_L2$$1O5  ,XQABMH(
M@28!T ,[#*<3A OH)%(  ##\+S=]^X ;1D""!PP1 S$@@0$F6E% (* "7I!
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M!F:K#T[ 6R>>,+ 7T8$&(\C +[AZ54%(M!I6E1P -( #O>%)L2Z@0;YX 58
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MJ7A# O"@!KY@+=U -YL, %P %N"@!N#@  K -]<R"N% -Y=O+[_@!PQ "K"
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M9&FC@0Z@VJP@!YX+ S0!"AS@QWK@"R:AJ8"@DQA.$!Q@W4R #0BA"S2@"SZ
M K(I(1.T#PZ,-AY  T8@C6;#R"+)'B> !G:!%*Q !J@@!JY@%VR@*=E@ ',7
M!WC "T3S-OH@#3X@15#@N90E;1[ !B!G-PI !C*@!CQW%T?T;2\O;R4D,*<U
M9#QXA!L$ [#I!Y[I 'J@6[_U.C83"BK !8WF%A@W3\! CUS($Q1 !1R!%_;
MWH+F"+I@F\2 SZ1 2#\ #."78#>X+!$V.&, ![:!!U@* 8XA_\MBA@6 M&!;
M5@)68 "CF!J^>..@( (J@!(Q;-I6CA<$X57LX W6[0>ZC;\N(1:^8 3"+B4[
M-0P<H _("$()"Z[RRA': *[8 XS8ML $P0I<P%';Q5,1BK) 8('JMTM_0 9
M((RV 0Q"X6)R0 ?.!%[>1@E(X"QIHPTFX<S&B NR=U8>X RR;,&2P,,*; 3R
MQ5E+E(0=Q"6I<1/I5I>!N3UZ[0:BH!!N !!HU$8)USHPH!J60!^V1TU]= :
MU#D*<(%G VPXX0U,10\B)PWT(0JB  9 0 A,3GE.P!KL"0=C@5T0(!8*$@L(
M2E_W#O7>.9(FP Y2+1;*: +P( ,Z0/_TOD_R" I.,V!#XR@6<M0V'B 7'*
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M""2#PH/JL(,:7/1D[^H !.# !13\QD1AX $G;/9$:HIVM-1$ ! *0DC2JC9
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M %+0!*7(BY,2 Z+ 9R,3!@/Y)S)@D@09D&+@9^#E >S(;3HH C2 B)J4D@M
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M ;>@$81@KH\0KWEC%8"VJG*AK9 ZKI>'!#5@@K\C(5[: A40!@4KHP=R)!4
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M( 0WT*4QL >2H(+!H0E+$[J_"[S7B0"! '9]\#8%4 -?T(*=<$>/$ &Q<!9
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M9\ ('6 ,/G0$3K '>$/($?%5(_%J1& )*H $%X4$(% 'D/  -8 &TV(Z^O]
M TH0!R; @5T@!%!J/YZLRNFLSD+'Q4"RSN^LSD% NIK3=FDL6K\J'C=5*7=G
M 8Z "4P0 DV #9:HA4V&FW?1!+N,%[I0J41S>DCF(5L8"CSA ;!0;/Z4!1W1
M ]N"F[L@!#[SSU0,SR--TB5MTB<=,$9X3>)A *[<34@*LY;1!FCP"1^!"5-(
M:M3!'_4S%R3';'<ALN=!<A!!!Y*P03$0T==B V46!0(6&-,26 >0!''P WE
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MS/A%ABL(08*&CH5-.PO#V=#A )R],* 3,TYH(@P')@B#;P 06($# "8HH04
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M"<##*Z.S%B0I@"!P!%T1@5,RBFJX 1I @R-H 2QX!&.0('$[DPG( "AXA'_
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M*:@&/?C#5=*%$TB0%C XM"F 6'!.A< $EQ(?$0O".GB8[<L^KZD#'8@ $#@
MO[2"!Q@!1T"!$FB !TB#$_@X*7@X+L #6E@ .I &_P=@Q@F@!<)D)T] H9P
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M.[W_C-NJD6#6,>@!.'"2[Y%9$^VE&QT!,WU5LJ0!"5F#-J"!-_6$5A#*'Z@
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ML#0X6(^),2BP 1. 5 ^ A0%"@!P0&?G1@$^X34 86Y=H@C18%8"< BC&88H
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M_FFBCJZ+=HIZ+FJE_JV:3KVU6VJH!JZ.]M:>CFJK9JV4=@KLNFJNGJV7=HJ
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M1100XIA@&(5DFA"&NND%.0#@EP$*T"E)S$,?'K #@W!8+.Y$,@R3) LX'8@
M.HRF?3M8@,'\5( 5K,'_ 8>[1 YDQJE0.,@ =CF7$J@HH"3(< ^^5(X,O/!,
M"H(TI"(=*4E+:E(3L4$2]VH=D-J !AVL@ E) ]%R]/&<&WQB!3][0!X@42XR
M+ &!2KC%'7C5"26U[@;:00$+,]0',]S@.?K@P-X@ 0 41 $6<_2E"PPA"@14
MHVDW\,*=/C!4*7AB,W^*X*!.:B$N(&J")$) X3C3M0-X\A.8D*D$_O%+3A&!
M7 R+R$P(08TT)+0.Q:)F<A @*RM0P%:;BH&62 > ,"ZH0F!@P@? 29HV6$(/
M3W1%'#<03%" H $;0%81;* U:WX" P<=EY X<,9Y[<,8$@#?3%?2T,?%S@L"
M_Z3"1\8@ 3Q X6TN.Q@37A &AC6"#Y;(@L3X=8"^%@%QT/0 QX0K/2L P0H3
MV4%O = ),TQAFYX411%X((W/\4*RI;&&(3AQ@D[\, 2:^4!+"-$"#'0"#6,
M%!>$M1)K"@< IB5!&T:P!I]]H X[B".NV, )$V" -8&UBQA6H(,&8$$-S\Q!
MV(9SDPGLS  (H, OC&,R\ZS%!"Z0P0N,( D1C%4RC-(./J_*72&DI5445@E
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M(  69--F2, :C8*?'.$><,+4/<![1(%PU8$5-<5PS,!866H:Z ,1H/]B'72
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M *V>0!,PPB] W+BJ!"^@@:>$P@>XS Q4]EL'P1[P@12+)P(,$?"6Q>'H&NZ
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M@B6+D (*QE $/-!""NXZ@0N!HPD=8& %,R"!]B1I&QHT($VUB $.!. ):4@
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M"ZR ^IQ/ S>0 SO0 S\P1FSE"+)@9AZA!A[A#/9 #S*00Q"@ J:@<FJ@"S0
M!:? "[0/25)B"K+@!&50 _!@!@8,21: Y,;/ZC"@2.0GZ!  "[*D@41A0SI!
M$PY#+N@ "A*0>FK@"@3+ZL2#-QX #IAN0S9 %S+ $N+B>11/2(AJ"*H$(@H
M##KO0B@@#&K@#/_LHPD@Y@()H@DL( 7H9 5X< C$$ 0+T1 /$1$34?60;P\*
MH1!NX!&/H+H8JP^,S!&QK!".  =>BK$D  \:$1+)0!\X 0HV#K32+DCPKOQ
MX$B"3J@*PK@RY DC0@KJ2D@>H :2X^HV( Y$*,5.!,RPX K6[!938TB$XP/
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M9LK,\& ,1H2P)I!:Z" #J"#&K$!2#F V'* "__S$E"#"0;+H#*R'EOK :;!
M!&)32Z1#070@"8Z WD"&#@B!PN" "H2JL+Z &LP "OQ@"(( !"C3,M= "BQI
MD>2S&MK$#6B213PL:GB!#V1O[G@3UPQJ"$"C$VQ@!7GAFQH(XQ+301\40B-4
M0CMPY,0/[T[O_(!.ZG"E@=:E!VZA$V2@ VK !G0")AJ(%GZCJ70 -"1@!6A
M%+BK":P$ 03  "2 !D< F.;""4@2)OC%<9)1%[)  UZ 3-S !%] &Z3 #*C"
M7'S  J"@!H0 $![I3G9 "VR 07C!1!TDQP[$/U"@%=CJ -R%&!4&.^0$!^ F
M8CS $9X, <BQ#HB@!O_P !N00! @#(VL0! P<(+D0 9*0 ."@! BA88J! -<
MP&WH8"XQI!*'H$P3Z[OF0DO;)1"GE$4G5%,WE5,[U5-;[O34+N]6$3)/3C+Y
MR*#6H A&P + X@O"K$/E@Q(B" %<H 9$P'K8 ./<P $HH ,J0M->$SN5:0*>
M !;\I%AI( ,TQ9$@  Y>0)%60 Q\"4HS( @RP#A= E^<H,0"!2*4 EX0U "$
MBDP1P('F \S(2!0L P*6E0IR@,HP8!M 806PX5IQ@!K2X <B[ Q^P!C3A!ID
MH%7O\ !:HN+<X!]H@EL(PC\!U$!:TW>XA3Z6I !J8,#<( 8N1G8^E6,[UF/_
M/Q9DZZX(+[1(,A3H D\*.M2@;@&%4K()\A(FU!5,,A4+X& ;<H (B@@UVX""
MI*H(P&#;YD)?<,A=V%(R2D4#1*$-! &/1D ;W(7W8*()/DF&C#,?[@6M1BF8
MNLY+*;5 ^,53'"&/_E!C2*$6-* #6L DVZ +U/:"L, )K"!@%L!6J2%/S: +
MSJ 6S$!4EC.K%N!EJ>H7'U(&3  +%K4*NF1H?@"'<L #Q" "YL<31 4/'"'%
MP-0 R*@BG2!+DB!C0A9T0U=T1_<01V]D51&UE,Y#HD 'W@@*L<*CE" *-O)X
M8A%6@A8#P& /!,P )F)WQ\ !7/((KN _VZ5'3<X3_SJH,40@"DJ@5HSL%\*@
M48AL0GK(OW1 "WSH7LS#MJ;@)[\5;-H%00W*.)I@"G[!$,@V(C; "/3A%PIM
M6W;73^CC=PE*=H\@W70EPMS3##Q@"IQ7(63W%QP! ^S,Y H@MWBW,8K72U)2
MQ7H!$ED ?/I@!*8 >T5$2Y6C F879@&@"7J)=$-8A$>8A.6.""W4]'Q$(#5T
M.5*LHPCB-]RRXA"  $Q$/IZ#'0?CA758"FZXK-H"!<JN-S# %I=C =A1\I[#
MA6WQ MR"B'\XH5A$.<YD @0!-.>#B ?7+7=X,"A)ADUL].H( VKQ/HC8%Q63
MBP'@/G)##7 ( W9HA\TX(O]^6(=WA(Y+&(_S6(_W^'U0,>^*Y!]:4>D&-^\P
M  @LX>X\@I"CYR68KP!&8!<TH 0<]N06V4*,#@'43WRHA1OYV),_&91+V!\O
M=!4Y\5-+:%BOKC32H .F-91?&99C698?=#%'2^Y,*W5G69=WF9=[V9<YU0!.
M-^Y2KOQ*]9>/&9F369F7>?%"U9B#[C&969JGF9JKV9H9RW11..Y.K_2NV9N_
M&9S#^9I'&75-5IS/&9W369T]^82[&>Z0T$=,>9WGF9[KV9XW-50;,^Y649#O
MV9__&: #^A#)>9M+6: /&J$36J$+6;3T&>ZB>:$C6J(GFJ(5JT)++H6+N:(W
MFJ/_.]JCV\*91S67A22+:[&N," "<)@<M: (UA$#0,$!8#J'01JE:_J(9WI#
MY!@QGX-9L/!"OC@B=)KM3/I"6YJG"QFGVV+T;!&E=P@ 1D^F:5HP]2ZI 8"H
M3^2)FYFGE[J3-V2IF26-3^2JT7BJ/WKVLMF=V0Z>S;D%4> &.*  TL +0D )
MA!(*)$ (R& )7 L6\OK*RI)"$* )@*L?T@L):. $NKIJFD"#$)&(?1H_[."*
MS2I',K!&:T-=/6(#8 "R;2XZ$(_MV@ -QJNLWX<>Y\[O+N0!*E>,4 "^;@B]
M=@"T%<8[IJ=&PYI%;H5=2J/[+*0(;-0V*COO?NDE5OM,_\<1IBLD.- B-%BE
MM!^RMRDD"0K)K V1H/=YI&.$#?JA"CH'568 "GC@"*Q@'^[ #X@ ":B!1)
M"4  L@V@""B $&JA"-J@S!1[)*C[$'&1,>;.#@K-(V*ELR.B&IPP-4*D (SA
MN9^/%&:;[5#@)FS.0:C 0CKI0C!@ KW/"9P4/\Z $ NBP?&[+7R@CRB$7W"H
M8@9\)#9V<1)G\?*,P$" "T)O0Q!@!!P\LLZ "T7$N>G'O3&D*:N[$-OYF6^.
MF^690]A  51@%T9 !^J@BX:Q=X6@8&ZD"CQB:/XO(;B4-_K@!8; "98$^8:@
M?Y@%")P@8P+.6:U *Q;04NS1&/_.7 R.> %% 3006%,TRY M!@>V80'ZH ;2
M: &PX!%L  <H7 ) X,SMW)##'#2*8 &OL#<H@M%=@$HXH@^4P"OMO#<&]2%V
MS@9L( SZ>S[8(&[(4P*,H4P0MGQ"BA%HX%O,X N"X H+8%#UZG-BP'94#!0T
MH :<H(TEH+R#@-$CW0%L_0,D  D:H V6;W."+ZB!P(I$ 11 0 YT 1:<@-/'
MG,W[  DTX OFG$7<P->_P(/<8!\T  X8%T>)??3NX-?MPQX#W1%JT0V00 ;7
M#P'8"P":??34CUJ8T-"I@# H1MI'SP5HO2,F(L^5O>>  (_\#$9!P_8&<3#<
MP 9@ 0W_[NX!'D$+ E "1,$-&' ;O"]Y",+W''QA=@$"6S0&AH +[K@(EOUS
M'N&(70#-&\#6Y9<W#)G6RP04AD,)B$XB>D#Y'KT''D';)ZX)1$ %+-[4:P#F
M1X\BH$">@Z/0\;U6@O[GE1W<E\_K(<#.@^/E<ZP(RGN&)FY_G& $; %-#%T
M7> 'EI/"(9W800,7@V#.)R (&*$$MOWE8Q[#\>!9HW8N)F'6.6(P'.<*X6<X
M/B!EZWR'/!WI'^'N88(7L'T(K"#D:6(?_N&.A5SU\OF/C61($( .^J%Y94 '
M**H/9* GSBR66B0*+" ,#O5H*60#B.L!+($(8"$-8DCJ11U __UE0,8 <'<P
M"'+V86#AMA8@O(+%3^@ :V1@^=@ R#2%73QA!TC4&+3C"RR0"J 4"BS0 2;
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M#%X0T$DCK1B 0!TJ7)%:0@@(P!];D<WI%0*NG7=8-<_-E,0(*430  )-"'+
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M#T9+.T+!V1\3L8 $BW6BQ!'*(>"#%U*\_8,,;TKP Q99F(  #WH T$<8 0)
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M \HRL@%2.&42NYA>&S)0HTUY\8M@#*,8QTC&,&+@4O\H0ADIA0 N>"I3D4(
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M$1<"BIO.I%>JHH'Q[N<"&ZS$#?OC\#XP(%^Y"/_B6J0#PP914$HZ\9.=6RK
M-C" A19@H#0_9<EB%4*'>0%  MN0ERFA*,Q:* 0#VI/5/A8' @R@@ DA2"L
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MH-+$R#N_L##%;%$ /JP!W*O'S>; 1Y:ZA0F]FF, ;H!U"/ //_67#B M7.8
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MT0%.L$!LT08B0 ,08!CI59(RX!2L'02X@064L0)>,!C!%Z]3T4X\< LFY !
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MP1>AH '3?:0"MVC>?\*PBVU( 47!BT@Z%4D#$-!S;]CYY M.(*?3\2TZ[?P
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M @C&,, $<,"8'E@ LA* 0K#8=@4(I( F9SA/0H! "TRE[GTK;C%28N"?3L2
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M%BB3J@ (+!D<39!AQ46&%KR>O+'QS4X770=<R#"1),P' !HU(O#$I(&/+ [
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M>FX@="#'D 9ZY].O;_\^_OSZ]_/O[_\_@ $*R!\&((#P3P0#*F@?"/N D."
M3>3"F4K_VIR%  I&<))"3S3IL\8""%C# B<\/9"&(198.-\$MT"5!!P-(&"&
M"?,A$(M1:*VP!Q,.8  &"T<X(@4/@-1@3Q89Z=6)!HOIA2$+.P2QB M5'-#)
M3B*R@ U&41'0 RW2 5  #S,0T4 G-7!@@&3;134!+$H"T(,0*CBBDA#ZZ" %
M&(#P  4LY_E40!UD%%((#/)UDL:=\]&Q1R&<U B #RG0]]4,-(P@FPTRFM$"
M  ^\,(:8@_(0Q0Y*)E&G*%)4\\F<<"R 19YKR(>)'O7E (4GK=1 0AMIZ$-#
M$#9UPD,A.SA P 1*%%(% !(H$:5\0.! X:KZ>$'A1G3H(@(G_V,!X D'/GDR
MPPY62$$')WL(V1D8A;S;(E0</3">1G2\2Q\==8ZA41-[E)@F%$,@(<@'3.X1
M!8=Z]?#+'C!DU,<(B*HZH49M"!'%8C.Z"0 0?NA9;U1?Z;-#$7#08L &MP@%
M9(EZM6%##;#TX%82PJZ1$B_"$@%51SQFA, CBQB  !UN\1+G!&E$X4$)4"T*
M*WU)^*$"L$D"0!@ .3]+,D=)6#(%UIVA(+"E4Y%<P I1<A&M$OID<0 "*YQP
MXUA61Z$#V/E6L< #-ISP52$TT" *'J*8\08/+9!)(J@/C###%424NE%Y-4I@
MPP<(3-)H5#_.\!$6H)4'*@(]&*V1)_\DUK8@[+'+/COMM=N^8('_/'C[@!AP
MT2"$O L_.P+#VU>\\<D/B$40:BC__'V\X*M?6P)2L#/TV6M_'P+[R*@)#F>E
M->GL23@AW_;IJ[\^^^V[O[T!N>_^?E0-SD\__OGK3WL;>%R[/^^DUS?[W.8_
M" #""\0%P 4&"$,TJ$$)&H6 ?UP.=BX(@IP8J,$-<K"#'MS( @YT/_P5R$!:
M^. #'I$2"=2 -AIY0 QH\(,*VJX *OP/%F9X/"" :C\'[&$!D, MV14@%@-<
M$ O1]T$%%< 8-*3/!%[G'RP\XHA+7&(!*O %'0KO ?L8XA7#*,8QDA%W!OI'
M$0#XNW^  H7_H!E3#T:@ _$!08Y/Q(\$_M&8_#Q@$DJ\3QM UX0A@#$JF@!=
M?CJ!&HW *8,""J1/%$F^,KZ/ ,JS)"4SJ<E-<K*3GHR=_()'0ON=T(,8P$!C
M$. #**02!5 H)'Y2MQ8?HE(_.5A/9W+P/_M@X(XVJD9M3KG' 6&B%5$IPC _
MJ<QE,K.9SGPF-/6' =VA<7\(X(*#1.F?">C" GMS '5L,(4S86@&0N+*5F(P
MAC:4 %1 >.->FH #-QC""CW0P0H*$0F2H< 6%$)!^.:#@K7TT7%M@X%@"M4/
M.QF ;2Q Z)+J4(@X9"0F9XB2(^MFA"44@@0 \,T>;K 8H@A,,#D(_ZFE, "$
M(%B"8\G$4Q0,,08IU.$&O^CA2<-UEIQR*)Q[(*<G&)$N0I%A"79" !B,((D>
M2JL09YH !*[@5$=&LZI6O2I6LZK5,AI A-JLI('V\57^3  -,*%-)_)0A2*
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MP!*Q/MR)D %%/1-U#) !T,'7:0\6U, Y;\ 7.DHHG//PP-AV;  1R$$F<#F
M%$!>Y,>*50&2@[B$"\]R!\@&D((5@( ,L!( 5(# '?* (( $_(">S\Y7?,P&
MS)DSJ1(21D4!3$*W;4\!:,#*S$<G5 . =0OW90]-4 T=5 $O$'KL=,(CA)A]
MY-"-WR05-N-5UX><T4TU7 L"V(# :03_*&C IR] )^Q##1B#?!1A#?RVKO_
M@SU"%SAT =BZ%5R(!&B ,2!! TC /@ [JSV)&R"[ PQ[ U2QH@ [$IQ0&M_Z
MM&L (^@ !6G$!HQ'@6B! 8#"%T%[#00[ !2!&W"[7NQS_'C/F-CZ# W[''L/
M!D@ "  !K@,@OP,[%YQ%E7?!-A1!L__ '0S\MN.Z1G3"]*A4#>@0AI"*C;!0
M%UA'= M\M+!QKD>[,:3$L-]Z ^!&OROP603.=C1ZL$M'#FA#(=$!$>PQPQ^[
M*,A'%8, 0\]QM/_VQL_0OB.!!OSV\=2!:6! #K1"&^B"*#R"%2S6L3M\G]]!
ML ,@>KQ[R'?/_QISALW?P0=4,1),_ )$=\;W!"BH<;#OM!HC0<CKQ<CC.@%T
M#[?_N3AWN'W:\W^DWP&<!J0A )XSQIYE0 8,@18D@>!? 6+QP@L(?JM0P.)G
MP%@,4Q;)P N40+57@ @<.0" 0@Q9@BN\01,8@A-8@H9%!1;( +6) E?H0 ]8
M_D=U0 :$0=Y<00;(Q,QD"M$/.GG(P)VP5@5A@0U0V\XDP0A0&]7L7^N#$T:D
M#NKS_@/83:3G0T? @."3\EZP 2<XP0O '.IOOQP\P0M,P16(Q 0$ >K_-AVX
MS-$T00<$009L!QV$ @V9-!-GA@@@M>7G@"X0RYZT0?>/!4"X>)'!$O^4!9AV
M.)$A9@& )'8:(O#1(<.0#P  3!!T &-'C'2.T+!4XD,?&QUDX'#0YL67,UD.
M8,&3X<48#!ID9+C2XL$9(D&N.#+@D2@ !-;T]%B$8@PO1C1>9/GP8$0&&5 <
ML.'DY(4.!T01)+F2(8,C!$W.N#(!H$ ,BGM(M+E" VB+(A6$7#* P$4:&F?"
MQ!S1P5(<CA[Y#K24 @ 6&2]D."HZF7)ERY<Q9]:\F7-GSY]!AQ8]FG1ITZ=1
MIU:]FC4 #/] _"O2FK0;$/LBA$8P@=&O*3!:$$!0 =)0.C .2'#B*(F:3CWL
M?*"SPXH;+ACPB#( _7#'3I-T;-OW%0&=*E__*42?\.13$T$?)L"X2!3%&BE)
MI/)*<\21\"0M.ED!!RFJ(4$*-WXPH!-VUNIH@XT 0$$'*7@88RBB)/AA@22>
M^""'#-1P8SZ/VABA!12R6*" ,QR1(@<^0ACA! 0F$04 'Y KP($+.V)#&@=X
MH:$D[9J@ 80G=GD"EB"X0*$* Y+(X ,$V-#+*!]HX *$!C#2J#N/"D#B@ ET
M,8&7%T[HI, F GM !A/JNX^(F'[ P <^LHKC@R*^(H""$AKJI XO(@#A*P"H
M.F$R7G8 < 1'<LC"@0>4..&!)RP$!8,85-H@#!"",,O)(LYH10I/GKP,DRI&
M@.$,4<@T80([')EN_P%>OK""#28<2 *"%GC$B TBJN,"HT[,4-37!CH10H\)
M.I"L#CTPRB'5)%X D)T3?-#!@!P,(XH +.KTX3PV"*FN 0QH:]?==^&-5]YY
MZ:W7WGOA-<" V$#(K5X$@.BBAAH$?J0&+H9:X+9^12,3%F.V(0 C3UH9"A-]
MHF!!A10>6.$("]JT88\=U'A "(Q9V&%$C,)28H8U&@(@T@40Z"$7*9 ]H0D[
M')B D"^-JJ.0C%4P 8,Z=N#2H1&.$ &'(I+%B-U.GF@0HPTRX2B)$N2HNB@$
M0 'CB"L,^0"4,T:VHJ@";( B.P/:.&.M#78(884TJQ&JAS6"[8A*O9* Q?^$
M GB8P@(BD!#DR"Z"H$+HC(]0%)-6.L+BC!F(F.^!,B<KP </+##$A"2"N&CR
MG1U UA%F4([D PF4:)J/!7*XA4<$<H 9HR32T,<KC I0HH6OZ>#C@)X \62&
MC*/@X $[K-"W@!6&9F$&4>0&8#H';& ,$T@PR^$72[ Y0@Q>LG[^#4_TP5@%
M2/7B!0*K.WI 9)*/W59FE1  (RX:3(  3U!+9D\*BQ,^0+4WU& , -@ <HH"
MNR,(87;3^XW:\)5!#6Z0@QWTX =!&$+*8  $L?%7O7)PA"X\@H4L')YKN+ /
MAH5F IEH  +\1IRAO$@+17!#!*IA"RWDP X-> #_%^X2!FK4R &@ $',.D(
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M ?_$U4"B=+ 2 C21A7V<09_:"V3?PB*#'U3 $"=(@@BRT(,P-" 'KF#K&AS
MILO"!%4@4(+Q:K< 'CV$2VK2 1 @P$XO3:9XR)QD$F@@"ISP!'HLV]DN*G"+
M$-1@"$BP8@&"X-CO(4 B)>"D1YSRB1QX@*!'?9X5VA"&+FB !BU8:!OF!Y:K
MUD E$V40HH( A1[ I0T5[A\!V6 +=KD @<@R 1!D@(051 )H&/"$#NZ@A% L
M0+LQL(4_=1ID(0^9R$4V\KL,P-,9V@L!_BS" @A0PG^ 0C3? 5H/'(N1OG1
M# ;H0U5A\8@;]L ")&%+!2R0!:41Y<L>Z*9#1!&1'ES_X07-=0$MO(R#,=9,
M!!6V,B@>H3;]E* &<9:("'2@M"18@@@O?  <8@82^GDDCA;H AP26($^SQ4C
M;GIS 32]B*]@JP-.4!L0XDP9.EBH#[M@%@\L  LH@  .5, #"!YQ@)I9H /1
MRPB$V,(#1!\F!TO]FJ:S$ ,SC> *00% $YY0YHL4H =]'IX$5A &6:_$(!YY
MP"3F\^5?8.4CV)V,!+""  T$$+ 6D$P!,.T=#3#Z(@^(@9L5A(0W&( "=01
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M8!L.<<W\Q@UXP X=()["\4) (1;/@ .*(/?<H"$*(#:*ZA\IL1+[41(%44Q
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M N)L F2 U\PB"48 *L5@;2H ]?9 #QZ !_;@23" P]0I.6* +@FO(S @!T2
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M]N4V)/\RVL ,1D3ZO+2&_:8. C_\D@\C),;;8X]27YUXBP/4F3 &B@L#;H<
M;%]J ( 8FX[UB2+U)T-B!$D*"!EZH^@R+J1*Q,LC?)\H"JKY<F>U5O_X8T9B
MDH\[FM\CB)]E</_V<=3X*?]C^_VF*,0?(X+%]\L?_&5F"#BI">A7]5DF,VKU
M%V2P$RJE] /_:B+3  0I]05HD &BDYD3  IB* C@( 8#!@$L0 @Q(0 "$0L^
M1$!@84(Z.QPPK @RI,B1)$N:/(DRI<J5+%NZ? DSILR9-&O:O(E3) 80(/X5
MR6FR@)(.5TI\,$!'#T,,7/:!B/"23J$E*M8XV+#GQIJ'GHSTB^*%(8(5GPR"
M87%$U,.(2=*PX.1("@4T^JQ61%!ACPHO"WK8<3 !QH<"/?: 7>")TQY.*3Z6
M[ 1GD0$@0O1E:5"@&@L5)@ DP29B!I%M8(PLT4<"I(0543A9<2$#A*$4.4*=
M^;7_Y\@; &U6S-C1HI.-#"*..$*ZQ_*!NRL*'1$CA8[B*#H</&B^0PT",&,
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MB388>+(#%6Y0@0$/7D@ 1W@1;9 )%4 8LP ;G'S@PA?4K."%%#U\T8 UK0
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M"<YPAL0 !NC)I9RW$YY<SR6\,(/V$(""&!:D2*1RDOBJ80%8V*"8$6G7%[K
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M$D!DS40"+N $Q@5GH&IR["(#:N "LI(08><=-- "F* "5! #8=  F-"E%4$
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MBP  !FEIHMZ3 ;/B"6DY$C463'<&C:8E$&/@!EXV4-6C!,52#24 AV6E"V+
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M!!#MVZ7G4E@0\WZZ@>CG^Q#2_G6# 7R09B4*@+A=@"X^ E#F$O 4Q9X0LFX
M!"#H(7T7_Z)^[]1=Y1>/\8[(C=+CD3QP' M! !F(A;-L$Q3 !PY K]ZT@#N(
MVN+D,IV-/*3:5R3S#VQ(SLGS>SG@M )' *L$A!D/]$$O]!/(D4\AH#&! =JT
M )U(\$!1<?5'P]^T@] <3MD2]<J3!#5@\1%! #V0JL9S';^A,@/7!QHZ]&>/
M]E2N7V+>O>A(\E7OZGH)D,>3[GW]$J"P]2"! ?".$NG>A2O-A1&+!*". (%P
M]&F/^(FO^ 2:L+!\/'SH& 10DFQO$Q(P\RUA'G<%$12@KYBR@:#(#Q/G)7H;
M@4GP42A1ER1:6VG0 6=,!R+0 ;2EBXM/^[5O^]?+O9#B7PNW</\\P 1=@'[D
M>V".@@!L$,$PX0*:SR[V;CQTH'8S84"T)1Q?CRUQCQ(X'++S1%)-LK&-5?>W
M#_[A+_[7^,IOOR@(8 U'  $U  <C0%E/%;&*W1(/( @OHA;V,05A4)0>=0=I
M8 NK 1!&]'4X@:!)C31AK!@H4&&*#@<(@!CC$4:4 2PCCEQ,8NF*AS$ )*R8
MX@4# " R7G1H <#E2P ](+PH804 AAA3:A:8] +6EXL(*GC0H07FT9=)B%CZ
MY4A"%RX&VL!Q@+1 #!$P/B#X]VC!!#M%E+"(<NM @3-$VI5H *#-B%^B%F#H
MT>7,3C-'<"QX8*:=H3!B7+I(TV%A 1[_OZ[8.8#TP8I?BQQ<W7/C%XD'9UCH
M"V/BZA0BC0%D].#(P&B-IB5HJ'$%1U6DL67/IEW;]FW<N77OYMW;]V_@P84/
M)U[<^''DR94O9][<^?.;($#\*P(]=H$:8;@LH%3%P6F77/:!B !\ AHH(+Y8
MV1#F1P\:'PHTXH/D$9<B8*IL6P# TPX0:F ,A2Q 6,$+ ]@X HH[NG @!AQ2
M,B$)$<9H@I / "BB CX::^(),7HH0328/&'B!S @HJ,$$"K0@1==(!#AA=?8
M( ()"&&;;8,HQ@#"DC<F@<* '&[1T24$>EA//PQBV6N#'0YH0X9%M@$  1YN
M7&&,(E: 8A\9_QQ!P(>--'#$+0T8 P"4U;!IZ8$G=M'@BP]\R&*?,\(@T:5.
M\, !A#-"*@(%)K:IZC$=J.FO"!?B:.R!(!A\XH0';/CS"1/:2*.$.W#8TSI0
M0Q5U5%)+-?545%-5=5564\5@.O),12")($3)H17PH@-AG_)^FT 7$Q"(0110
MR$.!AA8Z8>>3$EM!4I-69I6!&B&U:,*.#W+(HC$""L"CA!\B2B*##Y0UP:4<
M;(FHB3 <Z,2,$Y#R!!(B(9* /$_XD".3.V2H88@BZB"A"/@^18J.T#"HP MM
MQ>(@MF)!J4":(B!<@(Y;%B@@"-, *, &7%&HH@U!#ABS%;I*Z.\E"O_L@&TD
M$EQB(Q0'W,A@ES3.O/;3"<+(D(*2 6#C$O 0L":DE]KS,(C&W' @B1>L (4'
M/?HX@]E6L]9Z:ZZ[]OIKL,,6.VL,_IFNNE.QLZ2*E5W:-59?,SD  TT6D>",
M*2S QH1WXWT)$TA>\F0, K"0 80T]-DC"A@.H(,/'27@88\C)G2B@;ZOI",+
MHWK()2(SL(9)9  HR<(!33VP0%]=D/!WB! :T2>**(C(D+8D.@3 !VT>",.>
MH)$" BY+XI BEEPNCM+;%$Y#P(:0 $]"3P38J(*N-=I&H.7&$ !#&_ P*83V
M([H0I"4@F#YJ@_@ 2$+-H=NVQMF7)B"D,2#_OF@+ RDH0(-V%N@!4F<:6P$-
M>$ $)E"!"V1@ Y%B  / JE>DPH ;]J$!&T"A;1C@@G2,XBM=G* (DQ %"HC6
M!&0IRV\N 9SS-!&2),A@&Y,0@P$D\ \'Y  B+BG /_"C! Y0P GE8H??M-68
M'&!H H*X78GH10$=', 353" #_3%+QG88 @'J$;,L/"/_MSP2$BBPPY,( $;
MD* 36&&;56*PB 6@0!I2J,!>V+"#R> A'Q#\& F(5(4)R* %!:A&2%"PAEP!
MX%I5R0%CP,.&-3B@"$B@Q@I2,"8UP00L8DA2":I"AU$4#0Q(<XG2W!>$%@CK
M!+0R 0: \($V!,$=_S I @C:XD!<YE*7N^1E+WU9P%=-9X*BN@HLG  !.%B*
M1+OBE7D808,79.$#=,!&!H+PBQ-D+BD6H($HI' T VQ !A^@P LR<(5%&.!Q
ML!G3%3+0 1.X( B8@Y=+UBDT0]! !EX8(P J$#C3Y1 ;$+ $$:C1NM<][0H=
MZ  4JD(!1\6&#K_(@ RV*+0;/ PI"-" .\]PO^&50 G26$"29,"23MA #P;
M1!6D@((,9* $6^E!]F!"!\8\0 B<R, 7SM2)DXX@"PV((0VNP):C(" ',<T
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M=[37'>]MUWO?\_YWO@/^[GX/?.$'+_B]'][PB6<\X17_^,:CW0G/UG2I&-Z
MNO]BH @\T.O)*QZ<+@3!)2>I[DNJ>WH H#[UCF;]ZEU?>MBW/O:OEWWM:7_[
MV>?>]K,G?>M[[_K?E][UPQ=^\4U__)O</OAF)C[SC3_ZYB._]=,??O6%#X @
M=$'ZUH?)];W???!O__LO(</UFZV/,H^?^NKGOOC#O_[WMQ_^[J?__.TO?_RS
M7__QWW_]\\]_ $0^#(B"_KN_ OR_HWB$#G"V5ZLV8HH!#\B F?  !'&)!7 #
M4QN.&H  C1.;#*B!KBD$:6,!'^M K<$ ?>":1\@ RH.U4BF">^&",D,2+G!
ME9L\$_R:#'B$$!S!&<Q!KL& &> :)'B!9Z,V"0N5X=+_@"X8+!UY- \:#CC@
M0"#LFAWLFAL8P2KT&A1402-T-G,SM#. @QI(-"?  ?@J-8$#CAK P2W4&@@
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M^;F)"H"")E!?"WB-OF@>;P&K:R/>:_08#7@!&1 %-'*HF!B";:@ $4!>Y7B
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M0_B$#?AB\+CI,38O0*2!'CB"#"&,AK*2#U_F.Q Y/LF+]%@9+]8H%-C_93I
M@S#( A<@! 9C R8H@AI( 6UQ%R&@%SX1@JT&@%[@!"A094]Z *T^C5_!*A"0
M@7Q8&0RH!@\PAM9(@0GP@!2HKB2")2%HBJ01<.: $SVX$FOH@#-H<#S !E&X
M@S.><(6*PP[P9V6<@#00XNMRI3-0@7-YBR^ !26(A#OP@Q*H 1&H@A!8@4H_
M@QTP@)-^Y"[X@*!N"3J(A!#@@2.@ 1M@C"Z!]3-XL)=X"QJ^DA[X!2H @Q+
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M @##A@X?0HPH<2+%BA8O8LRH<2/'C1A @/A7I"/)C0BX[-L7H:3$(A7"? !
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M!A-L%6#&& O,QD<,7SB  !A51&#&&I"NX(4!;,3AE"99<&KC!)ET-ILV SW
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MB(0ITN'9*O8N$P%%#IA8,A%[F,+]73&+_5M.H3J!"R%800HA@H$7.^3&%4'
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=V:)MVJKMVK)MV[KMV\)MW,KMW-)MW=KMR 0$ #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g26122bgi002.gif
<DESCRIPTION>G26122BGI002.GIF
<TEXT>
begin 644 g26122bgi002.gif
M1TE&.#=A\ ,9!7<  "'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E "P
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M=^_]]^"'+_[XY)=O_OGHIZ_^^NRW[_[[\,<O__STUV___?CGK__^_/?O__\
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M78NH0<T!$,0!!C*'*4@Y '!00H!!T@$HPX$/ GG"(0+  5 C-P3T:,!#AI"
M/2.DTXGPLD(,P((,!( *,H:(#D*@A+@.(0!%X+-#X)R  !#9)(]VA!L(0F9]
M!" 0@U7RFHO@9H;,X0_/5;()&JT1-?S@!TD8A0^^S0H$)($1LF[($Q2!!6X_
MX0\>/D@''O!<!/@CW3AFQ A&T(9- T !7L#");[]@TFL(=<>F?<2OFV)S$Y:
M!8Q0]:OMD(6LHG72"NF ,3JQ8Y*LP-4#N0<@Q$#P4EA@#<+_QH@"YJ#;@OC#
MWP0Q0#9@/I1[Z",2"%]P#C!A78@,01]%,,@* D !)5CV&$.6^$%X*X(H8%6Z
M&)\("$3!@1F$(A2$@ $%.G[;-YC "@ H;,HATH,,0)NW9J:(G[O@!QS<."(&
M( ,!%" '$=SY('.  [0-0F$ =( :B5#U5T7[!E* W2(H0((C4H!A@0QA"GVX
MN@=RP($7S!C*%! S &P> %F8^B @&+32&7):? _D[S@8?4+4L 43S( !8U<(
M"@X1 \LB0@(@CTCB,5$/(%2\)!W8@B/>WFP?*[8#.:! YG.^$-YRX.  @/I'
M>M )IPND G) =T2>0(E1Q#C4G8@W_]\[L8FH6T0.@2! $ZK/9[KC.N3>N'M'
M>!MQ@2A:#&"=PR>*?'H\_'[&=E &S&=D?> $K<!_'?%Q"-<$?O!_". "G?!V
M&D%WVJ=KES" 0_%S,>8"@- &23 %9L *AA "$: $7,5ZCO #1B +?=!X39 '
M^H )I656+( )#S %M+ %4<8!3J<&(0 '<. #8$5KF' )+  'GT #*V<$ 2 !
M@#80=!=E0/!<0G9L"M $B@ '>S #DP8&Q48!@7 '.6 *VJ4 3H '<& *0 9>
M>:"%7%@03Y9ZE 8'P=9G/X@%*2!C!B '$8 &/Y '9J!J'< ")0 ',< *_R8'
M7; $@+!_!O\0!%. !3. 96X :XDF!]YP"4F@#Y]P!%@U5T9@"C,  ]X@?O<
M"D1'AF6V!D[@!Z9P!)-FAEL0A#T'A540 3P0!/K0#0+1 7F !8K%6X" <FHP
M"1D0A(I%A#( <';W;RX "G! "C-P!P"09X%0"B4@BH>E"+77 8-6:'E "VR0
M SO( S 0 ::&?(16$"!F!!R ?YNW 5&&!>(W!!' B_]6!3MP9D,P<NRF72A
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M*Y>]3V !?% !6U9QOJB@() $<MEIPT=W9D8 ]OM<^@=63D /KM6\>4F:06<
M#R" "J$&G>")0:!YZ@J, * "IZ!9S7NA!^H,O+4'P;@">^#!=H!R<T4/BJ6
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MODR.R- 0ZZ>:YL8(IF6F!F '-1"+55#)KT5^ , "56:_A(T!$J<#_I>;1$
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M3D=GY!SR';<")/]D5=VA"6#-"4%]ZKZ:G6QE+* $AJ (>[ $2_  >8#'  %
M(( GG;)4>)*'!XH_,A3(02-%((@<:SITBD) !R4^'8P5(3!0 1@L8I8L8>%M
MS4  "E:@8=6$$@\/;2:P5. %"!,F#QBQ.@"@0YX:00G]\3103HP% .[Y2=-
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M20",R+8X4<I1.<%"%GJ !$=<S@O+RI$^JJD 293 !@70 1((U@%J)"*;1&.
MT:Q /1AP8!3-6=5 Y@ 'IB"@"G0K0 _P$(,H#60(4Z#15NXX4%\M:P("%,%*
M4+ %#ESA!.D#P!SW  'I;:4#\XA3$XQ @3X4P L:Z(@B@'"$.X1J4U.2E +L
MH0\N$$ >+.C#M0Y1-WY)0!"PR0#'4""$FK$T3KC\P%4 Y36A$"U&_S=0 AO
MQ)\)U,M[DX%;H%86@-X, 0)K\%4@"? $2I1!90(1JT$1ZH$0B* HB/"KFXZ*
M# +T0 @Q8(-0XC:!'O!J 7=X1 :*<( Y9 ";.E"E)_YV.)R  0XO&%0 ',&
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M08!'< 1P*H<X XP@F *"80DP( 7_&@L(<$!_"($(\($46)4+@H ^6  O""$
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MA.W8DT797<78DV %3$O9EP4 -?@!-H+9^Y"'<:U9@E"5G.79GO79GP7:DU6
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M9HA@%Z;F73Y@ "CE;OA@5S9@ <;E69""%EX[>5B$;VEI G@&=J#A69BG8)Z
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M<&ZR*+D;I2;NHM3"N19@>RZQ)]TJ[K4FN2NJIP*?1+"X5QPL;I0 J-MMPP#
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M$,Q (9#!!X" *$C "Y1/NVD __6 'Q"? LA!!F#")OB#!VS!#<2 9: $&MY
M'T !V8 <WAE #MQ #0@B%)0"$E" ,RB  E1!"9R &&2-!Q@<!_"!2:  'B1
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MOL$BL:6$IK[,OK4!&>QI!BB!C5ZG/HSE'#!FL*;$8S: #N"!D[($6WI>5MZ
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M]NT..B?TD=NNM/_D9H"!P2*L)%ZKM.(!')#O20CL)["! GC!4'+8Q4[88B@
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M=*@!N("*GP(X2PX+M/_ VI%F'IQ<KI%X[J($T*%!'^+O!;3 %_PX2_A#BK<
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MV5"H+ NNTF- RQ!NB*$! ,!(  TR5&2Q30!4,$+&*!5)P)$%$*"P":FBN$.
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MPHXK,?9C5R).BR\CG "8&D#J@* /@J@44$=#K41ZF' [0$ (ENU9+P]'%#8
M8H 20,<H: %.H)0K(J &X.UI)DW.[,4%R.!NW# -LJB#N(PKS,QKX.R./DM=
M0H<K$H8#K0;5FM$#%B:R/$%<2M17CZF,H*DTR @B+F -W U5Q6PZ@( )0 %H
M_YBB2PD ;$SU67_ Y4#V;VWB5A<TJBA 5P'W<$,"I6[ !T:@<?_P.WPU.^S4
MTOKB'B8G.J:-ERYK!![ "#A@.*A5"?(@!MA@"#C@$NJA4&DJ"T! %&J.4+#6
M(Q3M*G"@B-9U)'>43Y\U70(A:W6D+VR(Y#Y"4A?+1-+ =%!J@]+H(2R( ^A!
MDAR@2NW%=8OM& !! V8@!/2&2YUA?^8.<<&7)1X137$U_\+W?#NB/9QCQB*7
M/."&]=Y&VE3(^/Q4AM1C,@!! OK@$;H@!>0 "U+@2K#I4NY*!21H-M1E>6VN
M1F6"12&5:G=46(@$-7HWEVY@L;IC;SV">S+@5F +:/\(P%=/( 6)Q 6(BB*,
M2L Z@FSL!I.<Q@E&H090  ^ZE*4"#GUQN"0$5T+8(*H:-(=S.$Y3P[HX#:4T
M0 Q^X <\H!3@Q M10 @HH LNH!.F8&B@AMID @@NP2^,PMHD 0(NX15L0&>4
M%P!00Q9:X +\X 9JJE 62W:_B).4V -J$0#F8 -H 7?=U0!C%X&!UP]&BB.>
M  \"P!0NX(2U2QY<2%335XL>8 LTH-V&EWHGP'HYH!(Z  ;,X >,  Y,8P7*
M27J!>)0U%I78=)1QV%>K)V=FY%DM]%AMQ$XCR%(=(G-YP!^86 .^:3+\Z@6:
M@!*Z -) X*. IGXY+RZ.(0/_S "7@H X50#M.L*"))AYRVG,*-AW+S@\!5@C
MG$ 3!"V0"@UJ;(0'Y%$%_$"[%, ^$F"9AS=5)\"%*Z$"FF 4Z,$M;@7(3$#Y
M0, 2P!:543E!SS)7_?E\1387L66;&*.%+,, !H$"X."A'SH!1G@"IFV*'B*0
M9BPOIN0%H(DBND&;1O@ 3L^A(1H.;H!R.@"*DS \'V%'PF*:&N .9%H !.!%
M[B&3<$0>FH"0*_A<PJ"/N2*!X24#K.4.G 7@",#@PK2D$V"&U*#/(FY3-J4"
M?BE6V. .U( % D#.-$4>T20K#N 8X 0O\E!CD"$O'B,&6.$.M. 1] &$+J:F
M!SI\_^<2*Q^F8^<:?%79^:ZP3ID&3PF #R=J+9 N0V;6HA,BL;# (106#KJ!
M@YVB-3;H#F*$"]Q$@U*446+5[V3C'AA8)FYEYJXBH[,&J,5%2%O(*[  -. -
MAP#@14W5H\@C"K#0D.Q&+SC5 #W,RS#P7@GB58%L,"2XLUP[KT$6H"TF*0O7
MN ]79!$5BG;F6%WH>TYL H\O3J#U(Z%;!%3E53C GR1!'U@T:D;XZ?#MLW16
MT.: H A"%KXQ4;W"8-LH#Q2$ B(IC="ECP'@=[<#!>A[E_9@.!0@"*:E=Z9#
MI=HW*:+-H^K[ 0<EL@3T(:CW !06\0I) MX7SBC!]62AE_^.+]Z8&W ?TZY?
M+35#_&_)[ %46"-*(;,80P%*0<4/H D>P&^)),;'IA3Z(8Y0X &8Q37; $]&
MX'L0H!"6@ S4 +,2"@4P*R'5P ,>X &(TZ:\B@F6@ D>@ GZP=!<\\HOH8XU
M0IX?8)S:: DT='L*X0$LBPUDZQZ7(!Z9T07&',;[(<O[ <M57"R*/,K;  J(
MQC6[ *EHW%\Z8+[ (\G[ 9=^1<U30 J>LM C\L1!=H<CI(?-5])/7+:B$C%5
M0"0Y8M,Q/=0!H)3OVL1%_=3_LM#I$]5973DH'4(<0*!;?=;C<B-I_=3/E,0E
MD7X\]M9]_=>!?2I?_4&4VW"#_=C_D3W9M8[42SPOE?W9H3W:'VS8'<32?UC:
ML3W;M3U_QE?7.=;4M[TQ48 %9I0_".$/VD"!-^(.,+$%PL1-Y.$16B W-\*_
MX6M[2H$23@'.30(!'" A.4(\:P"Z[C$/]N 2U!U;\IU7/LD)\N +..TC_'L4
M4A B6F#>$U(26N +(ETZKN#B07[C+9 %0O[B_: &ZS/<^9+:&R36E5+E&9.X
M1=DF= "*2W2#Q8/O*&"QQ6+H!-6U4< ]WGA)0@ ]>"3A.\+9/+TC/"H!K+!3
MW((B>GHCL' T9 $5W2\ 3N '/4)J Z!VGU7GX,]<&HL@U/!K-ILB7D -'H,\
MSASF^9+9_W=],N%>,8M,!G"#0I"%1=!& ?3>J+U%(P!?KKM>7"B "@ >5XR@
M,.PX<X*Z",C,"$AW>UR @!Z/G&Q@ H L!JV,[^] MB B Y+P #9](M&-8'JC
M P;!!&2@-1Q[-E4D(<QY4E[V*:((.G006#TB0N%  KJA<71J8%MJ\KFYBN%
M%B(@^9<-I62A""GBH=FI[OL2N1M& 8I=^A.SM4W4! PCS"ZB"9#D!_(@ SB@
MX0"@ O8%/TP@XK="!0#AK=$ Z0?M#\P_*B8*I;JDA=( +R)(%O#UC0&B0X@3
M40 8R'&BQ@0 #!EV2%(B  4T*0@,21! XIH##0$,T2?K0H88#/\8.LF@9(''
M!($(*)"3@4J!EQG6$#  @T,4B_IBS*R2H4C'CDX T6*1P$8!AB!$W>#0)24
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M !JRII6568<J*#N&"3L"@H'H9V9E4  8;M"2W>G#!A$$@1"F)A$T3(!H,?@
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MM%&I+Q3H@THZ, @)^. '#RC!D_8'/X,PAX@'@8,/+C%!;9IE!2=[#RJU&)H
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M3DIK>M.<[K2G(PW&L EIKN[]M*E/C>I4J[J<>U&O^:BUZEC+>M:TKG6R0AV
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M<6YG<$ZG+*?WA TQ!#M@>( Q!-:W># @5MC(?FS1!%UPA$.A *_ !9P88W9
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M"J! +K1AM'J$!\_5!"U0 _[@ 8^P!\\54E5;A/[9 +U7  C)2BM@*1W!D3R
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M&XU[!VJPY.)K(3F@3;Y3( Q!KRVQ("=Z>44@?_X3 E.%O8E^ "&UYVC1 90
MT&:A R0I&P><73!@N?<  :FQ M[@@U;Y&5!V_P<N(-DE4"!,OQ3S,=O9FP**
M9Z7T4'LX=>TFX8$7<BI3Q@*[1^6<)0928$2Z= S7_H UX!6]2@,=G[$$A(='
MZ 7J\16(8/#<O.#(094M8PQ"X3M^6R*64P9W( >.H!)W8 ">NP"ZZ/(=L $U
ML!0&\ I?A18(( !:\ ,9C2X1Z@-O>0=WT%U#,96]);Z>$)/&1<C"HHNXUP.4
MT *.=/AA[Y\+4 $,* =* 5@UX $'$'M!'2.2[",.(#4D>"P]X >EMQ[><(Z+
M_>;N9W[G*#F:DUR;,"E)VA2D*'I)FHT#?3-P$ %,/I,1\%QJP),"T?1<[@F3
M)P/WT?[D2RYZ,S7&8?^5,#\L/>U!.JQ<!@(03CK-( # (( A7?@8-! "S8(Y
M"0),G"BA6X<0-B8 , "#(D43GG3@66CP6)=* #H\V*0 AJ""!PTV4:0/3@0(
M<,H0F(.%QL$A6#S-Z>():)<4<F(L.-CD2\L<7"8TZ2*#(8Q/#0# >(C0IT$%
MDJ; "4!JTX>#<[X<D=FV80PI"KQ\6N!DK8(5B;3*5&.GQD:9"!P<:-M6#9XU
M"I(P6K"BB((A$+(00!3!DYH\90KT )3%( @8B0I(RO QP(DH!&(65K-%PR@(
M$+KP8&/PWHZ2($1185KXX+'.;9M0>N';N $6&63IBY" 2@$4G5(#4"#GDZ?_
M8SM2VO:V7291HP<5J#UR3Y_I $4(K-C# ,2KI0#>"SJH.Q"!.G_6J-:QP32%
M^&3JP Z)*#JA#,*,XP@&J=I28##,E-A(@2JJ BV& @Q202$*O_A))3R*.,
M.>"X*8(;;%B@ T7V,P@,4HY8H;2/@"!HM<!6\/"@Z'@ (8?G6,L!/4<8T.&0
M%PBXIRH >O##1;F*G&,*TTY8XPXO'-E+)@H_^1#$(A!JP1,< 7@"#V>HL^[#
M)O3KX)4"*<*A 2>+ T"'1IPIZ$WZ%%2@"2-.U <(&<(R0B(@+I'"0;7(-,@)
M2K+H:;M&#\+H+P 0D","%P%H0KHWT4MD 13L."^ _QA825!!5EMU]569#GB
M(@=@M?56!3\8)0 )+,#U5V"-PS-)H*;(+8>'5HC %$HN^.**M58%RX%'.AF%
M@R@.2,@3T&S(T*"@/%$!%#YP[ B+&5@0"EPL/%,IAQ@F"(&+W@  [Z0L$)BW
M-Q!"B.$..61IH1-GH3U"@5<:1 B'+Q^L]MIL-?R"()E4@,#.AN@:(@-3GFWA
MBE-F:*@K!%B 8V!G*1&#!AT Z>:@):VJH(HV_,'#W<!8Z&*34!Q (<0"P@7*
MIX2\(T^.]@XBY(]\&9RJ"W>1RZJZKH+Z$@ UDJ#$#PXPM?<+&583C S"D'NH
M.MZ& !L ,,Q@P,$@,+AZO/]U%>P 30"<P."'/ @:XH_4[ND.A<P.>"(XZMX8
MU04C3+F@V2\PV 0PWS#3S#?@7 0A#-Y8U<$;G*F3I 7O7!UBAQI"(<. W4CM
MA ?"% BBBR.. ?TWR0JK]" $@OB"@6-*</QQ9Q.KPD,%@-RH7QMB,B"'0#;#
MX_(.#I&%^,@9:PL%14;Y@GA0T+C:-[7&;Z(S-4*0D+H53"E4E.A-@B"*+C\T
M(.$)G( @=0<,"8$N->3 &=]:08RJ$($6> Q:,Y 6EUSPA?"8J1-7:EUA&A*!
M/4!.9>X10IKP18"?E0$P<C ##88 "L=Y3#K5*2'YZH8U2JP! "IH@54,DX,P
ME<S_2P;IP?3ZQ0%G78!@:&C <(A5O2)DZ#UZ4M#S/I&"4'Q@#A%P5]:NX(<(
M%(%R!GD@Q;XF@R' 83L;"IM!.D )]0"@5!"(P=L\)9WW +$%0KR ]A#0! M0
M8@JD*&.P_ BL)5 D%'\DI()"L:L ,*&0BWR5D\H%%"I^YA6!F(#:**8 ?WA@
M47S1!%/NT(00(:0H"@ #%LJ8OJS\C%Z9<H$F[H"5!?2P#TR9XG8ZD -OR:$J
M!0D@$6.&@!5\X@@'4,"X)*262_HC!1.XF\)LMQ<U>( -!+CC'VI0D/% L"T)
MB9J_%M F^AE$#9W$B$:H<SQ'*: 0FGS"(8K %!*9 9H/_TC"J%ACAP89X!$1
M0% 8UY A%/AK-#O@P49:<\PNS,"@+/#2CZ2RI.UTA(AHVT@/O/&A#FBB-IZB
MQ/H04 4,N)$A2'M;A KB!2KD#VQXL:=P6J"$#Q#FCGC@PK>,<R89/B$/]&@C
M0B1S@&-8I@.9(0!G<B,*T7RJH.+\P2:-0[C+%:8.)7BD;CJG(.!XYXY^4-BK
M2JD5!#C!""GM44& :0I/O&F5R(ED6\!S$ .XH 5K.,";G $8 UB" 7CQT'M6
MB1>?$%.L]VG"D[ ) R5(H2 &\  KW!*$'0)E8F7:WA]BP :9^F,+#QFJ#TJ:
M Q-8P27F%"4?/KHC,-TAF#^Y __C5'2W,!ED!5APPSVD$Y-,.K4PQ:0$I@PP
M.QE8=8L&Z1T:'$L=%ZBJ>DERRB;4B)AOS84&*.AM@M3P@[U*US=U\(-O*U2H
M.8RI3#I01)I 8)WC<O>?*W#;9YJ0 @)\*@H&:5D:^439@SRA$2_#FATX4 EY
M>( ,!D'!9NM%G1-BJB\^8,,01+ =%/RA#[5!@ O^L D"Z/,+?,/4IUHB!RTQ
MI!#P]0<4%B6[%I2$D2LNS!T".9%:L7B1NIK(%61\XX/@J5,SA$!)$ "O!2"G
M"Z>P0!Y>*E(>(F$/%LACNRK0A T8EW 0H,<5+B"+_50' A>P@+7*\ &LO$T2
M3T'(@\W_:(SF<<\4&*#'%K"0&GRI$0FFL, 5Z+&!Z#7$%/0H\DL7  *:?FLD
M[CJ&'Y9L@0N8@H$&F8,8D,QCC(6 -R ( @2(?$4T,&!DO=%I%Z[0Y1;\I66F
M^'0G=I!&@R3!#S#9K1PLS81.E.! VHK *3"01U)X9@X[^((%Z*&(=A&@ Y.0
MQ:<OL+\)*&!>3W,7 F#@"#940%DU8,#=2J+3%O"Y$RV(&  6<V![@6(/;38+
M ?"2MK6U;4L&J<!'1]$%/F- W&PY@!,>P( RL2A,U2E!'S:2$#AWQW(3:)F[
MY#(J38V"R/3P@P]^\@0F'"'?F1FN20 A0^I4T 7W;F /-D +_SXS>0J1+=DF
M"E !%#R !A5HBPIVL <F7 $4SEG $Z03NR"8@BVG6S(&*"&"T($+$(>&]10\
MR\4=<-G*7:!!AYJ^&\"TAA1,[H01HM>#/XB0BX;F,R6@9BZ_;#%]<%G)Y'8[
M!"/ N\Y^P$)*0, "#-;Y"E51 /R^=0]0S/=X]L/?'!0>\YF_MKS8+*4GD*/P
M.E/BZ"D?'T=8X#A$CT()"U#V585C9&VW '8@.$2:GF#H&>1'ZP#P@MLHA/@\
M&A< )&Q\I@)V 5B#XK(SK&&9$/ *4USB VLB\/3JJH@]=[D+ZC'BGAJ1QOD0
M0 T/&&9;;AE\/^CC!%D(: N8; $([/]XZ^-&],ZTU7:P!&$*2^Z$T7^BELD0
MQ3/R!2$>#GV!+J2F"GX@<AZ9_M&EXGB1"GAQ  :I?S\R! @(  I0) !D,4=:
MC3FX'?F8)(-* B,(@*[9* ?: @+\!(52B1#( *GH@3S(  K P*A+ E"00-H
M#2):$,\*"EO")=5H@CR0B"<BC)B9B0_$A'; 'ZQYA!(( %EH@VCSJ]Y0MC3A
M(@L, %,P.XY(@DUHH WIIOC(FA(\ 3$8L.<A+05  9/Q046Y$\1@@1+@ !Y
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M>_D#4W20*L@ ,V %%FA''FJ!G5 C4RF+2]@((Z*OSMN35Z"/)FB!)BR,PB)
M'W@ 0'"&/Z$$B:C$X8*,/[B$>@@ 1\C (8@ [S#*")0%40013-&43V  #RL(
M)_A ),1&H_0/"M#% _B1(#G /T* 68$QS006&@L >OA,1E( >=@BT[R#@Y"'
M55$ -6 #UH1)"[J##_@ !>"=#U!-ZI"'#Q" VQ0/ ZC-!#E-W*0FUF0W ?B
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M,GC93X(U>E@F-5H"5L C)J !G'/H26"$6KW44F"R(P ,B&N "KN$4/CGM:V
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M 8X/Y'(,4#PL@VZ@SX1 5P53:&D.OGE;#$(1"@+2+2,( ,D26* /('@"!'9
M@U   +XH&$ 4@J"8#A0($3GXYB!-\,,:=-:8TP6!?GVS3OJ4(#<'^,,"C"C
M@^:C,RH40 %):,.TO)"6AQB@$",8 1YT!#$_1,$Z[HJ!P6 0B#1RI((=N-<$
MP+"A5>V@$H,L%^@(T8+H 2!E6-#6;0(1B@]<<B48] $K#O($2IRB#3%9()D
M <F%1&YK)HJ!Y5S0@AE4,A3$>TX@[C _5UUH/HCH'T-"QY*W<8%"H"/8\A8R
M+.4=A",#=, '_^;0 N7@X3  T $>JB@'^H'.D#%Q@ ,V0X-/GN*!$02 "EK
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MTL^RP*A()>T"0*"(U0+WM:<=C^N,N0(TL.%<RD7(A,<<V2#$Y6!H1$A)LF
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M88WB_4% (4($[,'J,*0_S8?5Y:<=,&@+C$)YX,%"&M/_*YA"=_H!V\&3'W"
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M8:]5EAQ0 ,]PY;4ZJYT,"P14H Y<+)EV 9/ !_$QA Y4WQ>TP!0D !"0I1Q
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M-F<$VE"$-S^; CPG9C*$+T>?2YDSUS3!!>";.'>M!CZ,.3<>.9,S0M S0U2
M.:\S.C\$ K@4.N\SU]SS0O1S0BQ7_P4H\+E:0NM6S$%0S#KOE$1#(9V=Y$/X
M\T(L]$Q13"T7=$(<@WTB=$+0V=Y6ED)0-$K#<T80!<ZD]$,76T8W!+&]M$I?
MQ$%384T/A3HT*M<LD$RO-.A\;5 WA$WA%%$C=5)#88EUPFDI];-9)CV%YE-3
M-3P[P28 <E4_6QP]0EAJM4ZI2!_NSTA^===:=%FCM3>KP,VE-4U50-@0Q'16
MM=@Z6UO;=5D3IU/?==F$2J<!6 XXWEX+=MM4  HX\F#3E!-LP$<*)V)CQ+G1
MY;-\HF,7VZ.2,65C-D'O0[UF=D8(A-A,855;80!@86>;]G.JP0_ Z&F[[@\,
M88<L%FO+]O]L>TW6Q01M0X0+-'9"J $9X';9(, JS/!O$W=Q \ !P'6R:;78
MKHUQ._=S=PU%ZS1T4W=U6_=U8W=V"_905S4XCZUV@W=XB_=XDW=YF_=YFS<W
MQ[56*X!WDRUZPW=\R_=\TW=]V_=]SQ=W4[789J%@(P#LE8U(<79,=XT\.$!6
M%]M_[W9URP,;2'2#([C7(( !R$V$1\1A)X2 1[A"5,J".P2$(X #>'A"3+=#
M5(HC&SA0'X0\R,V([U#2*%N#IT=5WP&+PWC%L'B+J[A2[Y -'?@6 CC;3'B+
MO\H=J $47-).-7B)5Y:(<PT"& *2V] E2=!5;+AC6SEP.WEG@TW_-VNU=]>U
M8#]!M'H-" Q"(%RYUQ@ %(QX9BZNLB% (5!(CI;!C%^W*  M0D@6,LV42P0
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MI+)%R&H!-9KH+E($FPB0)+J0A0I$14(B]D,1%#.S_@:AQ(-QQEU:02X5,:(
M'=Q4$3[09Q0$H03.4( 3+AJMF:)A FI0Q!HBPJ_)2@P3_*G9#M# I!5(( 92
M4 QJ#%!E-AQQ!5W@CWEMJQ@TD*&@14!L# J@ABWD==/\F0,6TJ)-G<A!%ED(
M*EJ:@($N50 %E!AK(UYP'9=N,@]"(R4_F0V .\337<WF_R>]VG4%:4M;17F=
M"25"M@(LS, #X0X"%FB0O3TP81,&DF$@% "&5DS/K0W@6" JBP695, ?I7@
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M#"I ^"#@ DQ1E.H'-2H  :I@"KH (_V@FLK.+K<O!D1,$2#@(I]R8%K3#S)
M;GA ]SAEDQX B+;R+;"D"YC  BQ #%(@,;C*=XQM ?PI KK@ JY@%+A(1?AQ
M,"4B"1VN!T#A'X5O%+[ %)70<U@-E901"+*@ _"*1M3#;8C1UGK(+-\R!""@
M!3 2%%RJ6]XO1(R& GR J JQGBJ 7:(-0?.%V@* 'AKTG8XDP>ZJ!NX ##A
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MZ.&)_RBFJ.**++;HXHL:&H@@=89 8-=O,.:HXXX\]NCCCT!J>$=X=UGW01>
M;4> /!^4I@"3ZN6W66>$/3D36W<X0*%<"B36E@(?-#E8!7=LN18"8G[II5SR
MF D<?LK1I"5?"*SI807XN3E8GJWQR5:=<Y[I@)24"? !E:3A-ZA;6882R@1Z
M"O9DFFKYJ1>8!*J%9J:T6>I9F(+)<^6?=EXF#Z>(#:KG'?*$4NJ3#CP:9X\R
M6J=@ !+@F-T3BA2AF0'[*-0$'BSQ)0\4;JHQ'0(KF.+)KZ7NI082,<QV$1A8
M/+O7$XUTTU8/>)1A;6U-7"+?E^4^QE8'KS@S*ULZV$'#<O\*H,! 43[,U.I.
M<V Q[U[W0/""6PXX\"YF!D!Q,&''FJF L@:%$(.ZAAD0PB>LL(: '&B,JM8<
M"0!1"5LK)/#)OX,A$"Q)(=3 :68&R#$%$)O$.=4D&02@@0\IW'%1JR_G]00>
M@<PJA[]\]0"(5VP10BP!"QM6<-1MS:&584\<4@35:X$@AR,47S0'!!_MI8 _
M'K?501Y;7Z2 $Y0D0,$>-;=EP"-3!,"!#_<:5 H2 9S ,]<L@EAD>;VAIUT'
MQK2-V1 ^S*O#'V4$_=8<CMG-0@T[!=&%#(0+Y@(&*//500@V< H&$-KJI0,@
M [.% AY%C,MF$BE$+<\#*9B)0!#_H,?5!"-ANR9/#EY5T,0F$_Q./ !#X%"Z
M7"IT$7O7(3AC^V4*5#%Q9=UGSI8!=M1 @,4QG&M8$UM$D-QJS*+1]UJ(1 #!
M^Q>!D ,<)Q=6QQ_/0D ICA"IRLS.%&U@0)R.X8<],.&!BC#%1[HGAOF9#@E%
M6XL"5F"&Z<7E=4Q;2Q-:P /+58P%;3!A6ZIPM<+HX!"""-U2Y$"%XJE@!UF0
M80<4$<*VH( %-^!"6@R !U-8P )^2$/K/K:#4S#A"D;(8!,:R(1)@$)^/[*-
M>&;TG!K9Q439Z4 .'&>9#?:O#L3:GEL4X 4JO(QQYMN@LS*#@"KT;S!JR($-
MXJ0 ,)!B_R-[T0$>7C"KV:VA@&Q1@ N(AZ@ON2 ^AED!_G2CM!XN!0:9ZU<#
M^*("4%Q/+1UXF@P' P(8H 5\'"L>',\GL>()IHX8L #?X!>$CB6R7U>HB%J&
M1HD[#J9?@$3-/?Q0ML/(X1/3N<CI]K@Q6PYF:()HBQ<PX4&X**V8;AO6)"VC
MACQ4SFQSZ$(U7=<(9O!% :FL&@Z3!@AL:@IN+="'NPHR!&\<H2#W\$@B11$(
MA: S$0OP&AJFHX @?&$D/JH D<9CI 5M1QZ].E\2+N&!/)!P5 8H10M.P;RX
MS"$L$IP=4O+PA1DHYFQV:,$>+L&&[I4 #FBX9Z4>H0\.=,QS,_\H!27$P(K(
MO"T/76@#&PZF!A9LU*30 \4-/D$0!!0BI6(@ Z*TP (_H"%C':!$0@"  @ML
MHH\X2(%.?=!3FCBA$RVH0=\ZT AD\(0%E*B!/\*5%KA]0:@700'ODM )3Q@@
M"74CR2..JI\G6"!X7;.#5VIR!3^H%93&*)L:DM""%C"B;X1@1"C*QX *&,*H
M/-739#=*0*F4X@&;M2P9"*"&$-R %(R80!52N((=P"$&K(C>O#Q;U:N*AK4L
M^ (/G&"]\85 '[)X['HVVE&VE*1UY'O6'9I@424LJPI&T, >GO4VM-8@;6J9
M+B4(ZU*8RI0G-)7%0$/@ R@8E0<8U>C_!9KKE@Z4C[@(Y:H%CA $2IP"J0>)
M MQ6JI#?U< B%4 !$W(' 'D$H;(\E<H*L,B6(6"A'0#\&!J8<,?1_E<_!G#!
M!;[04?9)H M1^.LF#F!8L2H"#;VC21/0R@-+,,&#GGU$%^@18Q6,XK7?U6 Z
MU5*P T@"%/PCB@$*8=$$K@4%*64$5H4@1:]NT PI2,).DVF0LZ;U2D_PY$6*
MZ@<!_^%]4P'J)1Z#@B5X@ 5HH$&(T>KD\;$@ G!0PKWDH5,2!XV%_*5$'SQ&
M7<LJL"TZ,$(1"#$)/[M-'G#]@DR]5L.E^,,.)*YG#A/I@$<TD!$S>0(E;F"*
M;ZZE P_@@3^T_]:2/CIBDXL)00S_"FH0",%='.F"7UGP/ "LK5A_@N>'V]($
M>I#!!9T0:O=:P--1/D>+N+%5;W2%'<;Y2AXAD$7>=,8%A8@Q9SISV5OJF#,*
M.$.0IMBV++R35/<$K@\3\()=@$ 0M>31+M); 01:4(( 4*!_&]2'72@0 PM>
M1)#B 0(/"%"R -",X0+W-Q9&\C8_N"<!I,A"'JN% DIT[ !@@,,5<B8!1]PK
M9MN>&U&XY2T4;,$N$J#%*"J'3CBXA^";9,@H2B"R'OQA9+[&@W@XP /1Q&S%
MZVJ7UU*^AW_IH!4MF:*[)1 Y &"+#A*( 1OR*9Z)NZ4'1G W!S8Q0_]O3.'F
M!0>[O]'0 !AH_0UV,8$,- D )UC<+J:HM]IUUH((?-+7A[#+)Q@02CC810.Z
M[%H.!"&:(0"TCB6XN2ED4,J<<2 +Z.RWSJH^/CE$7&\KEK?#ZSWF'.";%3 @
MQ2C<@WAOAZ#<1[&<$UI >;>GI7I^D(!=2$$0(D)@VQ)PE\4^\9@A=*%F'4""
MS?'=@&:"U\*L",'[S#(#%NQADSH0PLTYP.[6NAL.W9Y#WBA0A ^4[P#'V$ 7
MP,V!D77/"##7!R:6N!05^&'@6##?"L3SO;4,80I*  69@D[S-@-WX'DWERU+
M,0?M@7<R$$J"H !-\ <^L  $X 4<< $"1P'_8%,4$2<!5[40[00 4J<S>S *
M"Z< ,.!N)[!5A* (HZ /0,  0?"!Q#<^@V 7:4 #8N1N!!<V"L" G;"! +<"
M*7<RLY(UM !_>O,^38 $%.!OW#=#F>,$0J<W5T V;7$/BB >6<< Z>=O2L I
M"G '%= !&^ ,.Z$ _.1385 M%N,(-'!-:G%-:M ):Z 8]B5NQO1Y6!!8;C,'
M0, $ G<"-2 )[G$#_6<?![!0(O(<)!(8BQ-7K$0*44  *D@*E=!'6. =ZQ%G
M<-$]3<=50H )(V$ KT %#;"'$X GCX QZ,1VLP)'!] ]$2 3T ,(6Z,"]U,0
M*& ,\,86_7**03 Q_]WS!?.B-+J$ CE@!@W06G-D7YJE1_Z0!V,H-C\( '-0
M LX  "Y@60J! D@@/T/S @J@8R,! BP@ KNX T4' *)F/N!2<!<Q!)WP+Q8V
M$AO3?W6D=>LB!$7033)! $_0"9>H $.P-;]##PR  (K4 N8X!,%7$'GD"%$1
M,Z"(/1TD%57001L3 >(V!SO@'1VP-(OA!3X@!0H 9Q9A83306ECT5\AH #"P
MD24A G_G:SG@+J6$!?<48E.P3=KH#9MD #F@! 0P++B81R>#3J=D?._X!'G0
M;;+3"2M6 5H@,1,0B[!V:L9@/OI#=+7( IJX05[W-B7E.U6 !@IA88!T#_\_
M<2^SDQ =4 \31P @( HXT #HTS=.\ >7. <8<P 5< ^ L 8;1&%KT2\T$ 05
MN!!0QP)-69/SHDBZ5E!=, ,7<0^4<(ENZ6OE,P$]D ']TP.-8 ,%X'+T"':8
M<%[*I AR6!2\1X+$]!:\ @=P( NA)6%8= P[<&!<A01@TP%;,'A<Y4VS$PA-
M$%?^M (BP 4S,0<1T W=$U3"H@@3 T('80I$(49 D!S2>8E<12P 4 > H$L[
MI$L^9TF@*40 L (FH!-O4P(QQ!95<(LSH31%< !31)7VA8MK\4(^Z6NPN0#V
M=4=!\ ='X)0+8)18I -(P %\8#-R4$$5H "2D)G_ / Z6=!(ZW((7% 0;!@(
M:0$"7H": 6J2![<T:\.'\N!-G-($:<E5BI!X:C$$^A ('U!0^I ZU8E8]E$K
MU>%%%$!MUZ$&7TD :W.-T(-#1DD%,B2*]P(N^'-,\_(@2< $>3 S(]%&;]0X
M!, LNC9FM'. 8^$!'A *DFEP'>$#_9 "#N S=82,[[F1F[D#E3"!VR1&6. '
MG]"5V )(.M (11"+\S,'+7 $K_,":R,N'/$'/$"35P$%:,H"8&-(D5%+CW$,
M1N"F<!HG*_"G2><,ZM@%8K $ I@_(5 V%>  I\4$1G ":V!UI* M%D91:%H*
M&KH6QP (-8"F'N *C6"._\?4-U1: -SB%0KPA@N  "RIC?XB'+_J 850"@8Y
M.]Y2?\6U+K1# ((TJSPA,>.251\AHY[0/<9Y$80P"EE@ &U4 ,[:!2D K"QP
M"@;78/[P  ^P!1GP:K&H2F!J,4H@'T. 0VJ !S$ K(6@"'SX9(T0@%@!"+AV
M#UW -.13<"#P"K4C-ME"DS<(/2U0-VIP6@\0=LZ 3OG2%BYY5N?J!85J?0V@
M--,:K(W@#*?S"?.*IG90$2Y)$G; !>BGHFQ80U:C+1LTIFNA @>U2Y2P</GD
M3LY5"$:%8E(A!RDK!P"E%HC@#94P>X 8=*9 !VRG%EY@"O_2 VE82BGI-BQ$
M _]/L#1WN'#J"I@."JP>8$H%0 B 61"E9*HCP H^TQ;=Y#(96Y]+X059JQ85
M, ?VI!8<PP!RD)G ^@BC&*"-$$TSA 4-,"Q] *RN0 F(^:[+.:'UJ(6<L0]!
MT \68 3<1P"5%!=LU38CFA8J>$IU.((@ ;?>%!GV!;1M(0^%H*_\:@-A(YV
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M'=9K9DAI$:J94M8/0 E8H)E+84?3PRZXMF0C, FCX!ASX+LE,5!2O<D$@"U
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MH/O6%@1 Q*"/T)EG7O\.VK] H>B1#TH8)N]B,@7X(P<6_-]&%$ (0+AS!G*
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MH"F%@"$!]D*/PM86<H#RR 1M$%$3\N"SGPOWGWAX34(04 5K4R";-QJC(A)
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M(\ "RYS_G&KCERH1G020@.\DB%& @-M4IX)  P]0A/O+B K 3'WP'>K9@@"
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M.J"A.P@+Q[6?\T  IM!<XHVD*?!2 K@K<N3 5/V 2B*+89%8$9@_N;C;WF4
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M4^TB"7J"$9(<T^# SGL/%,@!(/!4R )5"6.)6_NL230%>K@""S#N-?:')+
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M4F"$]VBX(G "FEL!QWZ+-:AXXT@:,#D^3T !(=#AEQF"3O7@AP-/CPX!4[B
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M70(+)( &U, 'V(5!_P#!*%:0$^#!E];AL13!(P#"1%407W@ A,7 7^U%"5!
M#SI)Y"E" IP %%F)F<C%;*1 ""2 (ZSF/)6"DR;11$R&$L I!=1 M@1-" @I
M#[S>"IB!!]A!!OP12MW 'HBJ;OA! )B 1!Z,#Y#JD[+"':A, )Q H@+ $R"!
M05 !&[  )J1 &H7J2,!?!DB $B3.8SA"*1B!5'5> G" GCK$'0Q8 @#!)A07
MK^'<=9(HO,:KO&*D.,I'1\ZEBHKD%$% "W2!F<H4"^'>%-R <#1!2\W4"%*$
M!T5 %[3 *,@";!B %VB UIG"%)Q$<0K+%LB"*8S"%$P< -R#KX"'N$5."_]
MP$M( @1,@2G@WRU]!"#L =A-@2,D@09.01KH#QKIE\>6V@-! +^.0I$!TQ1H
M@ ^ RNI% +].@2P43J!@@A\@(^3)0=#V+%D<FRQT@<=B@7H0 B $;0EPP1WL
M&P=\ AM4P0XXK+^:R[S( MQ]K$B(%-!J;0(LR)I@G=9"@'*L  =<0-[VP21D
M701(A%GL -QA76&%P-R.0@3\T9^!*=6@ /LT[03  ,-JW<5>K2) @-:6'UFL
M "FTP!--0- %K=X23TU%0 M,P> RP!#XP="QSKS.+NW6+CLJ'5B*9HJV9!.T
M 1E\P!VX  24P0&<' QV !* #-WHG\&:I%4L00K_W,$'2$GAB.E/-<$6:-/!
MP"'H#N*Q4<$$($\; H!U-L"E,,QCG"X $$+U34 /9( 1.H$^H$$4.9%(9,8,
MY,2$%D 31-47C0QN+,_C@<O1-.&[5"><D82T[ #SOMN;>>\6@.\<M, ,8) +
M0,N2.@G:AM06%,X<D (/Y,2\^!CR[HI]T9>52)51I8Y9*)JRW< :',"(%<U$
M/<986$E,O1+7FAP@'!WAQ?"<<$ 4Y 2)\ $(5(X#=4T-E)C S50(X)E1?4$6
MH)$/J%]-P<8Q7(WM;C$7=W'XU*M!D.-# B5=MF3D3<(54,(44(! B*F''(OI
M.$'GV(5QUH4_/$ G7  H_]P !U4!8%!*7VV3'2B!A&P-1<!- Q#"R)8%V,02
ME("'P\P%N%"%F :0R=F40UQ6%-S!&V"!&##! S"!KM1,"T3!<+# )WB. '<*
MZKA4UZR! :!+^-$-_2HJ&K"![U $& #&%'7!*51C5DG.-^V=0S@,&2R/NCC!
M9\A2L>"8&_3O'H R$S!!_DW K**$6<3-B%S4$-QJ*(<R(/"!E;2<.%&0HP!;
M+_T$=9;O[&U -X"9*4QS/S"!(G@9Z"8)"\7 /#/!) !"$=2!'V31O+B/C(*H
M%Q\T0B>T0U1D[A9FU 7 88JD9$6M!8C! _C!Q+CQ<'Q,Z]C!)I!5[0&/(K3
M-/^/@!_@Q0KP64F<Q/;>P3'5!.;4V$]5W#,A@1P]Q@<R:QY,S!.$LT, AX!\
MU"Q!&%ILB]!XB'VE\FE0P>-)PA=(#YC5@,=HF)+<Q8)50(*%PB/SB9\H0"%,
M0IQJ0.=,J S/1FVP"2N$D6\LA0Q,!MX!0#EPQ\>Y1K&E-#;CV%Q8S1',@9E$
MA004P9)6A1/I3D'3Q1-DJ RC<K8<BC,\&%H(&AF4R^:9',BA12"P+]987N%D
ML4$KM&=_]NP>*$&>HX*RI '8$1O< 0+4&"7W,'B@2[',P1K,S,[ $VT42JAY
M6;G(B1P0)\),=;&8!6" !)78D(^IP5:7V($]P1:TMH?_2(E@W0XE;+)8I$ 1
M%9$#3$ 3?,'?7%(J0R@K=X(UHD!([-DL8TL%(<P"O($-!+=Z3H<!A$(A/$($
M5(8=V&WE)(FTW+)8-&!C>()0,PLIT$ 3M, 3%A$4.  ;$, UEP48R$4'C@6'
M;,)UAT)VDS7.:,85'5T/4(+N((!8! 8+O7,(Q( '5#@99/-D]W0-5'@HL$&!
MC^) %Z\6@[:-WSB\FFAY(J18<N2*VA$#%$8(O$4/>(,E'PN?(4<>C) ")T$+
M[D4&>)D.($'ZW,%%*.E]+P#TK 'P?EU[JT$]W+ +;$ J3\9-5T%./T$>&$=/
M>PBTF<\IP@9L01$"R(,=X 5G_]>*8@. 73MDJ%W4!*"4*: @1Y\/"T0 5:1I
M"\C(.'$Y,/D!0VC?:B( (8"".!<':J(M<=V!$_@S :C !J5V_WZ"%)#593 :
M#4 $#U4 I_^$69R$#N=U%QQ!"D\-37V& 82!+'H&81MY; P,6.SG7#Q!";S
M_!CB 10&PDP &%36,(7J 9PK'G0#-\%+:"P-LSH/1;@@CG>[M_,F&)?63ZK6
M6,;DQYD)!<A"!!B'1I>%*( ,1?"M04]16L@"'"B81<1I )C"%@"&E5"%7?1U
MMST$D$;8)TS"<2<WFDMR'O3! 8AI)32$C H'LU)"P71?": [GASU3.T2;LR!
M/I <2?^P6%\3U@'LV1A5D!Q\@:4*:0U$D;1 6K(J]4#=@$'  ?U*2P;@  .
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M@S5(%"8=. 1"+^>%!%# $:!\A0;X8  [9&"X6Q.E,T:X!6[Z5 $YD&T?+&(
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M!T2 D6SB]DJKKA8 U@ @U$A!R9J)% :B\B[O &X//!;O+12++ORD73;C-M"
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MN4J"#2/+VQ)S%5-"_TH,CP8"(OAQF5JL/0D A[)S9=R1"Y*O:HYQ GJ0!^1
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M*,&([-!YY"PDTP*'1DT>\$S/%NTY-  R_@PZLZ X-XPE!),+1*@' .TH+ L
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M5R4@_XLUI$4!H%6*0(90 B!DH4<!<$1B0Y  &TC,)!CQ,%%#&PC;=/8%S.7
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MI3<*4W=Z^'4#,1 "(C!6!>>' P&(I$@ () #WH8H,'$#6D40A/]07V^G#UC
M &C57R@@!-1E7!(A83[1 5N@8;'!:F*68!R >V!W GC2 8=P%@Z8 +ZF0#EP
M WMP!1FP>N53 JOW91H@BR@Q;K4&C!JP=&YP(!M06'8F"U=$:BAA76G@!DQH
M$L#8B>4S!3S'8T"G&86!9+[!?2AY [(0!2WB!$)P@P0!C D9&]'X BG1 8,
M! ET($:P>_&T0TB  S8V3H,0 &(1&X^@#]ZF9OBH&%NPCP1&&(:A:@2A T:
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M\+2!&%CC!P<^P+!+, E38 *;<!'D2A@L,(,M@@"/T&G;&:(:$ &@B!<)& A
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M%U*0G>]YT  X 8*K%.L) '4ZI!*HFJO1!R#PS U53OV!N9]S.Y*+MZ^+N2:
M&@K8T1W5@"(8FR'9K:(2IAO840G0(@)(F2F@  DHTAUUA EP H\4I@"(GX,
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MNW8;V]SKKYW*P!CG^JDNQVQ/#!DI@%@18"!!"DH6 %#@A0*:!54V_]B8 ,"
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M-:L$>(+X9(!5K7(5 "A01 !HP8H/,#)VV"3>BF E$[8!(#D!4 (9/H""1V0
M-!H,DF*> YPHJLM8 0#")NY@"!<HXH4-$$H):.&<_G1OI#&-0!FP%((,'*\#
M6Y#:5M'J4;0@0E_J,4 (!B(+5!T#$ %P1 H^8(A2'"**/*T(7IHTVP8DD@8X
M_WP! 9Q@K;9UH+6+G102;(-5K*9U4U_-*E?3"ALL;((-'R $$K;9%0-4,1!A
ME0=7"6>X";#'6]HE1&O#N9X$)**,KY#%&IZ[U3L0(+8GR,('Y/'7LJF'>WZ8
M[5L-$823Q*  16H@"I PD.TQL2DIE(D:\K;* \J)<>R\*G73VI4*<$0)LU%
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MQ"5+:L(A7&("&H2/+ F^3U\"F! 8K,\T%4!$ LSPF [(M"\Q:!L"],<?UB8
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M*($"TA6+*(O[P0B%V0$H6 0%F (CK-^*O!$ 5!4%"&&J$&'3<4=FR$2P-1"
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MA"CQZ"F:]FAV22A?4JB8OJBZ%&H'(4"!WNECC@ 1+"AC8NA$E/_" _3##SB
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MNTA-F$I+ &A -T1%H< <"QZ%'-P W>T+.$.1B/E$ (!:'3++#W<S*JJ@,W2
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MA(=\WQHU4D%XG$S< WH,#R*PCAPN*_,@++-ZJ_6 ZV_X!01 P!144& DQPW
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M"45>$NRQ 4@;*011A$C@B,%1@@B")%"B4\&<#)]H  "3@%24 P2=X*' 92,
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M0 4>8+OIJ#2E'^A"=*X 4YNB2(T:Q 10Y/ 6WK&M" <HS1,C$TX R"2$(9J
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MA!RH 0'T%O\UF,#-!*3"[0QHQX5% :$,$MS)'5S 7M R8BH<U>X@.5"),B9
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M9,S <?PE &* -CU (CA FWK@$"0 +E: #UM#Z#0# U.S$*" #>Y@#O3A!-H
M+$O!8Z@Q6(X)*UO #[(2BUR#(H>#(?@P(8[3$:"R+Z$ .H_" "1&%KK@*EM@
M"N @#1A "G'+!_J2Y"YC+VS)9R0F%F%R9%SC?#X!*N_OAEHF O+D,Q3A!E81
M6A*C6,"K#;RR+\,2&5,@-;UR1,!#-%+3*BX1FZ1E+Q8%M#9!,DFNU^+2R+)N
M66)S-E'2-C%P+]0 0_1-(<S3$533 Z  +=T$TS#0)^_/EQCB!L:H!.73!W[
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M@WZW;R\H117 'WHW.C3 !^SB)1# ">S ;4FA#;@%-!LOKGH-834(3N2DLKC
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MU-V'EO/C)TG=!WX?190([3$A]UW<T35RQ>G\Q]OCB2 &+]06(*@LF)-!B10
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M"Q@00E"! >"A2BPAX,)S%&VBEG0(S*'>8GP!@,(6D*'1@'0>'5.<!EIY]%,
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MMX&57:'."4Y18TJ(8'7_EU-QC9EP"38\) - 6#&+-S$!J#CBPTJI".N2.AU
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M4P;&299.1QK$D%P+0:P3 W=#A"E=Q8@&+G !<64J9M_24K[NHDJT]CT#;NJ
M'60LK3:XN\.[],DKO%F.7PH3*;#F3F! 4(4IP&$47[  *X*ND!+ P59B  5*
M)S-R( (U4  8T54+-D#TH FH]Q$/U":2T!GW, IK\ 96<Q+ 91%@P'4?)DQP
M4!%!=QN) 4+B(EXQT "#0335YP?R-16(T%F$I1,%T2$!0WU4(P&(I 9X0"F%
M,V9R@X,%="7WH!H]QA4'(P%PD$R=XB+\AA"55%YIX/\0'^%% D$<K(4'7' '
M(? )KJ HR=,@$Z%@K?$5NJ%9010H$\$P>*(1['-!P^=!&G <1;0'. @*"[,
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M#*;U"61 &_X",#YH)BU1""R0$10 !SY A6YWE1+! 5N)(Q5%36D#2<QF"$D
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M*6SU)OK0C74K"\Z*MU"% WMK27Z;CC1@ ). "4N .$>D",E$ $,;I_UE!7(
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M Y8P I. .%HQ9:?Q$V8)(6KI+SQ809;PT#^@"2EP$5CUT3^0! 44"'=2 AK
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M?=,_\-RLUK6F:-J><!^J?;C9_=!\4Z*TO=L> )A6=[3#X7(A( *\44C;(5D
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MK__WBT+$<^_"0^R_!S]\\<<GOWSSM49>^<=')]OY\]^'/W[YYZ>__L01L#T
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M@C %YH4@&'(F LZJ3?_H "2@2HV(,!J($6=K@CQX"48L$"P)PBB2&,30(A\
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MB#\GX#H4\S0'@I=CT RCVHGD@XXR[X>9JKZ/<J4_/B.?6*4@BHQ[* %KC_
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M.#[Y"=ZQ((,.E+]^4!]0&("%[,L__Q 94 #'#7# $0 I1PB5@!EBES4C,*B
M ?!,B(S@"%90CEU[D9D$\@>PE:C@7@8,0,-$%24?L  +-!@"!-KPM2*$3#FJ
MVP F!*>#>DA  OK37YPXTH,,!" !#%K>@1#@ B/<( %PF.!1#J$!/N -"/YC
MR!T.4 &@($ F16@"*/IPAS!D@ HG4Y%IBO:DW1@K?$5[@F9V]*1Z<" *M*D"
M#0WHL9H%137_<-"8UG 0.[C@@ PP((4G%G."+#0.@2$+@=KL!@ P=$Q_^4M
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M'H,$CR =3)C&:P9=!F64Z"Q]A1JA06(T) +]2E3X35"YGM0- 5H8T$8  +"
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M!#B#-WA=#0?YNC1GC*UDB-Y1B4%BL,U;'E\0,VL(7PSJE6;AMI("HO21<4^
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MV3D^,!H9WX!H>&\.2*_?#_F;ORD(N\MU@"(X AM$B8T!(D!00!,*QO\-9P
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M8^0A"*[ 74*0"?%P$&&G#8$"UT+!'Y)@QS2"\PCQ$5WG"Y/_ HXN88XDJJP
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MG,$06'@?-UM?DM, 7/]@ S0@ O0A <H#4YZE+Y9E.R1YN!%BA!-7<7-:770
M#R@@3NXD 6*@ -9#AN'T4K#5_/PE);(&))Z :+!E#^R1/PZ9"^Y@;+9,-N
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M%(D2J)D!G%L!Z$40/N.BBV!OB=K"3!(Z19 ]76 *)* +KJ 31D$?LN9(U?P
M#("LDTP' ,$S0( %#+\_.GM)'KIK53Y.JD ?*OJ63%=4Z,6+K;:#S3<)Z.&(
MY: $2$(!7 ! >!3P^1XTW/^=#2(]YQ"!TFF@(A) $$1%#A"7Q5TCIZ^MAV,;
MWLM=C$==+4P%H,M%![9 SSO@ 0!"# T ! FJL,#C@((G1H!X4B"'@I()QS*8
M\01 A9$ S@#<,Y*F 0 #+"C4.#"D!!89'BV4*:!FRXD:!#J$"( )8T$ /4 !
MD5$SA(@B!'H@,7$$ ,0;2J3L5+ "#I4"!#_^!-#$#H\)50'= /*"H($03"<8
M2$*/E8(Y":B(!#"$WJ8#6(W@:*"F'I"M'5@(W(F@E(49!-:6B+&@PR%9W114
M*9&&@0(G@"@442!)WZ>D3C!L(K SM.C1I$N;/HTZM>K5K%N[?@T[MNS9M$4O
M"8#_.U3MW04_C,+-A+?PX<2+&S^.//EL X_TX<9]0LD" '>"Z(,S:@J<&")[
MV!VHP$N&0 44L+@A"PV#%3=B2.GPBD,6I7/T)9KN8H.&4:,@)' T4$IP0#!%
M6URIH<@-$/2G#Q!M4%601AHLF$   "HP" <O@#9$!I\,=,\&(O0'009 5!):
M> '(X@,#'>1 P8(-TA0:?!3(PI\^)T0!VAQ3[#=%>VR$UL,A^V4'QT0(1,3%
M!"_>.,H>?G TF1&.B#26""\A $, $$ 0P0EAK?7CEQ# D<9 @(&1  ?9B8#&
M=$W0D88; "QY0Y. K9"!#1"2! >.$6BP!E< V!1 9 7=_^,'!5UH]R$ 8 2
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GCXSD)"MYR4P<;K*3GPSE*$MYRE2NLI6OC.4L:WG+7.ZRE_D9$  [

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
